Filed pursuant to Rule 424(b)(4)
Registration No. 333-217409
PROSPECTUS
77,255,205 Common Shares
Zomedica Pharmaceuticals Corp.
This prospectus relates to the resale or other disposition of
up to 77,255,205 of
our common shares by the selling shareholders named in this prospectus. Our common shares are
listed on the NYSE American and the TSX Venture Exchange, or TSX-V, under the symbol “ZOM.” On March 23, 2018,
the last reported sale price of our common shares on the NYSE American was $2.19 per share.
The selling shareholders may, from time to time, sell, transfer or
otherwise dispose of any or all of their common shares or interests in their common shares on any stock exchange, market or trading
facility on which the common shares are traded or in private transactions. These dispositions may be at fixed prices, at prevailing
market prices at the time of sale, at prices related to the prevailing market price, at varying prices determined at the time of
sale, or at negotiated prices. We will not receive any of the proceeds from the sale or other disposition of the common shares
by the selling shareholders. See “Use of Proceeds” on page 29 and “Plan of Distribution” beginning on page
84 of this prospectus for more information.
We are an “emerging growth company” as that term is used
in the Jumpstart Our Business Startups Act of 2012, as amended, or the JOBS Act, and, as such, we have elected to comply with certain
reduced public company reporting requirements. See “Prospectus Summary – Implications of Being an Emerging Growth Company.”
Investing in our securities involves a high degree of risk. See
the section entitled “Risk Factors” beginning on page 7 of this prospectus for a discussion of the risks that you
should consider in connection with an investment in our securities.
Neither the Securities and Exchange Commission nor any state securities
commission has approved or disapproved of these securities or passed upon the adequacy or accuracy of this prospectus. Any representation
to the contrary is a criminal offense.
Prospectus, dated March 30, 2018.
TABLE OF CONTENTS
SUMMARY
|
1
|
The Offering
|
6
|
RISK FACTORS
|
7
|
CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS
|
28
|
USE OF PROCEEDS
|
29
|
PRICE RANGE OF COMMON SHARES
|
30
|
DIVIDEND POLICY
|
31
|
CAPITALIZATION
|
32
|
MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATION
|
33
|
BUSINESS
|
43
|
MANAGEMENT
|
54
|
SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT
|
64
|
SELLING SHAREHOLDERS
|
65
|
CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS
|
69
|
DESCRIPTION OF SHARE CAPITAL
|
70
|
MATERIAL UNITED STATES FEDERAL INCOME TAX CONSIDERATIONS
|
73
|
CERTAIN CANADIAN INCOME TAX CONSIDERATIONS
|
82
|
PLAN OF DISTRIBUTION
|
84
|
LEGAL MATTERS
|
86
|
EXPERTS
|
86
|
WHERE YOU CAN FIND MORE INFORMATION
|
86
|
INDEX TO FINANCIAL STATEMENTS
|
F-1
|
Neither we nor the selling
shareholders have authorized any other person to provide you with different or additional information other than that contained
in this prospectus. We and the selling shareholders take no responsibility for, and can provide no assurance as to the reliability
of, any other information that others may provide. We and the selling shareholders are not making an offer to sell these securities
in any jurisdiction where the offer or sale is not permitted. The information contained in this prospectus is accurate only as
of the date of this prospectus or such other date stated in this prospectus, and our business, financial condition, results of
operations and/or prospects may have changed since those dates.
For investors outside the United States: We have not, and the selling
shareholders have not, taken any action that would permit this offering or possession or distribution of this prospectus in any
jurisdiction where action for that purpose is required, other than in the United States. Persons outside the United States who
come into possession of this prospectus must inform themselves about, and observe any restrictions relating to, the offering of
the securities covered hereby and the distribution of this prospectus outside the United States.
Unless otherwise indicated, information contained in this prospectus
concerning our industry and the markets in which we operate, including our general expectations and market position, market opportunity
and market share, is based on information from our own management estimates and research, as well as from industry and general
publications and research, surveys and studies conducted by third parties. Management estimates are derived from publicly available
information, our knowledge of our industry and assumptions based on such information and knowledge, which we believe to be reasonable.
Our management estimates have not been verified by any independent source, and we have not independently verified any third-party
information. In addition, assumptions and estimates of our and our industry’s future performance are necessarily subject
to a high degree of uncertainty and risk due to a variety of factors, including those described in “Risk Factors.”
These and other factors could cause our future performance to differ materially from our assumptions and estimates. See “Cautionary
Note Regarding Forward-Looking Statements”
We own or have rights to various trademarks, service marks and trade
names that we use in connection with the operation of our business. This prospectus may also contain trademarks, service marks
and trade names of third parties, which are the property of their respective owners. Our use or display of third parties’
trademarks, service marks, trade names or products in this prospectus is not intended to, and should not be read to, imply a relationship
with or endorsement or sponsorship of us. Solely for convenience, the trademarks, service marks and trade names referred to in
this prospectus may appear without the
®
, TM or SM symbols, but such references are not intended to indicate, in
any way, that we will not assert, to the fullest extent under applicable law, our rights or the right of the applicable licensor
to these trademarks, service marks and trade names.
Unless the context provides otherwise, references herein to “we,”
“our,” “us,” “our company” and “Zomedica” refer to Zomedica Pharmaceuticals Corp.
together with, where applicable, our consolidated subsidiary, Zomedica Pharmaceuticals Inc., a Delaware corporation.
Unless otherwise noted herein, all references to “CDN$,”
“CAD$,” or “Canadian dollars” are to the currency of Canada and “$,” “dollars,”
“US$,” “United States dollars,” or “U.S. dollars” are to the currency of the United States.
SUMMARY
This summary highlights
information contained in greater detail elsewhere in this prospectus. This summary is not complete and does not contain all of
the information you should consider in making your investment decision. You should read the entire prospectus carefully before
making an investment in our common shares. You should carefully consider, among other things, our consolidated financial statements
and the related notes and the sections entitled “Risk Factors” and “Management’s Discussion and Analysis
of Financial Condition and Results of Operations” included elsewhere in this prospectus.
Our Company
We are a development stage veterinary diagnostic and pharmaceutical company creating products for companion animals (canine,
feline, and equine) by focusing on the unmet needs of clinical veterinarians. We believe that we have identified and are developing
diagnostics and therapeutics that have the potential to significantly improve the diagnosis and treatment of various diseases
affecting companion animals. We believe that there are significant unmet medical needs for pets, and that the pet diagnostic
and therapeutic segments of the animal health industry are likely to grow substantially as new diagnostic tools and treatments
are identified, developed, and marketed specifically for companion animals.
Together with our strategic partner, we are developing liquid biopsy assays and related consumables for the detection of cancer
in companion animals. The regulatory pathway to obtain pre-market regulatory approval of companion animal diagnostics is significantly
shorter than for similar diagnostic products intended for human use. In certain cases, pre-market regulatory approval may
be unnecessary, depending on the intended use of the diagnostic.
We also have identified a number of drugs that have proven safe and effective in humans that we are developing for use in
companion animals. We believe this development approach enables us to reduce the risks associated with obtaining regulatory
approval for unproven product candidates and shortens the development timeline necessary to bring our product candidates to
market. We have four drug product candidates in early development and have identified several other potential product candidates
for further investigation.
In addition, we are investigating the development of alternative drug delivery technologies for our drug product candidates.
Many of the human-approved therapeutics used in companion animals are only available in pill or injectable form. However,
it can be difficult to give a companion animal an injection or to assure that the animal has swallowed a pill. As a result,
we believe that compliance with treatment regimens is a significant problem for veterinarians and pet owners. The challenges
associated with medicating pets are unique, and we believe that developing product candidates that can be easily taken by
the pet or easily administered by pet owners will help increase compliance.
Product Pipeline
Diagnostics
Together with our strategic partner, we are developing a circulating tumor cell, or CTC, assay, also known as a “liquid
biopsy,” for use by veterinarians as a cancer diagnostic. The liquid biopsy is a blood test that we believe has the
potential to detect the presence of CTCs, which are cells that have shed from a primary tumor into neighboring blood vessels
and are transported throughout the body’s circulatory system. Diagnosing certain cancers in canines is difficult because
the location of the tumor may make it difficult or risky to obtain cell material through a biopsy. In addition, the overall
health of a canine may increase the risk of performing a biopsy. Other diagnostic technologies, such as advanced imaging,
are expensive while others, such as histopathologic examination, may take several days or more to provide a definitive diagnosis.
We believe that the detection of CTCs in the blood could provide strong clinical support for a cancer diagnosis without the
need for an invasive tissue biopsy or other expensive or time-consuming diagnostic test. We intend to develop and market ZM-017,
a liquid biopsy for the detection of certain cancers in canines. If we successfully develop ZM-017, we expect that ZM-017
will provide veterinarians with a faster, more affordable, and less invasive test for certain cancers in canines compared
to existing detection methods.
We expect to commence clinical validation of ZM-017 in the first half of 2018. Assuming that we successfully complete that
clinical validation, we expect to commence the marketing of ZM-017 during the second half of 2018
Therapeutics
We have four drug product candidates. Our lead drug product candidate is ZM-012, a novel tablet formulation of metronidazole
targeting the treatment of acute diarrhea in dogs. An Investigational New Animal Drug, or INAD, was opened for ZM-012 with
the Food and Drug Administration’s Center for Veterinary Medicine, or FDA-CVM, in April 2016. The API in ZM-012 is metronidazole,
which has been the subject of multiple studies in humans and has been approved for use in humans for decades. We do not believe
that the API in ZM-012 is protected by any patents or other proprietary rights of third parties in the U.S. We have finalized
the formulation of ZM-012 as a beef-flavored oral tablet intended for dogs greater than nine pounds or four kilograms and
we completed pilot testing of ZM-012 in the fourth quarter of 2017. In December 2017, we had a pre-submission meeting with
the FDA-CVM to present the regulatory strategy and development plan for ZM-012. Based on the feedback we received from the
FDA-CVM, we are making certain changes to the development plan for ZM-012 which we believe will not delay its development.
We expect to commence a pivotal safety study of ZM-012 in the first half of 2018, which we expect to complete in the second
half of 2018.
Our second drug product candidate is ZM-007, an oral suspension formulation of metronidazole and a complementary formulation
to ZM-012, targeting the treatment of acute diarrhea in small dog breeds and puppies under nine pounds or four kilograms.
An INAD was opened for ZM-007 with the FDA-CVM in October 2016. We have finalized the formulation and completed pilot testing
of ZM-012. We expect to hold a pre-submission meeting in the first half of 2018 with the FDA-CVM specific to the product development
strategy for ZM-007 as a bioequivalent to ZM-012. Drugs that are considered to be bioequivalent are, for regulatory purposes,
essentially the same, meaning the absence of significant difference between the extent and rate of absorption over the course
of a specific period of time at the same dose and under the same conditions. If deemed acceptable by the FDA-CVM, the implementation
of this bioequivalent strategy is contingent on FDA-CVM approval of the new animal drug application (NADA) for ZM-012. If
the FDA-CVM permits us to rely on the bioequivalence of ZM-007 to ZM-012, we anticipate that this regulatory pathway will
conserve significant development costs because a bioequivalence study could replace the need for pivotal safety and efficacy
studies for ZM-007.
Our third drug product candidate is ZM-006, a transdermal gel formulation of methimazole targeting hyperthyroidism in cats.
Hyperthyroidism is one of the most commonly diagnosed endocrine disorders in middle-aged to older cats according to the American
Association of Feline Practitioners. We are investigating ZM-006 pursuant to an INAD opened with the FDA-CVM in June 2016.
The API in ZM-006, methimazole, has been the subject of multiple studies in humans and has been approved for oral use in humans
for decades. Our transdermal gel formulation is intended to provide an alternative to an oral tablet formulation already approved
by the FDA-CVM for cats. We do not believe that the API in ZM-006 is protected by any patents or other proprietary rights
of third parties. ZM-006 is intended for application to the cat’s ear using an applicator pen. The formulation of ZM-006
has been completed. We expect to complete pilot testing of ZM-006 in the first half of 2018, and assuming that such pilot
testing is successful, we intend to commence and complete a pivotal safety study of ZM-006 in the second half of 2018.
Our fourth drug product candidate is ZM-011, a transdermal gel formulation of fluoxetine, most commonly known as Prozac®,
its human pharmaceutical brand name. Fluoxetine in pill or compounded form is frequently prescribed by veterinarians to treat
feline behavioral disorders such as inappropriate urination. We are investigating ZM-011 pursuant to an INAD opened with the
FDA-CVM in January 2017. The API, fluoxetine, has been the subject of multiple studies in humans and has been approved for
use in humans for decades. We do not believe that the API in ZM-011 is protected by any patents or other proprietary rights
of third parties. ZM-011 is a transdermal gel formulation intended for application to the cat’s ear using an applicator
pen. The formulation of ZM-011 has been completed. We expect to complete pilot testing of ZM-011 in the second half of 2018.
Summary Risks Associated with Our Business
An investment in our common shares involves a high degree of risk. You should carefully
consider the risks summarized below. The risks are discussed more fully in the “Risk Factors” section of this prospectus
immediately following this prospectus summary. These risks include, but are not limited to, the following:
|
•
|
We have a limited operating history, are not profitable and may never become profitable;
|
|
|
|
|
•
|
We will need to raise additional capital to achieve
our goals;
|
|
•
|
Our net loss and comprehensive loss for the years ended December 31, 2017 and December 31, 2016 was $8,065,072 and $5,740,492,
respectively, and we had an accumulated deficit of $15,626,100 as of December 31, 2017;
|
|
•
|
We anticipate that each of our drug product candidates will require from three
to five years of development at a cost of approximately $3 million to $5 million per drug product candidate before we expect to
be able to apply for marketing approval in the United States;
|
|
•
|
We will have no product revenue for the foreseeable future;
|
|
•
|
We are substantially dependent on the success of our lead product candidates, and cannot be certain that
any of them will be approved for marketing to the extent applicable or successfully commercialized;
|
|
•
|
The commercial potential of our product candidates is difficult to predict. The market for any product candidate, or for companion
animal diagnostics and therapeutics overall, is uncertain and may be smaller than we anticipate, which could significantly
and negatively impact our revenue, results of operations and financial condition;
|
|
•
|
All of our drug product candidates are based on APIs already demonstrated safe and effective in humans, and other companies may develop substantially similar products that may compete with our products;
|
|
•
|
Our product candidates may face significant competition and may be unable to compete effectively;
|
|
|
|
|
•
|
Development of product candidates for use in companion
animal health is an inherently expensive, time-consuming and uncertain, and any delay or discontinuance of validation or pivotal
studies for our current or future product candidates would significantly harm our business and prospects;
|
|
|
|
|
•
|
We will rely on third parties to conduct certain of our development and manufacturing activities. If these third parties do
not successfully carry out their contractual duties or meet expected deadlines, we may be unable to obtain regulatory approval
for or commercialize our product candidates;
|
|
•
|
Some of our products may or may not be covered by a patent. Further if an application was filed, it is not certain that a
patent will be granted or if granted whether it will be held to be valid. All of which may impact our market share and ability
to prevent others (competitor third parties) from making, selling, or using our products;
|
|
•
|
Third parties may have intellectual property rights, which may require us to obtain a license or other applicable rights to
make, sell or use our products. If such rights are not granted or obtained, it could have a material adverse effect on our
business, financial condition and results of operations;
|
|
|
|
|
•
|
Our diagnostic assay technology depends on certain
technology that is licensed to us. We do not control this technology and any loss of our rights to them could prevent us from
marketing our diagnostic assay product candidates;
|
|
•
|
Our ability to develop, manufacture and commercialize
our drug product candidates is dependent on our establishing and maintaining relationships with Good Manufacturing Practices,
or GMP-compliant third party manufacturers;
|
|
•
|
The results of earlier studies may not be predictive of the results of our pivotal trials, and we may be unable to obtain
regulatory approval for our existing or future drug product candidates under applicable regulatory requirements or maintain
any regulatory approval obtained. The denial, delay or loss of any regulatory approval would prevent or delay our commercialization
efforts and adversely affect our financial condition and results of operations;
|
|
•
|
We believe that we will be a “passive foreign
investment company,” or PFIC for the current taxable year, which could subject certain U.S. shareholders to materially adverse
U.S. federal income tax consequences.
See “
Material United States Federal Income Tax
Considerations.”
|
Corporate Information
Zomedica Pharmaceuticals Corp. (formerly, Wise Oakwood Ventures Inc.)
was originally incorporated as Wise Oakwood Ventures Inc. on January 7, 2013 under the
Business Corporations Act
(Alberta),
or the ABCA. On October 28, 2013, Wise Oakwood Ventures Inc., or Wise Oakwood, completed its initial public offering in Canada
and became classified as a Capital Pool Company, as defined under the rules of the TSX Venture Exchange, or TSX-V. On April 21,
2016, we changed our name to Zomedica Pharmaceuticals Corp. and consolidated our common shares on a one-for-two and one-half basis.
ZoMedica Pharmaceuticals Inc., or ZoMedica Inc., was incorporated on May 14, 2015 under the
Canada Business Corporations Act
.
On April 21, 2016, we completed a qualifying transaction, or the Qualifying Transaction, under TSX-V Policy 2.4 –
Capital
Pool Companies
, consisting of a three-cornered amalgamation among our company, ZoMedica Inc. and our wholly-owned subsidiary.
Under the Qualifying Transaction, ZoMedica Inc. and our subsidiary were amalgamated to form Zomedica Pharmaceuticals Ltd., or Zomedica
Ltd. As consideration for the amalgamation, shareholders of ZoMedica Inc. became the owners of 97.6% (non-diluted) of our common
shares, and ZoMedica Ltd. became our wholly-owned subsidiary. Subsequent to the Qualifying Transaction, Zomedica Ltd. was vertically
amalgamated into our company. We have one wholly-owned subsidiary, Zomedica Pharmaceuticals Inc., a Delaware company. ZoMedica
Inc. entered into the Qualifying Transaction in order to accomplish the following:
|
•
|
Enable its shareholders to own shares in a company that was publicly traded on the TSX-V;
|
|
•
|
Expand its shareholder base to include the public shareholders of Wise Oakwood; and
|
|
•
|
Obtain access to the cash resources raised by Wise Oakwood in its initial public offering.
|
Our principal executive offices are located at 100 Phoenix Drive, Suite 190, Ann Arbor, MI 48108, and our telephone number
is (734) 369-2555. Our website address is www.zomedica.com. The information contained in, or accessible through, our website
is not part of the registration statement of which this prospectus forms a part.
Implications
of Being an Emerging Growth Company
As a
company with less than $1.07 billion in revenue during our last fiscal year, we qualify as an “emerging growth company”
as defined in the Jumpstart Our Business Startups Act, or JOBS Act, enacted in April 2012. An “emerging growth company”
may take advantage of reduced reporting requirements that are otherwise applicable to public companies. These provisions include,
but are not limited to:
|
•
|
not being required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act;
|
|
•
|
reduced disclosure obligations regarding executive compensation in our periodic reports, proxy statements and registration statements; and
|
|
•
|
exemptions from the requirements of holding a non-binding advisory vote on executive compensation and shareholder approval of any golden parachute payments not previously approved.
|
We may take advantage of these provisions until December 31, 2022.
However, if certain events occur prior to December 31, 2022, including if we become a “large accelerated filer,” our
annual gross revenues exceed $1.07 billion or we issue more than $1.0 billion of non-convertible debt in any three-year period,
we will cease to be an emerging growth company before such date.
In addition, the JOBS Act provides that
an emerging growth company may delay adopting new or revised accounting standards until such time as those standards apply to private
companies. We have irrevocably elected not to avail ourselves of this exemption and, therefore, we will be subject to the same
new or revised accounting standards as other public companies that are not emerging growth companies.
The
Offering
Common shares offered by the selling shareholders
|
|
77,255,205 common shares.
|
|
|
|
Common shares outstanding
|
|
90,225,869 common shares.
|
|
|
|
Use of proceeds
|
|
The selling shareholders will receive all of the proceeds from the sale or other disposition of the common shares covered by this prospectus. We will not receive any proceeds from such sales or dispositions. See “Use of Proceeds.”
|
|
|
|
Risk factors
|
|
Investing in our common shares involves a high degree of risk. See “Risk Factors” beginning
on page 7 of this prospectus for a discussion of factors you should consider before making a decision to invest in our securities.
|
|
|
|
Listing information
|
|
Our common shares are listed on the NYSE American and TSX-V under the symbol “ZOM”.
|
The
number of our common shares outstanding is based on 90,225,869 common shares outstanding as of December 31, 2017 and excludes as
of that date the following:
|
•
|
8,080,000 common shares issuable upon the exercise of outstanding options with a weighted average exercise price of $0.96
per share; and
|
|
•
|
942,586 common shares reserved for future issuance under our stock option plan. Our stock option plan provides that the maximum
number of shares reserved for issuance upon exercise of stock options is equal to 10% of our issued and outstanding common
shares.
|
Financial
statements and related financial information contained herein have been converted to US dollars as in effect at the relevant
time. See “Management’s Discussion and Analysis of Financial Condition and Results of Operations -- Critical
Accounting Policies and Significant Judgments and Estimates – Translation of Foreign Currencies.” Except as
otherwise set forth herein, other amounts contained herein have been converted to US dollars at an exchange rate of
CDN$1.2986 to US$1.00, the exchange rate as published by the Bank of Canada as of December 29, 2017.
RISK FACTORS
Investing in our common shares involves a high degree of risk.
You should consider carefully the risks and uncertainties described below, together with all of the other information in this prospectus,
including the consolidated financial statements and the related notes included elsewhere in this prospectus, before deciding whether
to invest in our common shares. The risks and uncertainties described below are not the only ones we face. Additional risks and
uncertainties that we are unaware of, or that we believe are not material, may also become important factors that adversely affect
our business. If any of the following risks actually occurs, our business, financial condition, results of operations, and future
prospects could be materially and adversely affected. In that event, the market price of our common shares could decline, and you
could lose part or all of your investment.
Risks Related to Our Business
We have a limited operating history, are not profitable and
may never become profitable.
We are a development stage veterinary diagnostic and pharmaceutical
company creating products for companion animals (canine, feline, and equine) by focusing on the unmet needs of clinical veterinarians.
Since the commencement of our business in May 2015, our operations have been primarily limited to the identification of product
candidates and research and development of our diagnostic and drug product candidates, ZM-017, a non-invasive diagnostic assay
or blood test for the detection of certain cancers in canines, ZM-012 and ZM-007, an anti-diarrheal in pill form and oral suspension
respectively that is intended for use in dogs, ZM-006, a transdermal gel treatment for hyperthyroidism, a metabolic disorder, which
is intended for use in cats and ZM-011, a transdermal gel treatment for behavioral disorders intended for use in cats. As a result,
we have limited historical operations upon which to evaluate our business and prospects and we have not yet demonstrated an ability
to obtain approval for any of our product candidates or successfully overcome the risks and uncertainties frequently encountered
by companies in emerging fields such as the companion animal pharmaceuticals and health care solutions industry.
We also have not generated any revenue to date, and we expect to
continue to incur significant research and development costs and other expenses. Our net loss and comprehensive loss for the years
ended December 31, 2017 and December 31, 2016 was $8,065,072 and $5,740,492, respectively. Our accumulated deficit as of December
31, 2017 was $15,626,100. As of December 31, 2017, we had total shareholders' equity of $4,387,085. We expect to continue to incur
losses for the foreseeable future, which will increase significantly from historical levels as we expand our product development
activities (including conducting required clinical studies and trials), seek necessary approvals for our product candidates, and
begin commercialization activities. Even if we succeed in developing and broadly commercializing one or more of our product candidates,
we expect to continue to incur losses for the foreseeable future, and we may never become profitable. If we fail to achieve or
maintain profitability, then we may be unable to continue our operations at planned levels and be forced to reduce or cease operations.
We will need to raise additional capital to achieve our goals.
We do not have any products approved for sale. Although we believe
we do not require pre-market approval from the U.S. Food and Drug Administration’s Center for Veterinary Medicine, or the
FDA-CVM, to market and sell ZM-017, the CTC diagnostic assay we are developing, we do not expect to commence marketing of ZM-017
until the second half of 2018.
Until, and unless, we receive approval from the FDA-CVM for our drug
product candidates, we cannot market or sell our drug products in the United States and will have no material drug product revenue.
Our lead drug product candidates, ZM-012, ZM-007, ZM-006 and ZM-011 are in the formulation, optimization and/or pilot study stage,
and we have not yet begun pivotal trials. We anticipate that each of our drug product candidates will require from three to five
years of development at a cost of approximately $3 million to $5 million per drug product candidate before we expect to be able
to apply for marketing approval in the United States.
We are also seeking to identify potential complementary opportunities
in the veterinary diagnostics and therapeutics sectors. We will continue to expend substantial resources for the foreseeable future
to develop our existing product candidates and any other product candidates we may develop or acquire. These expenditures will
include: costs of identifying additional potential product candidates; costs associated with drug formulation; costs associated
with conducting pilot and pivotal trials and clinical studies; costs associated with completing other research and development
activities; costs associated with payments to technology licensors and maintaining other intellectual property; costs of obtaining
regulatory approvals; costs associated with securing contract manufacturers to meet our commercial manufacturing and supply capabilities;
and costs associated with marketing and selling any of our products approved for sale. We also may incur unanticipated costs. Because
the outcome of our development activities and commercialization efforts is inherently uncertain, the actual amounts necessary to
successfully complete the development and commercialization of our existing or future product candidates may be greater or less
than we anticipate.
As a result, we will need to obtain additional capital to fund the
development of our business. Except for our $5,000,000 unsecured working capital loan facility, we have no existing agreements
or arrangements with respect to any financings, and any such financings may result in dilution to our shareholders, the imposition
of debt covenants and repayment obligations or other restrictions that may adversely affect our business or the value of our common
shares.
Our future capital requirements depend on many factors, including,
but not limited to:
|
•
|
the scope, progress, results and costs of researching and developing our existing or future diagnostics and product candidates;
|
|
•
|
the timing of, and the costs involved in, obtaining regulatory approvals for any of our existing or future diagnostics or product candidates;
|
|
•
|
the number and characteristics of the diagnostics and/or product candidates we pursue;
|
|
•
|
the cost of contract manufacturers to manufacture our existing and future diagnostics and product candidates and any products we successfully commercialize;
|
|
•
|
the cost of commercialization activities if any of our existing or future diagnostics and product candidates are approved for sale, including marketing, sales and distribution costs;
|
|
•
|
the expenses needed to attract and retain skilled personnel;
|
|
•
|
the costs associated with being a public company;
|
|
•
|
our ability to establish and maintain strategic collaborations, licensing or other arrangements and the financial terms of such agreements; and
|
|
•
|
the costs involved in preparing and filing patent applications, maintaining any successfully obtained patents and protecting and enforcing any such patents.
|
Additional funds may not be available when we need them on terms
that are acceptable to us, or at all. If adequate funds are not available to us on a timely basis, we may be required to delay,
limit, reduce or terminate one or more of our product development programs or any future commercialization efforts.
We are substantially dependent on the success of our lead product
candidates, and cannot be certain that any of them will be approved for marketing, to the extent applicable, or successfully commercialized.
We have no products approved for sale in any jurisdiction and are
focused primarily on the development of our lead diagnostic and drug product candidates, ZM-017, ZM-012, ZM-007, ZM-006 and ZM-011.
Accordingly, our near-term prospects, including our ability to generate material product revenue, or enter into potential strategic
transactions, will depend heavily on the successful development and commercialization of one or more of our lead candidates, which
in turn will depend on a number of factors, including the following:
|
•
|
the successful completion of clinical validation of our diagnostic product candidate which may take significantly longer than we anticipate and will depend, in part, upon the satisfactory performance of third-party contractors;
|
|
•
|
the successful completion of pilot testing and pivotal efficacy and safety trials of one or more of our drug product candidates, which may take significantly longer than we anticipate and will depend, in part, upon the satisfactory performance of third-party contractors;
|
|
•
|
our ability to demonstrate to the satisfaction of the FDA-CVM or the USDA Center for Veterinary Biologics, or USDA-CVB, as applicable, the safety and efficacy of our drug product candidates and to obtain regulatory approvals;
|
|
•
|
the ability of our third-party contract manufacturers to manufacture supplies of any of our product candidates and to develop, validate and maintain viable commercial manufacturing processes that are compliant with Good Manufacturing Practices or GMP;
|
|
•
|
our ability to successfully market any product candidate for which marketing approval is received, whether alone or in collaboration with others;
|
|
•
|
the availability, perceived advantages, relative cost, relative safety and relative efficacy of our product candidates compared to alternative and competing treatments;
|
|
•
|
the acceptance of our product candidates as safe and effective by veterinarians, pet owners and the animal health community;
|
|
•
|
our ability to achieve and maintain compliance with all regulatory requirements applicable to our business; and
|
|
•
|
our ability to obtain and enforce our intellectual property rights and obtain marketing exclusivity for our product candidates, and avoid or prevail in any third-party patent interference, patent infringement claims or administrative patent proceedings initiated by third parties or the United States Patent and Trademark Office (“USPTO”).
|
Many of these factors are beyond our control. Accordingly, we cannot
assure you that we will be successful in developing or commercializing any of our product candidates. If we are unsuccessful or
are significantly delayed in developing and commercializing ZM-017, ZM-012, ZM-007, ZM-006 or ZM-011 or any of our other product
candidates, our business and prospects will be materially adversely affected and you may lose all or a portion of your investment.
We face unproven markets for our products candidates.
The companion animal therapeutic and diagnostic markets are less
developed than the human therapeutic and diagnostic markets and as a result no assurance can be given that our product candidates
will be successful. Veterinarians, pet owners or other veterinary health providers in general may not accept or utilize any products
that we may develop.
The companion animal care industry is subject to rapidly changing
technology, which could make our product candidates obsolete.
The companion animal care industry is characterized by rapid technological
changes, frequent new product introductions and enhancements, and evolving industry standards, all of which could make our product
candidates obsolete. Our future success will depend on our ability to keep pace with the evolving needs of our customers on a timely
and cost-effective basis and to pursue new market opportunities that develop as a result of technological and scientific advances.
We must continuously enhance our product offerings to keep pace with evolving standards of care. If we do not update our product
offerings to reflect new scientific knowledge or new standards of care, our product candidates could become obsolete, which would
have a material adverse effect on our business, financial condition, and results of operations.
Our ability to successfully develop and commercialize our existing
and any future product candidates will depend on several factors, including:
|
•
|
our ability to convince the veterinary community of the clinical utility of our products and their potential advantages over existing tests and therapies;
|
|
•
|
the willingness or ability by pet owners to pay for our products and the willingness of veterinarians to recommend our products;
|
|
•
|
the willingness of veterinarians to utilize our diagnostic tests; and
|
|
•
|
where applicable, the willingness of testing labs to buy our assay equipment.
|
Our dependence on suppliers could limit our ability to develop
and commercialize certain products
We rely on third-party suppliers to provide components in our product
candidates, manufacture products that we do not manufacture ourselves and perform services that we do not provide ourselves. Because
these suppliers are independent third parties with their own financial objectives, actions taken by them could have a materially
negative effect on our results of operations. The risks of relying on suppliers include our inability to enter into contracts with
third-party suppliers on reasonable terms, inconsistent or inadequate quality control, relocation of supplier facilities, supplier
work stoppages and suppliers’ failure to comply with applicable regulations or their contractual obligations. Problems with
suppliers could materially negatively impact our ability to complete development, supply the market, lead to higher costs or damage
our reputation with our customers.
In addition, we currently purchase many products and materials from
sole or single sources. Some of the products that we purchase from these sources are proprietary and, therefore, cannot be readily
or easily replaced by alternative sources. To mitigate risks associated with sole and single source suppliers, we will seek when
possible to enter into long-term contracts that provide for an uninterrupted supply of products at predictable prices. However,
some suppliers may decline to enter into long-term contracts and we are required to purchase products with short term contracts
or on a purchase order basis. There can be no assurance that suppliers with which we do not have contracts will continue to supply
our requirements for products, that suppliers with which we do have contracts will always fulfill their obligations under these
contracts, or that any of our suppliers will not experience disruptions in their ability to supply our requirements for products.
In cases where we purchase sole and single source products or components under purchase orders, we are more susceptible to unanticipated
cost increases or changes in other terms of supply. In addition, under some contracts with suppliers we have minimum purchase obligations,
and our failure to satisfy those obligations may result in loss of some or all of our rights under these contracts or require us
to compensate the supplier. If we are unable to obtain adequate quantities of products in the future from sole and single source
suppliers, we may be unable to supply the market, which could have a material adverse effect on our results of operations.
The commercial potential of our product candidates is difficult
to predict. The market for any product candidate, or for companion animal diagnostics and therapeutics overall, is uncertain and
may be smaller than we anticipate, which could significantly and negatively impact our revenue, results of operations and financial
condition.
We believe that the emerging nature of our industry and our unproven
business plan make it difficult to estimate the commercial potential of any of our product candidates. The market for any product
that we seek to commercialize will depend on important factors such as the cost, utility and ease of use of our diagnostic assays,
the safety and efficacy of our drug candidates compared to other available treatments, including potentially less expensive human
pharmaceutical alternatives with similar efficacy profiles, changing standards of care, preferences of veterinarians, the willingness
of pet owners to pay for such products, and the availability of competitive alternatives that may emerge either during the product
development process or after commercial introduction. If the market potential for our product candidates is less than we anticipate
due to one or more of these factors, it could negatively impact our business, financial condition and results of operations. Further,
the willingness of pet owners to pay for our product candidates, if approved, may be less than we anticipate, and may be negatively
affected by overall economic conditions. Because relatively few pet owners purchase insurance for their companion animals, pet
owners are more likely to have to pay for our products directly and may be unwilling or unable to pay for any such products.
All of our drug product candidates are based on APIs already
demonstrated safe and effective in humans, and other companies may develop substantially similar products that may compete with
our products.
Our lead drug product candidates, ZM-012, ZM-007, ZM-006 and ZM-011
include APIs already demonstrated safe and effective in humans and we expect that our future drug product candidates will be similarly
based on such APIs. We do not engage in research or discovery of novel therapeutics, but focus on drug product candidates with
APIs that have been successfully commercialized or demonstrated to be safe and effective in humans, which we sometimes refer to
as validated. We expect that there will be little, if any, third-party patent protection of the APIs in our drug product candidates.
As a result, our drug product candidates may face competition from their human equivalents in situations where such equivalents
are available and used in unapproved animal indications, which is known as off-label use. There is no assurance that the eventual
prices of our drug products will be lower than or competitive with the prices of the human equivalents used off-label, or that
a palatable, easy-to-administer formulation will be sufficient to differentiate them from their human equivalents.
Our product candidates will face significant competition and
may be unable to compete effectively.
The development and commercialization of veterinary diagnostics and
pharmaceuticals is highly competitive and our success depends on our ability to compete effectively with other products in the
market.
There are a number of competitors in the diagnostic market that have
substantially greater financial and operational resources and established marketing, sales and service organizations. We expect
to compete primarily with commercial clinical laboratories and hospitals’ clinical laboratories. Our principal competitors
in the veterinary diagnostic market are Idexx Laboratories, Inc., Antech Diagnostics, a unit of VCA Inc., Abaxis, Inc., Heska Corporation
and Zoetis Inc. We must develop our distribution channels and build our direct sales force in order to compete effectively in these
markets. If we are unable to effectively manage our distribution channels in our highly competitive industry, we may fail to retain
customers or obtain new customers and our business will suffer.
If our drug product candidates are approved, we expect to compete
with large animal health companies including Merck Animal Health, the animal health division of Merck & Co., Inc.; Elanco,
the animal health division of Eli Lilly and Company; Bayer Animal Health, the animal health division of Bayer AG; Novartis Animal
Health, the animal health division of Novartis AG; Boehringer Ingelheim Animal Health, the animal health division of Boehringer
Ingelheim GmbH; and Zoetis, Inc., as well as European companies such as Virbac S.A., Vetoquinol S.A., and Dechra Pharmaceuticals
PLC We are also aware of several smaller early stage companies that are developing products for use in the pet therapeutics market,
including Kindred Biosciences, Inc., Aratana Therapeutics, Inc., Parnell Pharmaceuticals Holdings Ltd., and Jaguar Animal Health,
Inc. We also expect to compete with academic institutions, governmental agencies and private organizations that are conducting
research in the field of animal health medicines.
We target drug product candidates for which the API, while having
been approved for use in human drugs, has not been previously approved for use in animals. If we are the first to gain approval
for the use of such API in animals, our drug products will enjoy between three and seven years of marketing exclusivity in the
United States for the approved indication. We also plan to differentiate our products where possible with alternative drug delivery
systems that are more conducive to dosing for the target companion animal species, but we cannot assure you that we will be able
to prevent our competitors from developing substantially similar products and bringing those products to market earlier than we
are able to.
Our drug product candidates will face competition from various products
approved for use in humans that are used off-label in animals, and all of our products will face potential competition from new
products in development. These and other potential competing products may benefit from greater brand recognition and brand loyalty
than our drug product candidates may achieve.
Many of our competitors and potential competitors have substantially
more financial, technical and human resources than we do. Many also have far more experience than we have in the development, manufacture,
regulation and worldwide commercialization of animal health medicines, including pet therapeutics. We also expect to compete with
academic institutions, governmental agencies and private organizations that are conducting research in the fields of animal diagnostics
and animal health. If such competing products are commercialized prior to our product candidates, or if our intellectual property
protection and efforts to obtain regulatory exclusivity fail to provide us with exclusive marketing rights for some of our therapeutic
products, we may be unable to compete effectively in the markets in which we participate.
Our ability to develop, manufacture and commercialize our drug
product candidates is dependent on our establishing and maintaining relationships with GMP-compliant third party manufacturers
.
We have no internal manufacturing capabilities and we do not plan
to develop such capabilities. As a result, our ability to manufacture and commercialize our product candidates is substantially
dependent on our ability to ensure a dependable and high quality supply of the APIs required for our pilot studies and pivotal
trials and for future commercial manufacturing. We currently believe that, because the APIs used in our drug product candidates
have been used in human drugs, there are multiple GMP-compliant manufacturers available that will be able to supply these APIs
and that the contract manufacturers we currently use for our trial supplies will be able to provide commercial supplies of any
of our drug product candidates. While we have historically been able to obtain the necessary supplies of our APIs for our development
work, we cannot be certain that either we or our contract manufacturers will continue to be able to provide the necessary API supply.
Neither we nor our contract manufacturers have long-term supply contracts with API manufacturers and we have no agreements in place
for the commercial-scale supply of any API or the manufacture of any of our drug product candidates. If we are unable to procure
the requisite apply of an API or to contract with a GMP-complaint third-party manufacturer, we may be unable to continue to develop,
manufacture or commercialize any of our product candidates and our business may fail to grow or develop.
The results of earlier studies may not be predictive of the
results of our pivotal trials, and we may be unable to obtain regulatory approval for our existing or future drug product candidates
under applicable regulatory requirements or maintain any regulatory approval obtained. The denial, delay or loss of any regulatory
approval would prevent or delay our commercialization efforts and adversely affect our financial condition and results of operations.
The research, testing, manufacturing, labeling, approval, sale, marketing
and distribution of our product candidates are subject to extensive regulation. We will not be permitted to market our drug product
candidates in the United States until we receive approval of a New Animal Drug Application, or NADA, from the FDA-CVM and may not
be able to market and sell any point-of-care diagnostic products without pre-marketing approval from the USDA-CVB. To gain approval
to market a pet pharmaceutical or point-of-care diagnostic product kit for a particular species, we must provide the FDA-CVM or
the USDA-CVB, as applicable, with efficacy data from pivotal trials that adequately demonstrate that our product candidates are
safe and effective in the target species for the intended indications. In addition, we must provide manufacturing data. For the
FDA-CVM, we must provide data from safety testing and clinical data, also called target animal safety studies. Similarly, for the
USDA-CVB, we must provide the results of specific tests required to be conducted in accordance with the USDA-CVB’s guidelines
demonstrating the sensitivity/specificity, reproducibility/repeatability/suitability and the ruggedness or robustness of the relevant
diagnostic kit. Either of the FDA-CVM or the USDA-CVB may also require us to conduct costly post-approval testing and/or collect
post-approval safety data to maintain our approval for any product candidate or diagnostic. The results of our pivotal studies
and other initial development activities, and the results of any previous studies in humans or animals conducted by us or third
parties, may not be predictive of future results of pivotal trials or other future studies, and failure can occur at any time during
or after pivotal studies and other development activities by us or our contract research organizations or CROs. Our pivotal studies
may fail to show the desired safety or efficacy of our product candidates despite promising initial data or the results in previous
human or animal studies conducted by others, and the success of a product candidate in prior animal studies, or in the treatment
of human beings, does not ensure success in subsequent studies. Clinical trials in humans and pivotal trials in animals sometimes
fail to show a benefit even for drugs that are effective, because of statistical limitations in the design of the trials or other
statistical anomalies. Therefore, even if our studies and other development activities are completed as planned, the results may
not be sufficient to obtain regulatory approval for our product candidates.
The FDA-CVM or the USDA-CVB can delay, limit, deny or revoke approval
of any of our product candidates for many reasons, including:
|
•
|
if the FDA-CVM or USDA-CVB disagrees with our interpretation of data from our pivotal studies or other development efforts;
|
|
•
|
if we are unable to demonstrate to the satisfaction of the FDA-CVM or the USDA-CVB that the product candidate is safe and effective for the target indication;
|
|
•
|
if the FDA-CVM or USDA-CVB requires additional studies or changes its approval policies or regulations;
|
|
•
|
if the FDA-CVM or USDA-CVB does not approve of the formulation, labeling or the specifications of our existing and future product candidates;
|
|
•
|
if the FDA-CVM or USDA-CVB fails to approve the manufacturing processes of our third-party contract manufacturers; and
|
|
•
|
if any approved product candidate subsequently fails post-approval testing required by the FDA-CVM or the USDA-CVB.
|
Further, even if we receive approval of our product candidates, such
approval may be for a more limited indication than we originally requested, the FDA-CVM or USDA-CVB may not approve the labeling
that we believe is necessary or desirable for the successful commercialization of our product candidates and we may be required
to conduct costly post-approval testing. Any delay or failure in obtaining applicable regulatory approval for the intended indications
of our product candidates would delay or prevent commercialization of such product candidates and would materially adversely impact
our business and prospects.
Development of product candidates for use in companion animal
health is an inherently expensive, time-consuming and uncertain, and any delay or discontinuance of validation or pivotal studies
for our current or future product candidates would significantly harm our business and prospects
.
Development of product candidates for use in companion animals is
an inherently lengthy, expensive and uncertain process, and there is no assurance that our development activities will be successful.
We do not know whether the validation study of ZM-017 or the pivotal studies of ZM-012, ZM-007, ZM-006 or ZM-011, or of any of
our other product candidates, will begin or conclude on time, and they may be delayed or discontinued for a variety of reasons,
including if we are unable to:
|
•
|
address any safety concerns that arise during the course of the studies;
|
|
•
|
complete the studies due to deviations from the study protocols, the occurrence of adverse events or, in the case of our validation studies, sensitivity and selectivity results that vary from our expectations;
|
|
•
|
address any conflicts with new or existing laws or regulations; or
|
|
•
|
reach agreement on acceptable terms with study sites, which can be subject to extensive negotiation and may vary significantly among different sites.
|
Any delays in completing our development efforts will increase our
costs, delay our product candidate development and any regulatory approval process and jeopardize our ability to commence product
sales and generate revenue. Any of these occurrences may significantly harm our business, financial condition and prospects. In
addition, factors that may cause a delay in the commencement or completion of our development efforts may also ultimately lead
to the denial of regulatory approval of our product candidates which, as described above, would materially, adversely impact our
business and prospects.
We will rely on third parties to conduct certain of our development
activities. If these third parties do not successfully carry out their contractual duties or meet expected deadlines, we may be
unable to obtain regulatory approval for or commercialize our product candidates.
We have used CROs to conduct our research and development activities
and expect to continue to do so, including with respect to our clinical validation, pilot studies and pivotal trials of ZM-017,
ZM-012, ZM-007, ZM-006 and ZM-011. These CROs are not our employees, and except for contractual duties and obligations, we have
limited ability to control the amount or timing of resources that they devote to our programs or manage the risks associated with
their activities on our behalf. We are responsible to regulatory authorities for ensuring that each of our studies is conducted
in accordance with the development plans and trial protocols, and any failure by our CROs to do so may adversely affect our ability
to obtain regulatory approvals, subject us to penalties, or harm our credibility with regulators. The FDA-CVM also requires us
and our CROs to comply with regulations and standards, commonly referred to as good clinical practices, or GCPs, and good laboratory
practices, or GLPs, for conducting, monitoring, recording and reporting the results of our studies to ensure that the data and
results are scientifically credible and accurate.
Our agreements with our CROs may allow termination by the CROs in
certain circumstances with little or no advance notice to us. These agreements generally will require our CROs to reasonably cooperate
with us at our expense for an orderly winding down of the CROs’ services under the agreements. If the CROs conducting our
studies do not comply with their contractual duties or obligations to us, or if they experience work stoppages, do not meet expected
deadlines, terminate their agreements with us or need to be replaced, or if the quality or accuracy of the data they obtain is
compromised due to the failure to adhere to our development protocols or GCPs or for any other reason, we may need to secure new
arrangements with alternative CROs, which could be difficult and costly. In such event, our studies also may need to be extended,
delayed or terminated as a result, or may need to be repeated. If any of the foregoing were to occur, regulatory approval and commercialization
of our product candidates may be delayed and we may be required to expend substantial additional resources.
The failure of any CRO to perform adequately or the termination of
any arrangements with any of them may adversely affect our business.
We rely on third-party manufacturers to produce our product
candidates. If we experience problems with any of these suppliers, the manufacturing of our product candidates or products could
be delayed.
We do not have the capability to manufacture our product candidates
and do not intend to develop that capability. As a result, we rely on CMOs to produce our product candidates. We expect to enter
into contracts with CMOs for the commercial scale production of the products we intend to commercialize. Reliance on CMOs involves
risks, including:
|
•
|
the inability to meet our product specifications and quality requirements consistently;
|
|
•
|
inability to access production facilities on a timely basis;
|
|
•
|
inability or delay in increasing manufacturing capacity;
|
|
•
|
manufacturing and product quality issues related to the scale-up of manufacturing;
|
|
•
|
costs and validation of new equipment and facilities required for commercial level activity;
|
|
•
|
a failure to satisfy any applicable FDA-CVM cGMP requirements on a consistent basis;
|
|
•
|
the inability to negotiate manufacturing agreements with third parties under commercially reasonable terms;
|
|
•
|
termination or nonrenewal of manufacturing agreements with third parties in a manner or at a time that is costly or damaging to us;
|
|
•
|
the reliance on a single sources of supply which, if unavailable, would delay our ability to complete the development and testing and commercialization of our products;
|
|
•
|
the lack of qualified backup suppliers for supplies that are currently purchased from a single source supplier;
|
|
•
|
operations of our CMOs or suppliers could be disrupted by conditions unrelated to our business or operations, including the bankruptcy of the CMO or supplier;
|
|
•
|
carrier disruptions or increased costs that are beyond our control; and
|
|
•
|
the failure to deliver products under specified storage conditions and in a timely manner.
|
Any of these risks could cause the delay of validation studies, clinical
trials, regulatory submissions, the receipt of any required approvals or the commercialization of our products, cause us to incur
higher costs and prevent us from commercializing our product candidates successfully. Manufacturing of our product candidates and
any approved products subject to cGMP could be disrupted or halted if our CMOs do not comply with cGMP, even if the compliance
failure does not relate to our product candidates or approved products. Furthermore, if our CMOs fail to deliver the required commercial
quantities of finished product on a timely basis and at commercially reasonable prices and we are unable to find one or more replacement
manufacturers capable of production at a substantially equivalent cost, in substantially equivalent volumes and quality and on
a timely basis, we would likely be unable to meet demand for our products and could lose potential revenue. It may take several
years to establish an alternative source of supply for our product candidates and to have any such new source approved by the FDA-CVM
in the event that such approval is required.
Even if our product candidates obtain regulatory approval,
they may never achieve market acceptance or commercial success.
Even if we obtain FDA-CVM, USDA-CVB or other regulatory approvals,
our product candidates may not achieve market acceptance among veterinarians and pet owners, and may not be commercially successful.
Market acceptance of any of our product candidates for which we receive approval depends on a number of factors, including:
|
•
|
the safety of our products as demonstrated in our target animal studies;
|
|
•
|
the indications for which our products are approved;
|
|
•
|
the acceptance by veterinarians and pet owners of the product as a safe and effective treatment;
|
|
•
|
the proper training and administration or use of our products by veterinarians;
|
|
•
|
the potential and perceived advantages of our product candidates over alternative treatments or diagnostics, including products approved for use by humans that are used off label;
|
|
•
|
the cost of treatment in relation to alternative treatments and willingness to pay for our products, if approved, on the part of veterinarians and pet owners;
|
|
•
|
the willingness of pet owners to pay for our treatments, relative to other discretionary items, especially during economically challenging times;
|
|
•
|
the relative convenience and ease of administration;
|
|
•
|
the prevalence and severity of adverse side effects; and
|
|
•
|
the effectiveness of our sales and marketing efforts.
|
If our approved products fail to achieve market acceptance or commercial
success, our business could fail and you could lose your entire investment.
Pharmaceuticals for companion animals, like human pharmaceuticals,
are subject to unanticipated post-approval safety or efficacy concerns, which may harm our business and reputation.
The success of our commercialization efforts
will depend upon the perceived safety and effectiveness of pharmaceuticals for companion animals, in general, and of our products,
in particular. Unanticipated safety or efficacy concerns can arise with respect to approved therapeutics after they enter into
commerce, which may result in product recalls or withdrawals or suspension of sales, as well as product liability and other claims.
It is also possible that the occurrence of significant adverse side effects in approved human compounds upon which our drug product
candidates are based could impact our products. Any safety or efficacy concerns, or recalls, withdrawals or suspensions of sales
of our products or other pet therapeutics, or of their human equivalents, could harm our reputation, in particular, or pet therapeutics,
generally, and materially, adversely affect our business and prospects or the potential growth of the pet therapeutics industry,
regardless of whether such concerns or actions are justified.
Changes in the distribution channels
for companion animal products could negatively impact our market share, margins and distribution of our products.
In most markets, pet owners typically purchase
their animal health products directly from veterinarians. In recent years, pet owners have increasingly been afforded the option
to purchase animal health products from sources other than veterinarians, such as Internet-based retailers, “big-box”
retail stores or other over-the-counter distribution channels. Pet owners also could decrease their reliance on, and visits to,
veterinarians as they rely more on Internet-based animal health information. Since we intend to market our products through the
veterinarian distribution channel, any decrease in visits to veterinarians by pet owners could reduce our market share for such
products and materially adversely affect our operating results and financial condition. In addition, pet owners may substitute
human health products for animal health products if human health products are deemed to be lower-cost alternatives.
We do not currently carry liability insurance; however, as
we continue our development and commercialization activities, future federal and state legislation may result in increased exposure
to product liability claims, which could result in substantial losses to us.
We do not currently carry any product liability insurance. Under
existing federal and state laws, companion animals are generally considered to be the personal property of their owners and, as
such, pet owners’ recovery for product liability claims involving their companion animals may be limited to the replacement
value of the animals. Pet owners and their advocates, however, have filed lawsuits from time to time seeking non-economic damages
such as pain and suffering and emotional distress for harm to their companion animals based on theories applicable to personal
injuries to humans. If new legislation is passed to allow recovery for such non-economic damages, or if precedents are set allowing
for such recovery, we could be exposed to increased product liability claims that could result in substantial losses to us if successful.
We do not currently have product liability insurance and we may not be able to obtain or maintain this type of insurance in the
future.
If we are unable to establish sales capabilities on our own
or through third parties, we may not be able to market and sell our existing or future product candidates, if approved, or generate
product revenue.
We do not currently have a sales organization. We intend to commercialize
any product candidate for which we received regulatory approval in the United States with a direct sales force and through third-party
distributors. To achieve this, we will be required to build a direct sales organization and to establish relationships with distributors
of veterinary products. We also will have to build our marketing, sales, managerial and other non-technical capabilities and make
arrangements with third parties for distribution and to perform certain of these other services, and we may not be successful in
doing so. Building an internal sales organization is time consuming and expensive and will significantly increase our compensation
expense. We may be unable to secure third-party distribution contracts with distributors on favorable terms or at all. We have
no prior experience in the marketing, sale and distribution of pharmaceuticals or diagnostic products for companion animals and
there are significant risks involved in building and managing a sales organization, including our ability to hire, retain and motivate
qualified individuals, generate sufficient sales leads, provide adequate training to sales and marketing personnel, and effectively
oversee a geographically dispersed sales and marketing team. If we are unable to build an effective sales organization and/or if
we are unable to secure relationships with third-party distributors for our product candidates, we will not be able to successfully
commercialize any product for which we receive marketing approval, our future product revenue will suffer and we would incur significant
additional losses.
In jurisdictions outside of the United States we intend to utilize
companies with an established commercial presence to market our products in those jurisdictions, but we may be unable to enter
into such arrangements on acceptable terms, it at all.
If we fail to attract and keep senior management and key scientific
personnel, we may be unable to successfully develop any of our existing or future product candidates, conduct our in-licensing
and development efforts and commercialize any of our existing or future drug candidates.
Our success depends in part on our continued ability to attract,
retain and motivate highly qualified management and scientific personnel. We are highly dependent upon our senior management, particularly
Gerald Solensky, Jr., our President and Chief Executive Officer, Bruk Herbst, our Chief Commercial Officer, Stephanie Morley, DVM,
our Chief Operations Officer and Vice President of Product Development, and Shameze Rampertab, CPA, CA, our Chief Financial Officer.
The loss of services of any of these individuals could delay or prevent the successful development of our existing or future product
pipeline, completion of our planned development efforts or the commercialization of our product candidates. Although we have entered
into employment agreements with Dr. Morley and Mr. Herbst for one year terms (automatically extending for one year terms thereafter)
there can be no assurance that either of Dr. Morley or Mr. Herbst will extend their terms of service. We have also entered into
employment agreements with Mr. Solensky and Mr. Rampertab, each without a fixed term of service.
Consolidation of our customers could negatively affect the
pricing of our products.
Veterinarians will be our primary customers for any approved products.
In recent years, there has been a trend towards the consolidation of veterinary clinics and animal hospitals. If this trend continues,
these large clinics and hospitals could attempt to leverage their buying power to obtain favorable pricing from us and other companion
animal pharmaceutical and diagnostic products companies. Any resulting downward pressure on the prices of any of our approved products
could have a material adverse effect on our results of operations and financial condition.
We will need to increase the size of our organization and may
not successfully manage our growth.
We will need to significantly expand our organization and systems
to support our future expected growth. If we fail to manage our growth effectively, we will not be successful and our business
could fail.
Our research and development relies on testing in animals,
which is controversial and may become subject to bans or additional regulations.
We must test our product candidates in target animals to obtain marketing
approval. Although our animal testing will be subject to GLP and GCP requirements, as applicable, animal testing in the human pharmaceutical
industry and in other industries has been the subject of controversy and adverse publicity. Some organizations and individuals
have sought to ban animal testing or encourage the adoption of additional regulations applicable to animal testing. To the extent
that such bans or regulations are imposed, our research and development activities, and by extension our operating results and
financial condition, could be materially adversely affected. In addition, negative publicity about animal practices by us or in
our industry could harm our reputation among potential customers for our products.
Because our directors may serve as directors or officers of
other companies, they may have a conflict of interest in making decisions for our business.
Our directors may serve as directors or officers of other companies
or have significant shareholdings in other veterinary pharmaceutical or diagnostic products companies and, to the extent that such
other companies may participate in ventures in which we may participate, our directors may have a conflict of interest in negotiating
and concluding terms respecting the extent of such participation. In the event that such a conflict of interest arises at a meeting
of our directors, we expect that the director who has such a conflict will declare his conflict, abstain from voting for or against
the approval of such participation or such terms and, if deemed necessary or advisable, recuse himself from any discussion concerning
the matters in question. In some circumstances, a director may be unable to manage such conflicts and may therefore need to resign.
Our directors are required to act honestly, in good faith and in our best interests. In determining whether or not we will participate
in a particular business opportunity or enter into a particular business arrangement, we expect that the directors and officers
will be guided by their fiduciary duties and take into account such matters as they deem relevant, including considering the degree
of risk to which we may be exposed and our financial position at that time.
We may seek to raise additional funds in the future through
debt financing which may impose operational restrictions on our business and may result in dilution to existing or future holders
of our common shares.
We expect that we will need to raise additional capital in the future
to help fund our business operations. Debt financing, if available, may require restrictive covenants, which may limit our
operating flexibility and may restrict or prohibit us from:
|
•
|
paying dividends and/or making certain distributions, investments and other restricted payments;
|
|
•
|
incurring additional indebtedness or issuing certain preferred shares;
|
|
•
|
selling some or all of our assets;
|
|
•
|
entering into transactions with affiliates;
|
|
•
|
creating certain liens or encumbrances;
|
|
•
|
merging, consolidating, selling or otherwise disposing of all or substantially all of our assets; and
|
|
•
|
designating our subsidiaries as unrestricted subsidiaries.
|
Debt financing may also involve debt instruments that are convertible
into or exercisable for our common shares. The conversion of the debt to equity financing may dilute the equity position
of our existing shareholders.
We may not be able to obtain or maintain sufficient insurance
on commercially reasonable terms or with adequate coverage against potential liabilities in order to protect ourselves against
product liability claims.
Our business exposes us to potential product liability risks that
are inherent in the testing, manufacturing and marketing of veterinary therapeutic and diagnostic products. We may become subject
to product liability claims resulting from the use of our product candidates. We do not currently have product liability insurance
and we may not be able to obtain or maintain this type of insurance for any future trials or product candidates. In addition, product
liability insurance is becoming increasingly expensive. Being unable to obtain or maintain product liability insurance in the future
on acceptable terms or with adequate coverage against potential liabilities could have a material adverse effect on our business.
We may acquire other businesses or form joint ventures that
may be unsuccessful and could adversely dilute your ownership of our company.
As part of our business strategy, we may pursue in-licenses or acquisitions
of other complementary assets and businesses and may also pursue strategic alliances. We have no experience in acquiring other
assets or businesses and have limited experience in forming such alliances. We may not be able to successfully integrate any acquisitions
into our existing business, and we could assume unknown or contingent liabilities or become subject to possible stockholder claims
in connection with any related-party or third-party acquisitions or other transactions. We also could experience adverse effects
on our reported results of operations from acquisition-related charges, amortization of acquired technology and other intangibles
and impairment charges relating to write-offs of goodwill and other intangible assets from time to time following an acquisition.
Integration of an acquired company requires management resources that otherwise would be available for ongoing development of our
existing business. We may not realize the anticipated benefits of any acquisition, technology license or strategic alliance.
To finance future acquisitions, we may choose to issue shares of
our common stock as consideration, which would dilute your ownership interest in us. Alternatively, it may be necessary for us
to raise additional funds through public or private financings. Additional funds may not be available on terms that are favorable
to us and, in the case of equity financings, may result in dilution to our stockholders.
Risks Related to Government Regulation
Various government regulations could limit or delay our ability
to develop and commercialize our products or otherwise negatively impact our business
In the U.S., the manufacture and sale of certain of our diagnostic
product candidates are regulated by agencies such as the USDA, the FDA or the EPA. While our diagnostic test for canine cancer
does not require approval by the USDA prior to sale in the U.S., our diagnostic test will be subject to post-marketing oversight
by the FDA-CVM. In addition, delays in obtaining regulatory approvals for new products or product upgrades could have a negative
impact on our growth and profitability.
The manufacture and sale of our products, as well as our research
and development processes, are subject to similar and potentially more stringent laws in foreign countries.
We are also subject to a variety of federal, state, local and international
laws and regulations that govern, among other things, the importation and exportation of products; our business practices in the
U.S. and abroad, such as anti-corruption and anti-competition laws; and immigration and travel restrictions. These legal and regulatory
requirements differ among jurisdictions around the world and are rapidly changing and increasingly complex. The costs associated
with compliance with these legal and regulatory requirements are significant and likely to increase in the future.
Any failure to comply with applicable legal and regulatory requirements
could result in fines, penalties and sanctions; product recalls; suspensions or discontinuations of, or limitations or restrictions
on, our ability to design, manufacture, market, import, export or sell our products; and damage to our reputation.
Even if we receive regulatory approval for a product candidate,
we will be subject to ongoing FDA-CVM or USDA-CVB obligations and continued regulatory oversight, which may result in significant
additional expense. Additionally, any product candidates, if approved, will be subject to labeling and manufacturing requirements
and could be subject to other restrictions. Failure to comply with these regulatory requirements or the occurrence of unanticipated
problems with our products could result in significant penalties.
If the FDA-CVM or USDA-CVB approves any of our existing or future
therapeutic product candidates, the manufacturing processes, labeling, packaging, distribution, adverse event reporting, storage,
advertising, promotion and recordkeeping for the product will be subject to extensive and ongoing regulatory requirements. These
requirements include submissions of safety and other post-marketing information and reports, establishment registration, and product
listing, as well as continued compliance with GMP, GLP and GCP for any studies that we conduct post-approval. Later discovery of
previously unknown problems with a product, including adverse events of unanticipated severity or frequency, or with our third-party
manufacturers or manufacturing processes, or failure to comply with regulatory requirements, may result in, among other things:
|
•
|
restrictions on the marketing or manufacturing of the product, withdrawal of the product from the market, or voluntary product recalls;
|
|
•
|
fines, warning letters or holds on target animal studies;
|
|
•
|
refusal by the FDA-CVM or USDA-CVB to approve pending applications or supplements to approved applications filed by us or our strategic collaborators, or suspension or revocation of product license approvals;
|
|
•
|
product seizure or detention, or refusal to permit the import or export of products; and
|
|
•
|
injunctions or the imposition of civil or criminal penalties.
|
The FDA-CVM’s or USDA-CVB’s policies may change and additional
government regulations may be enacted that could prevent, limit or delay regulatory approval of our product candidates. We cannot
predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative action
in the United States or abroad. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements
or policies, or if we are not able to maintain regulatory compliance, we may lose any marketing approval that we may have obtained
and we may not achieve or sustain profitability, which would adversely affect our business.
Our ability to market our drug candidates in the United States,
if approved, will be limited to use for the treatment of the indications for which they are approved, and if we want to expand
the indications for which we may market our product candidates, we will need to obtain additional FDA-CVM approvals, which may
not be granted.
We expect to seek FDA-CVM approval in the United States for our lead
product candidates, ZM-012, an anti-infective in pill form that is intended for use in canines, ZM-007, an anti-infective oral
suspension for use as an anti-diarrheal in smaller dogs, ZM-006, a transdermal gel treatment for the metabolic disorder hyperthyroidism
intended for use in cats, and ZM-011, a transdermal gel formulation treatment for behavioral disorders intended to use in cats.
If these drug product candidates are approved, the FDA-CVM will restrict our ability to market or advertise them for the treatment
of indications other than the indications for which they are approved, which could limit their adoption by veterinarian and pet
owners. We may attempt to develop, promote and commercialize new treatment indications and protocols for our drug product candidates
in the future, but we cannot predict when or if we will receive the approvals required to do so. In addition, we would be required
to conduct additional target animal studies to support our applications, which would utilize additional resources and may produce
results that do not result in FDA-CVM approvals. If we do not obtain additional FDA-CVM approvals, our ability to expand our business
in the United States will be limited.
If approved, any of our existing or future therapeutic products
may cause or contribute to adverse medical events that we are required to report to regulatory authorities and, if we fail to do
so, we could be subject to sanctions that would materially harm our business.
If we are successful in commercializing any of our existing or future
therapeutic product candidates, we will be required to report adverse medical events if those products may have caused or contributed
to those adverse events. The timing of our obligation to report would be triggered by the date we become aware of the adverse event
as well as the nature of the event. We may fail to report adverse events we become aware of within the prescribed timeframe. We
may also fail to appreciate that we have become aware of a reportable adverse event, especially if it is not reported to us as
an adverse event or if it is an adverse event that is unexpected or removed in time from the use of our products. If we fail to
comply with our reporting obligations, the regulatory authorities could take action including criminal prosecution, seizure of
our products or delay in approval or clearance of future products.
Legislative or regulatory reforms with respect to veterinary
pharmaceuticals or health care solutions may make it more difficult and costly for us to obtain regulatory clearance or approval
of any of our existing or future product candidates and to produce, market, and distribute our products after clearance or approval
is obtained.
From time to time, legislation is drafted and introduced in the U.S.
Congress that could significantly change the statutory provisions governing the testing, regulatory clearance or approval, manufacture,
and marketing of regulated products. In addition, FDA-CVM and USDA-CVB regulations and guidance are often revised or reinterpreted
by the FDA-CVM and USDA-CVB in ways that may significantly affect our business and our products. Similar changes in laws or regulations
can occur in other countries. Any new regulations or revisions or reinterpretations of existing regulations in the United States
may impose additional costs or lengthen review times of any of our existing or future product candidates. We cannot determine what
effect changes in regulations, statutes, legal interpretation or policies, when and if promulgated, enacted or adopted may have
on our business in the future. Such changes could, among other things, require:
|
•
|
changes to manufacturing methods;
|
|
•
|
recall, replacement or discontinuance of certain products; and
|
|
•
|
additional record-keeping.
|
Each of these would likely entail substantial time and cost and could
materially harm our financial results. In addition, delays in receipt of or failure to receive regulatory clearances or approvals
for any future products would harm our business, financial condition, and results of operations.
Risks Related to Intellectual Property
Our ability to obtain intellectual property protection for
our product candidates is uncertain.
Insofar as our business strategy is to develop APIs already approved
for use in humans for veterinary use, our ability to obtain a proprietary intellectual property position for our product candidates
is uncertain. We do not have any issued patents for our lead product candidates. We have not filed patent applications for any
of our other product candidates to date. Our current and future patent applications may never result in the issuance of patents,
and/or patents issued to us may be dominated by the patents of third parties, including for example, patents issued to analogous
human drugs or biological compositions and their usages. Furthermore, even if any future patents are unchallenged by third parties,
our patents, if issued, may not adequately protect our intellectual property or prevent others from designing around them. It is
possible that we will not receive patents to cover any future approved products, and/ or that we will have little to no commercial
protection against competing products. In such cases, we would then have to rely solely on other forms of exclusivity, such as
regulatory exclusivity provided by the FDA-CVM approval, which may provide less protection to our competitive position.
Patent reform legislation could increase the uncertainties and costs
surrounding the prosecution of any future patent applications and the enforcement or defense of any patents that issue. On September
16, 2011, the Leahy-Smith America Invents Act, or the Leahy-Smith Act, was signed into law. The Leahy-Smith Act includes a number
of significant changes to U.S. patent law. These include provisions that affect the way patent applications are prosecuted, redefine
prior art, may affect patent litigation, and switch the U.S. patent system from a “first-to-invent” system to a “first-to-file”
system. Under a “first-to-file” system, assuming the other requirements for patentability are met, the first inventor
to file a patent application generally will be entitled to the patent on an invention regardless of whether another inventor had
made the invention earlier. The USPTO recently developed new regulations and procedures to govern administration of the Leahy-Smith
Act, and many of the substantive changes to patent law associated with the Leahy-Smith Act, and in particular, the first-to-file
provisions, only became effective on March 16, 2013. Accordingly, it is not clear what, if any, impact the Leahy-Smith Act will
have on the operation of our business. However, the Leahy-Smith Act and its implementation could increase the uncertainties and
costs surrounding the prosecution of our patent applications and the enforcement or defense of any patents that issue, all of which
could have a material adverse effect on our business and financial condition.
Some of our products may or may not be covered by a patent.
Further if an application is filed, it is not certain that a patent will be granted or if granted whether it will be held to be
valid. All of which may impact our market share and ability to prevent others (competitor third parties) from making, selling,
or using our products.
We intend to rely upon a combination of regulatory exclusivity periods,
patents, trade secret protection, confidentiality agreements, and license agreements to protect the intellectual property related
to our current product candidates and our development programs. We may not be successful in protecting our intellectual property
rights, including our unpatented proprietary know-how and trade secrets, or in avoiding claims that we infringed on the intellectual
property rights of others. In addition to relying on patent and trademark rights, we rely on unpatented proprietary know-how and
trade secrets, and employ various methods, including confidentiality agreements with employees and consultants, customers and suppliers
to protect our know-how and trade secrets. However, these methods and our patents and trademarks may not afford complete protection
and there can be no assurance that others will not independently develop the know-how and trade secrets or develop better production
methods than us. Further, we may not be able to deter current and former employees, contractors and other parties from breaching
confidentiality agreements and misappropriating proprietary information and it is possible that third parties may copy or otherwise
obtain and use our information and proprietary technology without authorization or otherwise infringe on our intellectual property
rights. In the future, we may also rely on litigation to enforce our intellectual property rights and contractual rights, and,
if not successful, we may not be able to protect the value of our intellectual property. Any litigation could be protracted and
costly and could have a material adverse effect on our business and results of operations regardless of its outcome.
We have pending trademark applications in Canada and the European
Union however trademark registration is not yet complete, and failure to finally secure these registrations could adversely affect
our business.
We have pending trademark applications for our company name and design
marks and our “Voice of the Vet” program in Canada and the European Union. We cannot make assurances that these trademarks
will become registered in any pending jurisdiction. We may face rejections to one or more of our pending trademark applications.
Although we are given an opportunity to respond to those rejections, we may be unable to overcome such rejections. In addition,
in many foreign jurisdictions, third parties are given an opportunity to oppose pending trademark applications and to seek to cancel
registered trademarks. Opposition or cancellation proceedings may be filed against our trademarks, and our trademarks may not survive
such proceedings. Additionally, we may need to enforce our trademark rights against third parties and expend significant additional
resources to enforce such rights against infringements. Moreover, any name we propose to use with our product candidates in the
United States must be approved by the FDA-CVM or the USDA-CVB regardless of whether we have registered it, or applied to register
it, as a trademark. The FDA-CVM typically conducts a review of proposed product names, including an evaluation of potential for
confusion with other product names. If the FDA-CVM or the USDA-CVB object to any of our proposed proprietary product names, we
may be required to expend significant additional resources in an effort to identify a suitable substitute name that would qualify
under applicable trademark laws, not infringe the existing rights of third parties and be acceptable to the FDA-CVM and the USDA-CVB.
Third parties may have intellectual property rights, which
may require us to obtain a license or other applicable rights to make, sell or use our products. If such rights are not granted
or obtained, I could have a material adverse effect on our business, financial condition and results of operations.
Our success depends in part on our ability to obtain, or license
from third parties, patents, trademarks, trade secrets and similar proprietary rights without infringing on the proprietary rights
of third parties. Although we believe our intellectual property rights are sufficient to allow us to conduct our business without
incurring liability to third parties, our products may infringe on the intellectual property rights of such persons. Furthermore,
no assurance can be given that we will not be subject to claims asserting the infringement of the intellectual property rights
of third parties seeking damages, the payment of royalties or licensing fees and/or injunctions against the sale of our products.
Any such litigation could be protracted and costly and could have a material adverse effect on our business, financial condition
and results of operations.
Our diagnostic assay technology depends on certain technology
that is licensed to us. We do not control this technology and any loss of our rights to them could prevent us from marketing our
diagnostic assay product candidates.
Our diagnostic assay technology is dependent on a license from Celsee.
We do not own the intellectual property rights that underlie this license. Our rights to use the technology we license are subject
to the negotiation of, continuation of and compliance with the terms of our license. We do not control the prosecution, maintenance,
or filing of the patents and other intellectual property licensed to us, or the enforcement of these intellectual property rights
against third parties. The patents and patent applications underlying our license were not written by us or our attorneys, and
we do not have control over the drafting and prosecution of such rights. Celsee might not have given the same attention to the
drafting and prosecution of patents and patent applications as we would have if we had been the owners of the intellectual property
rights and had control over such drafting and prosecution. We cannot be certain that drafting and/or prosecution of the licensed
patents and patent applications has been or will be conducted in compliance with applicable laws and regulations or will result
in valid and enforceable patents and other intellectual property rights.
Our intellectual property agreements with third parties may
be subject to disagreements over contract interpretation, which could narrow the scope of our rights to the relevant intellectual
property or technology or increase our financial or other obligations to our licensors.
Certain provisions in our intellectual property agreements may be
susceptible to multiple interpretations. The resolution of any contract interpretation disagreement that may arise could affect
the scope of our rights to the relevant intellectual property or technology, or affect financial or other obligations under the
relevant agreement, either of which could have a material adverse effect on our business, financial condition, results of operations
and prospects.
In addition, while it is our policy to require our employees and
contractors who may be involved in the conception or development of intellectual property to execute agreements assigning such
intellectual property to us, we may be unsuccessful in executing such an agreement with each party who in fact conceives or develops
intellectual property that we regard as our own. Our assignment agreements may not be self-executing or may be breached, and we
may be forced to bring claims against third parties, or defend claims they may bring against us, to determine the ownership of
what we regard as our intellectual property.
We may be subject to claims that our employees, consultants
or independent contractors have wrongfully used or disclosed confidential information of third parties.
We have received confidential and proprietary information from third
parties. In addition, we employ individuals who were previously employed at other pharmaceutical or animal health companies. We
may be subject to claims that we or our employees, consultants or independent contractors have inadvertently or otherwise improperly
used or disclosed confidential information of these third parties or our employees’ former employers. Litigation may be necessary
to defend against any such claims. Even if we are successful in defending against any such claims, such litigation could result
in substantial cost and be a distraction to our management and employees.
Risks Related to Our Common Shares
We believe that we will be a “passive foreign investment
company,” or PFIC for the current taxable year, which could subject certain U.S. shareholders to materially adverse U.S.
federal income tax consequences.
We believe we were classified as a PFIC during our taxable year ended
2017 and based on current business plans and financial expectations, we believe we may be a PFIC for the current and future taxable
years. If we are a PFIC for any year in which you hold shares and you are a U.S. Holder (as defined below, in “Material United
States Federal Income Tax Considerations”), unless you make a timely and effective Qualified Electing Fund election, or QEF
Election or a mark-to-market election, or Mark-to-Market Election with respect to our common shares, you will not be eligible for
the reduced tax rates associated with “qualified dividend income” with respect to distributions made to you or long-term
capital gain upon a disposition of your common shares. Instead, all such distributions and gain will be taxable to you at the higher
rates for ordinary income. In addition, a portion of any gain and distribution may be allocated to prior years during which you
have owned our common shares and subjected to tax at the highest tax rate applicable to ordinary income in each such year. You
would also be required to pay an interest charge on that portion of such gain or distribution.
If you are a U.S. Holder and make a timely and effective QEF Election,
you generally must report on a current basis your share of our net capital gain and ordinary earnings for any year in which we
are a PFIC, whether or not we distribute any amount to you, thus giving rise to so-called “phantom income” and to a
potential tax liability.
If you are a U.S. Holder and make a timely and effective Mark-to-Market
Election, you generally must include as ordinary income each year the excess of the fair market value of your common shares over
your tax basis therein, thus also possibly giving rise to phantom income and a potential tax liability. Ordinary loss generally
is recognized only to the extent of net mark-to-market gains previously included in income.
This paragraph is qualified in its entirety by the discussion below
under the heading “Material United States Federal Income Tax Considerations.” Each U.S. shareholder should consult
its own tax advisors regarding the PFIC rules and the U.S. federal income tax consequences of the acquisition, ownership, and disposition
of our common shares.
If the Internal Revenue Service determines that we are not
a PFIC and you previously paid taxes pursuant to a QEF Election or a Mark-to-Market Election, you may pay more taxes than you legally
owe.
If the Internal Revenue Service, or the IRS, makes a determination
that we are not a PFIC and you previously paid taxes pursuant to a QEF Election or Mark-to-Market Election, then you may have paid
more taxes than you legally owed due to such election. If you do not, or are unable to, file a refund claim before the expiration
of the applicable statute of limitations, you will not be able to claim a refund for those taxes.
If securities or industry analysts do not publish research
or reports about our company, or if they issue adverse or misleading opinions regarding us or our stock, our stock price and trading
volume could decline.
Although we have research coverage by securities and industry analysts,
if coverage is not maintained, the market price for our stock may be adversely affected. Our stock price also may decline if any
analyst who covers us issues an adverse or erroneous opinion regarding us, our business model, our intellectual property or our
stock performance, or if our target animal studies and operating results fail to meet analysts’ expectations. If one or more
analysts cease coverage of us or fail to regularly publish reports on us, we could lose visibility in the financial markets, which
could cause our stock price or trading volume to decline and possibly adversely affect our ability to engage in future financings.
We expect that the price of our common shares will fluctuate
substantially.
You should consider an investment in our common shares risky and
invest only if you can withstand a significant loss and wide fluctuations in the market value of your investment. The price of
our common shares that will prevail in the market after the sale of our common shares by a selling shareholder may be higher or
lower than the price you have paid. Numerous factors, including many over which we have no control, may have a significant impact
on the market price of our common shares. These risks include those described or referred to in this “Risk Factors”
section and elsewhere in this report as well as, among other things:
|
•
|
any delays in, or suspension or failure of, our existing and future studies;
|
|
•
|
announcements of regulatory approval or disapproval of any of our existing or future product candidates or of regulatory actions affecting us or our industry;
|
|
•
|
delays in the commercialization of our existing or future product candidates;
|
|
•
|
manufacturing and supply issues related to our development programs and commercialization of our existing or future product candidates;
|
|
•
|
quarterly variations in our results of operations or those of our competitors;
|
|
•
|
changes in our earnings estimates or recommendations by securities analysts or adverse publicity about us or our product candidates;
|
|
•
|
announcements by us or our competitors of new product candidates, significant contracts, commercial relationships, acquisitions or capital commitments;
|
|
•
|
announcements relating to future development or license agreements including termination of such agreements;
|
|
•
|
adverse developments with respect to our intellectual property rights or those of our principal collaborators;
|
|
•
|
commencement of litigation involving us or our competitors;
|
|
|
|
|
|
•
|
any major changes in our board of directors or management;
|
|
•
|
new legislation in the United States relating to the prescription, sale, distribution or pricing of pet pharmaceuticals or diagnostic products;
|
|
•
|
product liability claims, other litigation or public concern about the safety of our product candidates or future products;
|
|
•
|
market conditions in the animal health industry, in general, or in the pet therapeutics sector, in particular, including performance of our competitors; and
|
|
•
|
general economic conditions in the United States and abroad.
|
In addition, the stock market, in general, or the market for stocks
in our industry, in particular, may experience broad market fluctuations, which may adversely affect the market price or liquidity
of our common shares. Any sudden decline in the market price of our common shares could trigger securities class-action lawsuits
against us. If any of our shareholders were to bring such a lawsuit against us, we could incur substantial costs defending the
lawsuit and the time and attention of our management would be diverted from our business and operations. We also could be subject
to damages claims if we are found to be at fault in connection with a decline in our stock price.
Our management owns a significant percentage
of our common shares and will be able to exert significant control over matters subject to shareholder approval.
Based on shares outstanding as of February 27, 2018, our executive
officers and directors and their respective affiliates beneficially own 56,733,040 or 59.3% of our voting shares. These shareholders
will have the ability to influence us through this ownership position and may be able to determine all matters requiring shareholder
approval. For example, these shareholders may be able to control elections of directors, amendments of our organizational documents,
or approvals of any merger, sale of assets or other major corporate transaction. This may prevent or discourage unsolicited acquisition
proposals or offers for our common shares that you may feel are in your best interest as one of our shareholders.
We are an “emerging growth company,” as defined
under the JOBS Act and if we take advantage of reduced disclosure requirements applicable to “emerging growth companies,”
our common shares could be less attractive to investors.
We are an “emerging growth company,” as defined in the
Jumpstart Our Business Startups Act of 2012, as amended, or the JOBS Act, and, for as long as we continue to be an “emerging
growth company,” we may choose to take advantage of certain exemptions from various reporting requirements applicable to
other public companies but not to “emerging growth companies,” including, but not limited to, not being required to
comply with the auditor attestation requirements of Section 404(b) of the Sarbanes-Oxley Act of 2002, as amended, or SOX, reduced
disclosure obligations regarding executive compensation in our periodic reports and proxy statements, and exemptions from the requirements
of holding a nonbinding advisory vote on executive compensation and shareholder approval of any golden parachute payments not previously
approved. We could be an “emerging growth company” for up to five years, or until the earliest of (i) the last day
of the first fiscal year in which our annual gross revenues exceed $1.07 billion, (ii) the date that we become a “large accelerated
filer” as defined in Rule 12b-2 under the Exchange Act, which would occur if the market value of our common shares that is
held by non-affiliates exceeds $700 million as of the last business day of our most recently completed second fiscal quarter, or
(iii) the date on which we have issued more than $1 billion in non-convertible debt during the preceding three year period. We
cannot predict if investors will find our common shares less attractive if we choose to continue to rely on these exemptions. If
some investors find our common shares less attractive as a result of any choices to reduce future disclosure, there may be a less
active trading market for our common shares and our stock price may be more volatile.
In addition, Section 107 of the JOBS Act provides that an “emerging
growth company” can take advantage of the extended transition period provided in Section 7(a)(2)(B) of the Securities Act
for complying with new or revised accounting standards. An “emerging growth company” can delay the adoption of certain
accounting standards until those standards would otherwise apply to private companies. We have chosen to “opt out”
of such extended transition period, however, and, as a result, we are required to comply with new or revised accounting standards
on the relevant dates on which adoption of such standards is required for non-emerging growth companies. Section 107 of the JOBS
Act provides that our decision to opt out of the extended transition period for complying with new or revised accounting standards
is irrevocable.
Our Articles of Incorporation (as amended and restated) authorize
us to issue an unlimited number of common shares and preferred shares without shareholder approval and we may issue additional
equity securities, or engage in other transactions that could dilute your ownership interest, which may adversely affect the market
price of our common shares
Our Articles of Incorporation (as amended or restated) authorize
our Board of Directors, subject to the provisions of the ABCA, to issue an unlimited number of common shares and preferred shares
without shareholder approval. Our Board of Directors may determine from time to time to raise additional capital by issuing common
shares, preferred shares or other equity securities. We are not restricted from issuing additional securities, including securities
that are convertible into or exchangeable for, or that represent the right to receive, common shares or preferred shares. Because
our decision to issue securities in any future offering will depend on market conditions and other factors beyond our control,
we cannot predict or estimate the amount, timing, or nature of any future offerings, or the prices at which such offerings may
be affected. Additional equity offerings may dilute the holdings of our existing shareholders or reduce the market price of our
common shares, or both. Holders of our common shares are not entitled to pre-emptive rights or other protections against dilution.
New investors also may have rights, preferences and privileges that are senior to, and that adversely affect, the then-current
holders of our common shares. Additionally, if we raise additional capital by making offerings of debt or preference shares, upon
our liquidation, holders of our debt securities and preferred shares, and lenders with respect to other borrowings, may receive
distributions of our available assets before the holders of our common shares.
We will incur significant costs as a result of operating as
a U.S. public company, and our management will devote substantial time to new compliance initiatives.
As a Canadian public company, we were not required to comply with
certain U.S. corporate governance and financial reporting practices and policies required of a U.S. publicly-traded company. As
a U.S. publicly-traded company, we will incur significant legal, accounting and other expenses that we were not required to incur
in the recent past, particularly after we are no longer an “emerging growth company” as defined under the JOBS Act.
In addition, new and changing laws, regulations and standards relating to corporate governance and public disclosure, including
the Dodd-Frank Wall Street Reform and Consumer Protection Act and the rules and regulations promulgated and to be promulgated thereunder,
as well as under the Sarbanes-Oxley Act, the JOBS Act, and the rules and regulations of the U.S. Securities and Exchange Commission,
or SEC, have created uncertainty for U.S. public companies and increased our costs and time that our board of directors and management
must devote to complying with these rules and regulations. We expect these rules and regulations to increase our legal and financial
compliance costs and lead to a diversion of management time and attention from revenue generating activities.
Furthermore, the need to establish the corporate infrastructure demanded
of a U.S. public company may divert management’s attention from implementing our growth strategy, which could prevent us
from improving our business, results of operations and financial condition. We have made, and will continue to make, changes to
our internal controls and procedures for financial reporting and accounting systems to meet our reporting obligations as a U.S.
public company. However, the measures we take may not be sufficient to satisfy our obligations as a U.S. public company.
For as long as we remain an “emerging growth company”
as defined in the JOBS Act, we may choose to take advantage of certain exemptions from various reporting requirements that are
applicable to other U.S. public companies that are not “emerging growth companies.” These exceptions provide for, but
are not limited to, relief from the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act, less extensive
disclosure obligations regarding executive compensation in our periodic reports and proxy statements, exemptions from the requirements
to hold a nonbinding advisory vote on executive compensation and shareholder approval of any golden parachute payments not previously
approved and an extended transition period for complying with new or revised accounting standards. We may take advantage of these
reporting exemptions until we are no longer an “emerging growth company.” We may remain an “emerging growth company”
for up to five years. See “JOBS Act” in this report. To the extent we are no longer eligible to use exemptions from
various reporting requirements under the JOBS Act, we may be unable to realize our anticipated cost savings from those exemptions.
Our internal control over financial reporting does not meet
the standards required by Section 404 of the Sarbanes-Oxley Act, and failure to achieve and maintain effective internal control
over financial reporting in accordance with Section 404 of the Sarbanes-Oxley Act could have a material adverse effect on
our business and share price.
As a Canadian public company, we were not required to evaluate our
internal control over financial reporting in a manner that meets the standards of U.S. public companies required by Section 404
of the Sarbanes-Oxley Act, or Section 404. We were required to meet these standards in the course of preparing our financial
statements as of and for the year ended December 31, 2017, and our management has reported on the effectiveness of our internal
control over financial reporting for such year. Additionally, under the recently enacted JOBS Act, our independent registered public
accounting firm is not required to attest to the effectiveness of our internal control over financial reporting pursuant to Section 404
of the Sarbanes-Oxley Act until we are no longer an “emerging growth company.” The rules governing the standards that
must be met for our management to assess our internal control over financial reporting are complex and require significant documentation,
testing and possible remediation.
In connection with the implementation of the necessary procedures
and practices related to internal control over financial reporting, we may identify deficiencies that we may not be able to remediate
in time to meet the deadline imposed by the Sarbanes-Oxley Act for compliance with the requirements of Section 404. In addition,
we may encounter problems or delays in completing the implementation of any requested improvements and receiving a favorable attestation
in connection with the attestation provided by our independent registered public accounting firm. We will be unable to issue securities
in the public markets through the use of a shelf registration statement if we are not in compliance with Section 404. Furthermore,
failure to achieve and maintain an effective internal control environment could have a material adverse effect on our business
and share price and could limit our ability to report our financial results accurately and timely.
If we sell common shares in future financings, shareholders
may experience immediate dilution and, as a result, our share price may decline.
We may from time to time issue additional common shares at a discount
from the existing trading price of our common shares. As a result, our shareholders would experience immediate dilution upon the
sale of any shares of our common shares at such discount. In addition, as opportunities present themselves, we may enter into financing
or similar arrangements in the future, including the issuance of debt securities, preferred shares or common shares. If we issue
common shares or securities convertible into common shares, our common shareholders would experience additional dilution and, as
a result, our share price may decline.
We have never and do not, in the future, intend to pay dividends
on our common shares, and your ability to achieve a return on your investment will depend on appreciation in the market price of
our common shares.
We have never paid and do not expect to pay dividends on our common
shares in the future. We intend to invest our future earnings, if any, to fund our growth and not to pay any cash dividends on
our common shares. Since we do not intend to pay dividends, your ability to receive a return on your investment will depend on
any future appreciation in the market price of our common shares. There is no assurance that our common shares will appreciate
in price.
An active, liquid and orderly market for
our common shares may not develop or be sustained, and you may not be able to sell your common shares.
Our common shares trade on the TSX-V and NYSE American exchanges.
We cannot assure you that an active trading market for our common shares will develop or be sustained. The lack of an active market
may impair your ability to sell the common shares at the time you wish to sell them or at a price that you consider reasonable.
An inactive market may also impair our ability to raise capital by selling common shares and may impair our ability to acquire
other businesses, applications or technologies using our common shares as consideration, which, in turn, could materially adversely
affect our business.
We can provide no assurance that our
common shares will continue to meet NYSE American listing requirements. If we fail to comply with the continuing listing standards
of the NYSE American, our common shares could be delisted.
If we fail to satisfy the continued listing
requirements of the NYSE American, such as the corporate governance requirements or the minimum closing bid price requirement,
the NYSE American may take steps to delist our common shares. Such a delisting would likely have a negative effect on the price
of our common shares and would impair your ability to sell or purchase common shares when you wish to do so. In the event of a
delisting, we can provide no assurance that any action taken by us to restore compliance with listing requirements would allow
our common shares to become listed again, stabilize the market price or improve the liquidity of our common shares, prevent our
common shares from dropping below the NYSE American minimum bid price requirement or prevent future non-compliance with NYSE American’s
listing requirements.
If our common shares are not listed on
the NYSE American or another national securities exchange, compliance with applicable state securities laws may be required for
subsequent offers, transfers and sales of our common shares.
The common shares offered hereby are being offered pursuant to one
or more exemptions from registration and qualification under applicable state securities laws. If our common shares are delisted from the NYSE American and are not
eligible to be listed on another national securities exchange, subsequent transfers of our common shares offered hereby by U.S.
holders may not be exempt from state securities laws. In such event, it will be the responsibility of the holder of the common
shares to register or qualify the common shares for any subsequent offer, transfer or sale in the United States or to determine
that any such offer, transfer or sale is exempt under applicable state securities laws.
If the selling shareholders sell a substantial number of our
common shares in this offering, the market price of our common shares could decline.
The sale of a substantial number of our common shares in the public
market, or the perception that such sales could occur, could harm the prevailing market price of our common shares. Upon the effectiveness
of the registration statement of which this prospectus forms a part, all of the common shares registered hereby will be eligible
for immediate sale. These sales, or the possibility that these sales may occur, also might make it more difficult for you to sell
your common shares at a time and at a price that you deem appropriate, if at all.
CAUTIONARY NOTE REGARDING
FORWARD-LOOKING STATEMENTS
This prospectus contains forward-looking statements made pursuant
to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 under Section 27A of the Securities Act of
1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that are based on management’s beliefs
and assumptions and on information currently available to management. Some of the statements under “Prospectus Summary,”
“Risk Factors,” “Management’s Discussion and Analysis of Financial Condition and Results of Operations”
and “Business” and elsewhere in this prospectus contain forward-looking statements. In some cases, you can identify
forward-looking statements by the following words: “may,” “will,” “could,” “would,”
“should,” “expect,” “intend,” “plan,” “anticipate,” “believe,”
“estimate,” “predict,” “project,” “potential,” “continue,” “ongoing”
or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words.
These statements involve risks, uncertainties and other factors that
may cause actual results, levels of activity, performance or achievements to be materially different from the information expressed
or implied by these forward-looking statements. Although we believe that we have a reasonable basis for each forward-looking statement
contained in this prospectus, we caution you that these statements are based on a combination of facts and factors currently known
by us and our projections of the future, about which we cannot be certain. Forward-looking statements in this prospectus include,
but are not limited to, statements about:
|
•
|
the success, cost and timing of our research and development activities, validation studies and pivotal trials, including
with respect to our lead product candidates, ZM-017, ZM-012, ZM-006, ZM-007 and ZM-011;
|
|
•
|
our ability to obtain regulatory approval from the FDA-CVM and/or the USDA-CVB for our pharmaceutical and diagnostic product candidates, as applicable;
|
|
•
|
our ability to obtain funding for our operations;
|
|
•
|
the ability of our CROs to appropriately conduct our safety studies and certain development activities;
|
|
•
|
the ability of our CMOs to manufacture and supply our product candidates in accordance with cGMP and our clinical needs;
|
|
•
|
our plans to develop and commercialize our product candidates;
|
|
•
|
our ability to develop and commercialize product candidates that can compete effectively against the product candidates developed and commercialized by our competitors;
|
|
•
|
the size and growth of the veterinary diagnostics and therapeutics markets;
|
|
•
|
our ability to obtain and maintain intellectual property protection for our current and future product candidates;
|
|
•
|
regulatory developments in the United States;
|
|
•
|
the loss of key scientific or management personnel;
|
|
•
|
our expectations regarding the period during which we will be an “emerging growth company” under the JOBS Act;
|
|
•
|
the accuracy of our estimates regarding expenses, future revenues, capital requirements and needs for additional financing; and
|
|
•
|
our status as a PFIC for U.S. federal income tax purposes.
|
In addition, you should refer to the “Risk Factors” section
of this prospectus for a discussion of other important factors that may cause actual results to differ materially from those expressed
or implied by these forward-looking statements. As a result of these factors, we cannot assure you that the forward-looking statements
in this prospectus will prove to be accurate. Furthermore, if the forward-looking statements prove to be inaccurate, the inaccuracy
may be material. In light of the significant uncertainties in these forward-looking statements, you should not regard these statements
as a representation or warranty by us or any other person that we will achieve our objectives and plans in any specified time frame,
or at all. We undertake no obligation to publicly update any forward-looking statements, whether as a result of new information,
future events or otherwise, except as required by law.
USE OF PROCEEDS
We will not receive any proceeds from the sale of any of our
common shares by the selling shareholders. We will pay estimated transaction expenses of approximately $550,000 in connection
with this offering.
PRICE RANGE OF COMMON
SHARES
Our common stock commenced trading on the NYSE
American on November 21, 2017 under the symbol “ZOM”. The following table sets forth the high and low sale prices for
our common stock for the periods indicated as reported on the NYSE American:
Fiscal Year 2017
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Fourth Quarter (from November 21, 2017)
|
|
$
|
|
|
|
|
2.47
|
|
|
$
|
|
|
|
|
1.88
|
|
Fiscal Year 2018
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
First Quarter (through March 23, 2018)
|
|
$
|
|
|
|
|
2.23
|
|
|
$
|
|
|
|
|
1.75
|
|
The closing price of our common shares on the
NYSE American on March 23, 2018 was $2.19 per share. As of that date, there were approximately 200 registered holders
of record of our common shares.
DIVIDEND POLICY
We have never declared or paid any cash dividends on our common shares.
We intend to retain future earnings, if any, to finance the operation and expansion of our business and do not anticipate paying
any cash dividends in the foreseeable future. Any future determination related to dividend policy will be made at the discretion
of our board of directors after considering our financial condition, results of operations, capital requirements, business prospects
and other factors the board of directors deems relevant, and subject to the restrictions contained in any future credit facilities
or other financing arrangements.
CAPITALIZATION
The following table sets forth our cash and cash equivalents and
total capitalization as of December 31, 2017.
This table should be read in conjunction with, and is qualified in
its entirety by reference to, “Management’s Discussion and Analysis of Financial Condition and Results of Operations”
and our financial statements and related notes appearing elsewhere in this prospectus.
|
|
December 31, 2017
|
|
|
(unaudited)
|
|
|
|
Cash and cash equivalents
|
|
$
|
3,448,147
|
|
Shareholders’ equity:
|
|
|
|
|
Common shares, without par value, unlimited common shares authorized, 90,225,869 common shares issued and outstanding as of December 31, 2017
|
|
|
18,244,659
|
|
Additional paid-in capital
|
|
|
1,768,526
|
|
Accumulated deficit
|
|
|
(15,626,100
|
)
|
Total shareholders’ equity
|
|
$
|
4,387,085
|
|
Total capitalization
|
|
$
|
4,387,085
|
|
The outstanding share information in the table above is based on
90,225,869 common shares outstanding as of December 31, 2017, and excludes as of such date the following:
|
•
|
8,080,000 common shares issuable upon the exercise of outstanding options with a weighted average exercise price of $0.96 per share; and
|
|
•
|
942,586 common shares reserved for future issuance under our stock option plan. Our stock option plan provides that the maximum number of shares reserved for issuance upon exercise of stock options is equal to 10% of our issued and outstanding common shares.
|
MANAGEMENT’S
DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATION
You should read the following discussion and analysis of our
financial condition and results of operations together with our financial statements and the related notes and other financial
information included elsewhere in this prospectus. Some of the information contained in this discussion and analysis or set forth
elsewhere in this prospectus, including information with respect to our plans and strategy for our business, includes forward-looking
statements that involve risks and uncertainties. See “Cautionary Note Regarding Forward-Looking Statements.” You should
review the “Risk Factors” section of this prospectus for a discussion of important factors that could cause our actual
results to differ materially from the results described in or implied by the forward-looking statements contained in the following
discussion and analysis.
Overview
We are a development stage veterinary diagnostic and pharmaceutical
company creating products for companion animals (canine, feline, and equine) by focusing on the unmet needs of clinical veterinarians.
We believe that we have identified and are developing diagnostics and therapeutics that have the potential to significantly improve
the diagnosis and treatment of various diseases affecting companion animals. We believe that there are significant unmet medical
needs for pets, and that the pet diagnostic and therapeutic segments of the animal health industry are likely to grow substantially
as new diagnostic tools and treatments are identified, developed, and marketed specifically for companion animals.
Together with our strategic partner, we are developing liquid biopsy
assays and related consumables for the detection of cancer in companion animals. The regulatory pathway to obtain pre-market regulatory
approval of companion animal diagnostics is significantly shorter than for similar diagnostic products intended for human use.
In certain cases, pre-market regulatory approval may be unnecessary, depending on the intended use of the diagnostic.
We also have identified a number of drugs that have proven safe
and effective in humans that we are developing for use in companion animals. We believe this development approach enables us to
reduce the risks associated with obtaining regulatory approval for unproven product candidates and shortens the development timeline
necessary to bring our product candidates to market. We have four drug product candidates in early development and have identified
several other potential product candidates for further investigation.
In addition, we are investigating the development of alternative
drug delivery technologies for our drug product candidates. Many of the human-approved therapeutics used in companion animals are
only available in pill or injectable form. However, it can be difficult to give a companion animal an injection or to assure that
the animal has swallowed a pill. As a result, we believe that compliance with treatment regimens is a significant problem for veterinarians
and pet owners. The challenges associated with medicating pets are unique, and we believe that developing product candidates that
can be easily taken by the pet or easily administered by pet owners will help increase compliance.
We are a development-stage company with no products approved for
marketing and sale, and we have not generated any revenue. We have incurred significant net losses since our inception. We incurred
net losses of $8,065,072 and $5,740,492 for the year ended December 31, 2017 and December 31, 2016, respectively. These losses
have resulted principally from costs incurred in connection with investigating and developing our product candidates, research
and development activities and general and administrative costs associated with our operations. As of December 31, 2017, we had
an accumulated deficit of $15,626,100 and cash and cash equivalents of $3,448,147.
For the foreseeable future, we expect to continue to incur losses,
which will increase significantly from historical levels as we expand our product development activities, commercialize them if
they do not require U.S. Food and Drug Administration’s Center for Veterinary Medicine, or FDA-CVM, pre-market approval,
seek regulatory approvals for our product candidates where required from the FDA-CVM or the United States Department of Agriculture
Center for Veterinary Biologics, or the USDA-CVB.
For further information on the regulatory, business and product
pipeline, please see “Business.” For further information on the risk factors, please see “Risk Factors.”
Revenue
We do not have any products approved for sale, have not generated
any revenue from product sales since our inception and do not expect to generate any revenue from the sale of products in the near
future. If our development efforts result in clinical success and regulatory approval or collaboration agreements with third parties
for any of our product candidates, we may generate revenue from those product candidates.
Operating Expenses
The majority of our operating expenses to date have been for the
general and administrative activities related to general business activities, capital market activities and stock-based compensation,
and research and development activities related to our lead product candidates.
Research and Development Expense
All costs of research and development are expensed in the period
in which they are incurred. Research and development costs primarily consist of salaries and related expenses for personnel, stock-based
compensation expense, fees paid to consultants, outside service providers, professional services, travel costs and materials used
in clinical trials and research and development.
We have a non-invasive diagnostic assay or blood test, ZM-017, that
we are developing as an aid for veterinarians in diagnosing cancer in canines.
We have four drug product candidates in development. Our lead drug
product candidate is ZM-012, a novel tablet formulation of metronidazole targeting the treatment of acute diarrhea in dogs. Our
second drug product candidate is ZM-007, an oral suspension formulation of metronidazole and a complementary formulation to ZM-012,
targeting the treatment of acute diarrhea in small breeds and puppies under nine pounds or four kilograms. Our third drug product
candidate is ZM-006, a transdermal gel formulation of methimazole targeting hyperthyroidism in cats. Our fourth drug product candidate
is ZM-011, a transdermal gel formulation of fluoxetine, most commonly known as Prozac®, its human pharmaceutical brand name.
We are also investigating the development of alternative drug delivery
systems for our drug product candidates. We typically use our employee and infrastructure resources across multiple development
programs. We track outsourced development costs by product candidate, but do not allocate personnel or other internal costs related
to development to specific programs or product candidates.
General and Administrative Expense
General and administrative expense consists primarily of personnel
costs, including salaries, related benefits and stock-based compensation for employees, consultants and directors. General and
administrative expenses also include rent and other facilities costs and professional and consulting fees for legal, accounting,
tax services and other general business services.
Professional Fees
Professional fees include attorney’s fees, accounting fees
and consulting fees incurred in connection with product investigation and analysis, regulatory analysis, government relations,
audit, securities offerings, investor relations, and general corporate and intellectual property advice.
Income Taxes
As of December 31, 2017, we had net operating loss carryforwards
for federal and state income tax purposes of $5,008,180 and non-capital loss carryforwards for Canada of approximately $6,526,850
respectively, which will begin to expire in fiscal year 2035.
We have evaluated the factors bearing upon the realizability
of our deferred tax assets, which are comprised principally of net operating loss carryforwards and non-capital loss carryforwards.
We concluded that, due to the uncertainty of realizing any tax benefits as of December 31, 2017, a valuation allowance was necessary
to fully offset our deferred tax assets.
Critical Accounting Policies and Significant Judgments and Estimates
Our management’s discussion and analysis of financial condition
and results of operations is based on our consolidated financial statements, which have been prepared in accordance with accounting
principles generally accepted in the United States, or U.S. GAAP. The preparation of our consolidated financial statements and
related disclosures requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities, and
revenue, costs and expenses and related disclosures during the reporting periods. On an ongoing basis, we evaluate our estimates
and judgments, including those described below. We base our estimates on historical experience and on various other factors that
we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying
value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates
under different assumptions or conditions.
While our significant accounting policies are more fully described
in Note 3 of the notes to our financial statements appearing elsewhere in this document, we believe that the estimates and assumptions
involved in the following accounting policies may have the greatest potential impact on our financial statements.
JOBS Act
The Jumpstart Our Business Startups Act, or the JOBS Act, contains
provisions that, among other things, reduce certain reporting requirements for an “emerging growth company.” We have
irrevocably elected not to avail ourselves of the JOBS Act provision that an emerging growth company may delay adopting new or
revised accounting standards until such times as those standards apply to private companies.
In addition, we are in the process of evaluating the benefits of
relying on the other exemptions and reduced reporting requirements provided by the JOBS Act. Subject to certain conditions set
forth in the JOBS Act, if as an “emerging growth company” we choose to rely on such exemptions, we may not be required
to, among other things, (i) provide an auditor’s attestation report on our system of internal controls over financial reporting
pursuant to Section 404, and (ii) comply with any requirement that may be adopted by the Public Company Accounting Oversight Board
regarding mandatory audit firm rotation or a supplement to the auditor’s report providing additional information about the
audit and the financial statements (auditor discussion and analysis). These exemptions will apply until December 31, 2022 or until
we no longer meet the requirements of being an “emerging growth company,” whichever is earlier.
Use of Estimates
The preparation of consolidated financial statements in conformity
with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities
and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses
during the year. Actual results could differ from those estimates.
Areas where significant judgment is involved in making estimates
are: the determination of the functional currency; the fair values of financial assets and liabilities; the determination of fair
value of stock-based compensation; and forecasting future cash flows for assessing the going concern assumption.
Research and Development Costs
Research and development expenses comprise costs incurred in performing
research and development activities, including salaries and benefits, safety and efficacy studies and contract manufacturing costs,
contract research costs, patent procurement costs, materials and supplies and occupancy costs. Research and development activities
include internal and external activities associated with research and development studies of current product candidates and advancing
product candidates towards a goal of obtaining regulatory approval to manufacture and market the product candidate.
Research and development costs related to continued research and
development programs are expensed as incurred in accordance with ASC topic 730.
Translation of Foreign Currencies
The functional currency, as determined by management, is U.S. dollars,
which is also our reporting currency. Transactions denominated in currencies other than U.S. dollars and the monetary value of
assets and liabilities are translated at the period end exchange rates. Revenue and expenses are translated at rates of exchange
prevailing on the transaction dates. All of the exchange gains or losses resulting from these other transactions are recognized
in the consolidated statements of operations and comprehensive loss.
Stock-Based Compensation
We measure the cost of equity-settled transactions by reference
to the fair value of the equity instruments at the date at which they are granted if the fair value of the goods or services received
by us cannot be reliably estimated.
We calculate stock-based compensation using the fair value method,
under which the fair value of the options at the grant date is calculated using the Black-Scholes Option Pricing Model, and subsequently
expensed over the vesting period of the option. The provisions of our stock-based compensation plans do not require us to settle
any options by transferring cash or other assets, and therefore we classify the awards as equity. Stock-based compensation expense
recognized during the period is based on the value of stock-based payment awards that are ultimately expected to vest. We estimate
forfeitures at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates.
Volatility is determined based on volatilities of comparable companies when the Company does not have its own trading history.
The expected term, which represents the period of time that options granted are expected to be outstanding, is estimated based
on an average of the term of the options. The risk-free rate assumed in valuing the options is based on the Canadian treasury yield
curve in effect at the time of grant for the expected term of the option. The expected dividend yield percentage at the date of
grant is Nil as we are not expected to pay dividends in the foreseeable future.
Loss Per Share
Basic loss per share, or EPS, is computed by dividing the loss attributable
to common shareholders by the weighted average number of common shares outstanding. Diluted EPS reflects the potential dilution
that could occur from common shares issuable through the exercise or conversion of stock options, restricted stock awards, warrants
and convertible securities. In certain circumstances, the conversion of options, warrants and convertible securities are excluded
from diluted EPS if the effect of such inclusion would be anti-dilutive.
The dilutive effect of stock options is determined using the treasury
stock method. Stock options and warrants to purchase our common shares issued during the period were not included in the computation
of diluted EPS, as the effect would be anti-dilutive.
Comprehensive Loss
We follow ASC topic 220. This statement establishes standards for
reporting and display of comprehensive (loss) income and its components. Comprehensive loss is net loss plus certain items that
are recorded directly to shareholders' equity. We currently have no other comprehensive loss items.
Results of Operations
Year ended December 31, 2017 compared to year ended December
31, 2016
Our results of operations for the year ended December 31, 2017 and
December 31, 2016 are as follows:
|
|
Year ended
|
|
Year Ended
|
|
|
|
|
|
|
December 31, 2017
|
|
December 31, 2016
|
|
Change
|
|
|
$
|
|
$
|
|
$
|
|
%
|
Expenses
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Research and development
|
|
|
2,751,326
|
|
|
|
1,518,589
|
|
|
|
1,232,737
|
|
|
|
81
|
%
|
General and administrative
|
|
|
3,946,270
|
|
|
|
2,916,604
|
|
|
|
1,029,666
|
|
|
|
35
|
%
|
Professional fees
|
|
|
1,294,044
|
|
|
|
1,245,182
|
|
|
|
48,862
|
|
|
|
4
|
%
|
Amortization
|
|
|
2,797
|
|
|
|
2,690
|
|
|
|
107
|
|
|
|
4
|
%
|
Depreciation
|
|
|
89,613
|
|
|
|
43,131
|
|
|
|
46,482
|
|
|
|
108
|
%
|
Loss from operations
|
|
|
8,084,050
|
|
|
|
5,726,196
|
|
|
|
2,357,854
|
|
|
|
41
|
%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Gain on settlement of liabilities
|
|
|
(5,000
|
)
|
|
|
-
|
|
|
|
(5,000
|
)
|
|
|
N/A
|
|
Foreign exchange loss (gain)
|
|
|
(13,978
|
)
|
|
|
14,296
|
|
|
|
(28,274
|
)
|
|
|
-198
|
%
|
Loss before income taxes
|
|
|
8,065,072
|
|
|
|
5,740,492
|
|
|
|
2,324,580
|
|
|
|
40
|
%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Income tax expense
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
N/A
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net loss and comprehensive loss
|
|
|
8,065,072
|
|
|
|
5,740,492
|
|
|
|
2,324,580
|
|
|
|
40
|
%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Revenue
We did not generate any revenue during the years ended December
31, 2017 and December 31, 2016.
Research and Development
Research and development expense for the year ended December 31,
2017 was $2,751,326 compared to $1,518,589 for the year ended December 31, 2016, an increase of $1,232,737 or 81%. The increase
was primarily due to the licensing fees paid upon entering into a license and supply agreement with Celsee Inc. as part of our
development of ZM-017, ramping up of R&D activities related to the establishment of labs, the hiring of additional full-time
employees, new product candidate development and contracted outsourcing activities. More specifically, contracted outsourced activities
of $821,927, salaries of $620,694, licensing fees of $480,131, consultant fees of $325,388, and supplies of $239,292 relating to
an increased level of contracted outsourced activities, lab activities, including in vitro and in vivo work, to support the further
development of our product candidates ZM-017, ZM-012, ZM-006, ZM-007 and ZM-011. We expect that our R&D expenditures in 2018
will be significantly higher than in 2017, due to the initiation of pilot and pivotal studies related to our four INADs, work related
to verification and validation of ZM-017, and additional veterinary pharmaceutical candidates, diagnostic developments and technologies.
General and Administrative
General and administrative expense for the year ended December 31,
2017 was $3,946,270, compared to $2,916,604 for the year ended December 31, 2016, an increase of $1,029,666 or 35%. The increase
was primarily due to expenses related to the addition of personnel, accounting for salaries of $2,703,865, which included share-based
compensation expense of $849,679, primarily as a result of the granting of options to purchase an aggregate of 535,000 common shares
in February 2017, all of which vested immediately upon the date of grant, and the granting of options to purchase an aggregate
of 1,280,000 common shares in August 2017, of which 1,242,500 have vested. Other expenses included travel and accommodation of
$338,738, office expenses of $199,843, insurance costs of $182,753, marketing and investor relations costs of $168,623, rent of
$164,250, and regulatory expense of $138,289. We expect that general and administrative expense will increase in 2018 and future
periods as we increase our level of activity.
Professional Fees
Professional fees for the year ended December 31, 2017 were $1,294,044
compared to $1,245,182 for the year ended December 31, 2016, an increase of $48,862 or 4%. The increase was primarily due to expenses
in connection with the preparation of our initial U.S. registration statement and work on our application to list our common shares
on the NYSE American. Professional fees for the 2016 period consisted primarily of consulting fees incurred in connection with
establishing our initial operations and preparing to execute our business plan, as well as legal fees incurred in connection with
the Qualifying Transaction and our initial fundraising efforts.
Net Loss
Our net loss for the year ended December 31, 2017 was $8,065,072,
or $0.09 per share, compared with a net loss of $5,740,492, or $0.07 per share, for the year ended December 31, 2016, an increase
of $2,324,580 or 40%. The net loss in each period was attributed to the matters described above. We expect to continue to record
net losses in future periods until such time as have sufficient revenue from our product candidates to offset our operating expenses.
Cash Flows
Year ended December 31, 2017 compared to year ended December
31, 2016
The following table shows a summary of our cash flows for the periods
set forth below:
|
|
Year ended
|
|
Year ended
|
|
|
|
|
|
|
December 31, 2017
|
|
December 31, 2016
|
|
Change
|
|
|
$
|
|
|
$
|
|
|
$
|
|
|
%
|
|
Cash flows used in operating activities
|
|
|
(7,093,017
|
)
|
|
|
(4,562,168
|
)
|
|
|
(2,530,849
|
)
|
|
|
55
|
%
|
Cash flows provided by financing activities
|
|
|
7,486,220
|
|
|
|
4,786,353
|
|
|
|
2,699,867
|
|
|
|
56
|
%
|
Cash flows used in investing activities
|
|
|
(171,736
|
)
|
|
|
(241,215
|
)
|
|
|
69,479
|
|
|
|
-29
|
%
|
Increase (decrease) in cash
|
|
|
221,467
|
|
|
|
(17,030
|
)
|
|
|
238,497
|
|
|
|
-1400
|
%
|
Cash and cash equivalents, beginning of year
|
|
|
3,226,680
|
|
|
|
3,243,710
|
|
|
|
(17,030
|
)
|
|
|
-1
|
%
|
Cash and cash equivalents, end of year
|
|
|
3,448,147
|
|
|
|
3,226,680
|
|
|
|
221,467
|
|
|
|
7
|
%
|
Operating Activities
Net cash used in operating activities for the year ended December
31, 2017 was $7,093,017, compared to $4,562,168 for the year ended December 31, 2016, an increase of $2,530,849, or 55%. The increase
resulted primarily from our net loss of $8,065,072 for the year ended December 31, 2017, compared to our net loss of $5,740,492
for the year ended December 31, 2016. The largest uses of cash stemmed from an increase in salaries, bonus and benefits as we had
20 employees at December 31, 2017 compared to 11 employees at December 31, 2016. Other significant increases in uses of cash include
a licensing fee payment of $500,000 to Celsee, Inc., professional fees and consulting expenses related to the preparation of our
initial U.S. registration statement, work on our application to list our common shares on the NYSE American, and an increase in
the current portion of the prepaid expenses and deposits. The increase in prepaid expenses and deposits was due to increased deposits
with our contract manufacturing organization and increased prepaid health insurance premiums from an overall increase in the number
of employees.
Net cash used in operating activities for the year ended December
31, 2016 was $4,562,168, which resulted primarily from our net loss of $5,740,492. The largest uses of cash were for employee salaries,
bonus and benefits, fees paid to various consultants related to the Qualifying Transaction, and an increase in prepaid expenses
and deposits. In 2016, we entered into lease agreement for our new headquarters in Ann Arbor, Michigan and prepaid $801,973 in
rent for the entire five-year term. The increase in prepaid expenses and deposits was also due to increased deposits with our contract
manufacturing organization and increased prepaid health insurance premiums from an overall increase in the number of employees.
Financing Activities
Net cash provided by financing activities for the year ended December
31, 2017 was $7,486,220, compared to net cash provided by financing activities of $4,786,353 for the year ended December 31, 2016,
an increase of $2,699,867, or 56%. The increase resulted primarily from the private placement of $6,570,000 of our common shares
in 2017, and proceeds from the exercise of stock options for $979,522, partially offset by stock issuance costs of $56,576 and
repayment on a shareholder loan of $6,726.
Net cash provided by financing activities for the year ended December
31, 2016 was $4,786,353, which relates to cash acquired in the Qualifying Transaction, partially offset by cash paid for the stock
issuance in the Qualifying Transaction.
Investing Activities
Net cash used in investing activities for the year ended December
31, 2017 was $171,736, compared to $241,215 for the year ended December 31, 2016, a decrease of $69,479, or 29%. The decrease resulted
primarily from reduced leasehold improvements and reduced purchases of furniture and equipment for our additional office space
in Ann Arbor.
Net cash used in investing activities for the year ended December
31, 2016 was $241,215, which primarily resulted from the investment in research equipment in support of the expanding R&D activities.
Liquidity and Capital Resources
We have incurred losses and negative cash flows from operations
and have not generated any revenue since our inception in May 2015. As of December 31, 2017, we had an accumulated deficit of $15,626,100.
We have funded our working capital requirements primarily through the sale of our common shares and the exercise of stock options.
At December 31, 2017, we had cash and cash equivalents of $3,448,147.
Working capital (defined as current assets minus current liabilities)
was $3,433,955 as at December 31, 2017. This was primarily due to cash and cash equivalents of $3,448,147 and prepaid expenses
and deposits of $786,273, partially offset by accounts payables and accrued liabilities of $828,737.
On October 17, 2017 we entered into a five-year $5,000,000 unsecured
working capital facility with Equidebt LLC, one of our shareholders (the “Equidebt Facility”). Amounts borrowed under
the Equidebt Facility bear interest at a rate of 14% per annum payable at maturity. All amounts borrowed under the Equidebt Facility
become due and payable on October 17, 2022. We can make two borrowing per month under the Equidebt Facility, each of which must
be for a minimum of $250,000. The Equidebt Facility is unsecured; however Gerald A. Solensky Jr., our Chairman of the Board, President
and Chief Executive Officer, has personally guaranteed our obligations under the Equidebt Facility.
We believe that our existing cash and available borrowings under
the Equidebt Facility will be sufficient to fund our operations through the next twelve months. Our ability to continue as a going
concern is ultimately dependent upon our ability to achieve sustainable positive cash flow from operations. However, we do not
expect to generate revenue from the sale of our product candidates for the foreseeable future. To the extent that we do not generate
sufficient cash flow from our operations, we intend to finance our working capital requirements through equity and/or debt financings,
development agreements or marketing license agreements, the collection of revenues resulting from future commercialization activities
and/or new strategic partnership agreements. There can be no assurance that we will be able to obtain any such capital on terms
or in amounts sufficient to meet our needs or at all. The availability of equity or debt financing will be affected by, among other
things, the results of our research and development activities, our ability to obtain regulatory approvals, market acceptance of
any products for which we receive marketing approval, conditions in the capital markets generally and in the veterinary products
industry, strategic alliance agreements and other relevant commercial considerations.
If we raise additional funds by issuing equity securities, our existing
security holders will likely experience dilution, and the incurring of indebtedness would result in increased debt service obligations
and could require us to agree to operating and financial covenants that could restrict operations. In the event that we are unable
to obtain sufficient capital to meet our working capital requirements, we may be required to change or curtail current or planned
operations in order to conserve cash until such time, if ever, that sufficient proceeds from operations are generated. In such
an event, we may not be able to take advantage of business opportunities, and may have to terminate or delay safety and efficacy
studies, curtail our product development programs, or sell or assign rights to our product candidates, products and technologies.
Based on the closing price of our common shares on December 31,
2017, the market price of our common shares exceeded the exercise price of our outstanding stock options. To the extent that some
or all of such stock options are exercised, we would receive the proceeds of such exercises which would provide additional capital
for our company. However no assurance can be given that any of such stock options will be exercised or as to the proceeds and timing
of any exercises that do occur. The willingness of option holders to exercise their options depends on a number of factors, including,
without limitation: the future market price of our common shares; the availability of capital to fund the payment of the exercise
price of such options, the tax consequences of any such exercises and the ability of such option holders to resell some or all
of the common shares received upon such exercises.
Our future capital requirements depend on many factors, including,
but not limited to:
|
•
|
the scope, progress, results and costs of researching and developing our current or future product candidates;
|
|
•
|
the timing of, and the costs involved in, obtaining regulatory approvals for any of our current or future product candidates;
|
|
•
|
the number and characteristics of the product candidates we pursue;
|
|
•
|
the cost of manufacturing our current and future product candidates and any products we successfully commercialize;
|
|
•
|
the cost of commercialization activities if any of our current or future product candidates are approved for sale, including marketing, sales, service, customer support and distribution costs;
|
|
•
|
the expenses needed to attract and retain skilled personnel;
|
|
•
|
the costs associated with being a public company;
|
|
•
|
our ability to establish and maintain strategic collaborations, licensing or other arrangements and the financial terms of such agreements; and
|
|
•
|
the costs involved in preparing, filing, prosecuting, maintaining, defending and enforcing possible patent claims, including litigation costs and the outcome of any such litigation.
|
Off Balance Sheet Arrangements
Since inception, we have not engaged in the use of any off-balance
sheet arrangements, such as structured finance entities, special purpose entities or variable interest entities.
Quantitative and Qualitative Disclosures about Liquidity and Market Risk
Liquidity risk is the risk that we will encounter difficulty raising
liquid funds to meet our commitments as they fall due. In meeting our liquidity requirements, we closely monitor our forecasted
cash requirements with expected cash drawdown.
We are exposed to interest rate risk, which is affected by changes
in the general level of interest rates. Due to the fact that our cash is deposited with major financial institutions in an interest-bearing
savings account, we do not believe that the results of operations or cash flows would be affected to any significant degree by
a sudden change in market interest rates given their relative short-term nature.
We are also exposed to credit risk at period end from the carrying
value of our cash. We manage this risk by maintaining bank accounts with a Canadian Chartered Bank and a U.S. bank that is a member
of the Federal Deposit Insurance Corporation. Our cash is not subject to any external restrictions.
We are exposed to changes in foreign exchange rates between the
Canadian and United States dollar which could affect the value of our cash. We had no foreign currency hedges or other derivative
financial instruments as of December 31, 2017. We do not enter into financial instruments for trading or speculative purposes and
do not currently utilize derivative financial instruments.
We have balances denominated in Canadian dollars that give rise
to exposure to foreign exchange (“FX”) risk relating to the impact of translating certain non-U.S. dollar balance sheet
accounts as these statements are presented in U.S. dollars. A strengthening U.S. dollar will lead to a FX loss, while a weakening
U.S. dollar will lead to a FX gain. For each Canadian dollar balance of $1.0 million, a +/- 10% movement in the Canadian currency
held by us versus the U.S. dollar would affect our loss and other comprehensive loss by $100,000.
Recent Accounting Pronouncements
In May 2014, the Financial Accounting Standards Board (“FASB”)
issued Accounting Standards Update (“ASU”) No. 2014-09, Revenue from Contracts with Customers, requiring an entity
to recognize the amount of revenue to which it expects to be entitled for the transfer of promised goods or services to customers.
The updated standard will replace most existing revenue recognition guidance in U.S. GAAP when it becomes effective. In March 2016
the FASB issued ASU No. 2016-08 to clarify the implementation guidance on considerations of whether an entity is a principal or
an agent, impacting whether an entity reports revenue on a gross or net basis. In April 2016, the FASB issued ASU No. 2016-10 to
clarify guidance on identifying performance obligations and the implementation guidance on licensing. In May 2016, the FASB issued
amendments ASU No. 2016-11 and 2016-12 to amend certain aspects of the new revenue guidance (including transition, collectability,
noncash consideration and the presentation of sales and other similar taxes) and provided certain practical expedients. The guidance
is effective for annual reporting periods beginning after December 15, 2017 (including interim reporting periods). Early adoption
is permitted but not before the annual reporting period (and interim reporting period) beginning January 1, 2017. Entities have
the option of using either a full retrospective or a modified approach to adopt the guidance. We are in the process of evaluating
the amendments to determine if they have a material impact on our financial position, results of operations, cash flows or disclosures.
In January 2016, the FASB issued ASU No. 2016-01, which makes limited
amendments to the guidance in U.S. GAAP on the classification and measurement of financial instruments. The new standard significantly
revises an entity’s accounting related to (1) the classification and measurement of investments in equity securities and
(2) the presentation of certain fair value changes for financial liabilities measured at fair value. It also amends certain disclosure
requirements associated with the fair value of financial instruments. ASU No. 2016-01 is effective for fiscal years beginning after
December 15, 2017, and interim periods within those annual periods. We are in the process of evaluating the amendments to determine
if they have a material impact on our financial position, results of operations, cash flows or disclosures.
In February 2016, the FASB issued new guidance, ASU No. 2016-02,
Leases (Topic 842). The main difference between current U.S. GAAP and the new guidance is the recognition of lease liabilities
based on the present value of remaining lease payments and corresponding lease assets for operating leases under current U.S. GAAP
with limited exception. Additional qualitative and quantitative disclosures are also required by the new guidance. Topic 842 is
effective for annual reporting periods (including interim reporting periods) beginning after December 15, 2018. Early adoption
is permitted. We are in the process of evaluating the amendments to determine if they have a material impact on our financial position,
results of operations, cash flows or disclosures.
In August 2016, the FASB issued ASU 2016-15, Statement of Cash Flows
(Topic 230) Classification of Certain Cash Receipts and Cash Payments, which will make eight targeted changes to how cash receipts
and cash payments are presented and classified in the Statement of Cash Flows. ASU 2016-15 will be effective on May 1, 2018, and
will require adoption on a retrospective basis unless it is impracticable to apply, in which case we would be required to apply
the amendments prospectively as of the earliest date practicable. We are in the process of evaluating the amendments to determine
if they have a material impact on our financial position, results of operations, cash flows or disclosures.
In August 2016, the FASB issued ASU 2017-01 that changes the definition
of a business to assist entities with evaluating when a set of transferred assets and activities is a business. The guidance requires
an entity to evaluate if substantially all of the fair value of the gross assets acquired is concentrated in a single identifiable
asset or a group of similar identifiable assets; if so, the set of transferred assets and activities is not a business. ASU 2017-01
also requires a business to include at least one substantive process and narrows the definition of outputs by more closely aligning
it with how outputs are described in ASC 606.1. ASU 2017-01 is effective for public business entities for fiscal years beginning
after December 15, 2017, and interim periods within those years. Early adoption is permitted. We are in the process of evaluating
the amendments to determine if they have a material impact on our financial position, results of operations, cash flows or disclosures.
In May 2017, FASB issued ASU 2017-09 in relation to Compensation
—Stock Compensation (Topic 718), Modification Accounting. The amendments provide guidance about which changes to the terms
or conditions of a share-based payment award require an entity to apply modification accounting in Topic 718. The amendments are
effective for all entities for annual periods, and interim periods within those annual periods, beginning after December 15, 2017.
Early adoption is permitted, including adoption in any interim period, for (1) public business entities for reporting periods for
which financial statements have not yet been issued and (2) all other entities for reporting periods for which financial statements
have not yet been made available for issuance. The amendments should be applied prospectively to an award modified on or after
the adoption date. We are in the process of evaluating the amendments to determine if they have a material impact on our financial
position, results of operations, cash flows or disclosures.
BUSINESS
Overview
We are a development stage veterinary diagnostic and pharmaceutical
company creating products for companion animals (canine, feline, and equine) by focusing on the unmet needs of clinical veterinarians.
We believe that we have identified and are developing diagnostics and therapeutics that have the potential to significantly improve
the diagnosis and treatment of various diseases affecting companion animals. We believe that there are significant unmet medical
needs for pets, and that the pet diagnostic and therapeutic segments of the animal health industry are likely to grow substantially
as new diagnostic tools and treatments are identified, developed, and marketed specifically for companion animals.
Together with our strategic partner, we are developing liquid biopsy
assays and related consumables for the detection of cancer in companion animals. The regulatory pathway to obtain pre-market regulatory
approval of companion animal diagnostics is significantly shorter than for similar diagnostic products intended for human use.
In certain cases, pre-market regulatory approval may be unnecessary, depending on the intended use of the diagnostic.
We also have identified a number of drugs that have proven safe and
effective in humans that we are developing for use in companion animals. We believe this development approach enables us to reduce
the risks associated with obtaining regulatory approval for unproven product candidates and shortens the development timeline necessary
to bring our product candidates to market. We have four drug product candidates in early development and have identified several
other potential product candidates for further investigation.
In addition, we are investigating the development of alternative
drug delivery technologies for our drug product candidates. Many of the human-approved therapeutics used in companion animals are
only available in pill or injectable form. However, it can be difficult to give a companion animal an injection or to assure that
the animal has swallowed a pill. As a result, we believe that compliance with treatment regimens is a significant problem for veterinarians
and pet owners. The challenges associated with medicating pets are unique, and we believe that developing product candidates that
can be easily taken by the pet or easily administered by pet owners will help increase compliance.
Market Opportunity
U.S. consumers spent an estimated $69.4 billion on their pets in
2017, according to the American Pet Products Association, or APPA, an increase of 4% from 2016. The veterinary care segment has
been among the fastest growing segments of the overall U.S. pet market. This segment accounted for an estimated $16.6 billion in
revenue in 2017, an increase of 4% from 2016. According to dvm360 Magazine’s State of the Profession survey for 2015, diagnostics
comprise 18%, and vaccinations, pharmaceuticals and biologicals comprise 25% of gross revenue at the veterinary practice level.
The dvm360 Magazine survey also states that 61% of respondents indicated
that they were providing more diagnostic services than the prior year. Similarly, a 2016 Credit Suisse survey of veterinarians
found that 73% of respondents expected their diagnostic testing to increase over the next 12 months. According to MarketsandMarkets™,
the veterinary diagnostics market is expected to grow at a CAGR of 9.3% between 2017 and 2022, reaching $3.62 billion in sales
by 2022, with North America accounting for the largest market share in 2016. The companion animal segment is expected to register
the highest growth during the forecast period.
Packaged Facts’ Pet Medications, in its U.S. report for 2017,
estimated the size of the U.S. pet medication market, the largest companion animal market worldwide, at $8.6 billion in 2017, up
from $7 billion in 2015. Future Market Insights estimates that the global companion animal drug market is expected to grow at a
compounded annual growth rate of 4.9% from 2015 - 2025.
We believe that several factors have contributed and will continue
to contribute to an increase in spending on pet therapeutics. Companion animals are generally living longer, with the average lifespan
for dogs increasing by half a year to 11 years between 2002 and 2012, according to a study by Banfield Pet Hospital. As a result,
companion animals increasingly require medical treatment. In 2015, the American Animal Hospital Association estimated that the
average dog will account for approximately $3,600 in veterinary bills over its lifespan. According to Pet Supplies Plus, baby boomers
are adopting pets in record numbers. In its December 2015 issue, Pet Business magazine predicted that the millennial generation
would continue the trend of the baby boomers in their enthusiasm for and interest in their pets and pet products and services.
This, we believe, along with the increasing awareness of, as the U.S. Public Health Service states, “the mental and emotional
benefits of companion animals” and our use of companion animals to address or assist in a range of health and wellness issues
including post-traumatic stress disorder and autism, will bolster the growth and development of the pet therapeutics market.
Pet owners in the United States generally pay for diagnostics and
therapeutics for their companion animals out-of-pocket. According to statistics from the North American Pet Health Insurance Association,
only about 1.8 million dogs and cats were covered by an insurance plan in 2016. This represents less than 1% of the nearly 184
million dogs and cats that the American Pet Products Association estimates are owned in the United States. We believe that this
results in less pricing pressure than in human health care, although the limited adoption of insurance may also reduce pet owners
ability to pay for diagnostics and therapeutics recommended by their veterinarians.
Development of Companion Animal Diagnostics
The development of companion animal diagnostics continues to evolve
with the addition of new technologies to diagnostic portfolios. We believe that these new technologies may allow for the following:
|
·
|
Enhanced capability to detect the frequency of occurrence and severity of diseases and conditions that impact companion animals;
|
|
·
|
Increased accuracy, lower cost and faster means to obtain test results;
|
|
·
|
Wider availability of new diagnostic tools; and
|
|
·
|
Enhanced economic benefits for veterinarians.
|
Compared to human diagnostic development, the development of companion
animal diagnostics is generally faster and less expensive since it typically requires smaller clinical studies, with fewer subjects.
We believe that the lower cost of developing companion animal diagnostics enables us to pursue multiple diagnostic candidates simultaneously
and to spread the risk of failure across a number of candidates, rather than concentrating all of our resources on one diagnostic
candidate that may ultimately fail to achieve regulatory approval or market acceptance.
Development of Companion Animal Therapeutics
Compared to human drug development, the development of companion
animal therapeutics is generally faster, more predictable, and less expensive, since it requires fewer clinical studies involving
fewer subjects and can be conducted directly in the target species. Based on our progress since commencing business in May 2015,
we believe that we will be able to develop a product candidate, from the initial opening of an INAD with the FDA-CVM through to
marketing approval, in approximately three to five years at a cost of approximately $3 million to $5 million per product candidate.
According to the Tufts Center for the Study of Drug Development, the successful development of a new drug for use in humans can
take more than 10 years and requires an average out-of-pocket expenditure of approximately $1.4 billion. The lower cost associated
with the development of companion animal therapeutics permits us to pursue multiple product candidates simultaneously and to spread
the risk of failure across a number of product candidates, rather than concentrating all of our resources on one novel candidate
that may ultimately fail to achieve regulatory approval or market acceptance.
Because we are developing product candidates based on drugs that
have been successfully developed and approved for human use—as opposed to drugs based on new active pharmaceutical ingredients
(APIs)—we believe that we will be able to avoid or minimize the expenses associated with the human drug development process
and more rapidly advance our development programs, while continuing to comply with current good manufacturing practices, or cGMP,
for our product candidates. Since we are not pursuing entirely new chemical entities with our drug product candidates, we believe
the risk of failure of a specific drug product candidate is significantly lower compared to developing a novel compound.
The respective businesses of developing and commercializing therapeutics
for companion animals and humans share a number of characteristics, including the need to:
|
·
|
Demonstrate safety and efficacy in clinical trials;
|
|
·
|
Obtain FDA-CVM or other regulatory approval for marketing;
|
|
·
|
Manufacture the therapeutics in facilities compliant with cGMP requirements; and
|
|
·
|
Market the therapeutics only for their intended indication based on claims permitted in the product label, and not for other uses, which is referred to as “off-label” use.
|
However, despite these similarities, there are a number of important
differences between the companion animal therapeutics and human therapeutics businesses, including:
|
·
|
Faster, less expensive and more predictable development.
The development of therapeutics for companion animals requires fewer clinical studies in fewer subject animals than the development of human therapeutics and, unlike human therapeutics, studies are conducted directly in the target species. We believe that our strategy of selecting APIs with demonstrated efficacy and safety in humans and that are currently being used by veterinarians in their human compounded form enhances the predictability of results and probability of success of our pivotal trials relative to novel compounds that have not been previously validated.
|
|
·
|
Role and incentives for veterinary practices.
In the United States, veterinarians generally serve the dual role of doctor and pharmacist, and pet owners typically purchase medications directly from their veterinarians. However, veterinarians often are required to have human drugs specially compounded by third-party compounding pharmacies for use in smaller companion animals, resulting in the loss of much of the associated prescription revenue and an increase in the uncertainty around precise dosing and administration. We believe that therapeutics specifically developed for companion animals will enable veterinarians to provide potentially superior treatment options, while also increasing revenue streams from the sale of these therapeutics.
|
|
·
|
Less generic competition and strong brand loyalty.
There is less generic competition in the companion animal therapeutics industry than in the human health care industry. According to the Generic Animal Drug Alliance, 86% of FDA-approved animal drugs do not have a generic version. We believe that stronger brand loyalty and a lack of the mandatory generic drug substitution that exists in the human pharmaceutical market, partially explains the low penetration of generics in veterinary medicine.
|
Unmet Medical Needs
Diagnostics
We believe that there is a significant unmet medical need for cost-effective
and accurate disease/condition detection solutions for veterinarians. We believe that we have identified potential diagnostic assays
that have the potential to satisfy unmet needs or improve upon existing diagnostic processes frequently used by companion animal
veterinarians.
For example, cancer is a prevalent disease in canines that can be
difficult and costly to diagnose using existing diagnostic testing. According to the Veterinary Cancer Society, 50% of all dogs
over the age of 10 will develop cancer and one in four dogs will develop cancer at some stage in their life. Diagnosing certain
cancers in canines is difficult because the location of the tumor may make it difficult or risky to obtain cell material through
a biopsy. In addition, the overall health of a canine may increase the risk of performing a biopsy. Other diagnostic technologies,
such as advanced imaging, are expensive while others, such as histopathologic examination, may take several days or more to provide
a definitive diagnosis. Many more canine cancer cases may go undetected due to cost constraints and other factors. To address these
shortcomings, we are developing a circulating tumor cell detection assay for use in the detection of certain cancers in companion
animals.
Therapeutics
Despite the growing market for pet therapeutics, there are relatively
few treatment options approved for use in companion animals, as compared to those approved for humans. As a result, veterinarians
often must resort to prescribing products approved for use in humans, but not approved or formulated for use in companion animals.
According to the FDA’s Electronic Animal Drug Product Listing Directory, approximately 54% of the therapeutics used in animals
are unapproved for such use. As a result, veterinarians must rely upon trial and error or untested rules of thumb to assess the
proper dosage needed to be effective in the particular species without undue risk of side effects. The veterinarian must also find
a way to administer the human product to animals and determine the actual dosage amount, tasks which are important and potentially
overlooked as practical considerations in the treatment of companion animals. To do this, veterinarians often rely on compounding
pharmacies to formulate human drugs into species’ appropriate doses and formulations. As a result, veterinarians are forced
to rely on therapeutics not proven safe and effective for their patients and on formulations for which no regulatory approval has
been obtained. At the same time, the use of compounding pharmacies results in the veterinary clinic’s loss of much of the
associated prescription revenue.
We believe that therapeutics specifically developed for companion
animals can extend and improve the quality of the lives of such animals, help veterinarians achieve improved medical outcomes,
and make the process of administering therapeutics to companion animals much safer and more convenient. Advances in human medicines
have created new therapeutics for managing many chronic diseases. Pets often suffer from many of these same diseases. In many cases,
the biology of these diseases in companion animals is very similar to that in humans, which explains why animal efficacy models
are used for human drug development. Because of the similarity of the diseases and their symptoms and effects, many human drugs,
when formulated properly and administered in proper doses, are effective in companion animals. However, most human drugs are not
specially formulated or approved for use in animals.
Many of the human therapeutics used in companion animals are only
available in pill or injectable form. However, it can be difficult to give a companion animal a shot or to assure that it has swallowed
a pill. It can also be difficult to divide human pills into small enough portions to achieve an appropriate dosage for companion
animals. Consequently, we believe that compliance with treatment regimens is a significant problem for veterinarians and pet owners.
The challenges associated with medicating pets are unique, and we believe that developing product candidates that can be easily
taken by the pet or that can be easily administered by pet owners will help increase compliance.
Product Pipeline
Diagnostics
Together with our strategic partner, we are developing a circulating
tumor cell, or CTC, assay, also known as a “liquid biopsy,” for use by veterinarians as a cancer diagnostic. The liquid
biopsy is a blood test that we believe has the potential to detect the presence of CTCs, which are cells that have shed from a
primary tumor into neighboring blood vessels and are transported throughout the body’s circulatory system. Diagnosing certain
cancers in canines is difficult because the location of the tumor may make it difficult or risky to obtain cell material through
a biopsy. In addition, the overall health of a canine may increase the risk of performing a biopsy. Other diagnostic technologies,
such as advanced imaging, are expensive while others, such as histopathologic examination, may take several days or more to provide
a definitive diagnosis. We believe that the detection of CTCs in the blood could provide strong clinical support for a cancer diagnosis
without the need for an invasive tissue biopsy or other expensive or time-consuming diagnostic test. We intend to develop and market
ZM-017, a liquid biopsy for the detection of certain cancers in canines. If we successfully develop ZM-017, we expect that ZM-017
will provide veterinarians with a faster, more affordable, and less invasive test for certain cancers in canines compared to existing
detection methods.
We expect to commence clinical validation of ZM-017 in the first
half of 2018. Assuming that we successfully complete that clinical validation, we expect to commence the marketing of ZM-017 during
the second half of 2018.
Therapeutics
We have four drug product candidates. Our lead drug product candidate
is ZM-012, a novel tablet formulation of metronidazole targeting the treatment of acute diarrhea in dogs. An Investigational New
Animal Drug, or INAD, was opened for ZM-012 with the Food and Drug Administration’s Center for Veterinary Medicine, or FDA-CVM,
in April 2016. The API in ZM-012 is metronidazole, which has been the subject of multiple studies in humans and has been approved
for use in humans for decades. We do not believe that the API in ZM-012 is protected by any patents or other proprietary rights
of third parties in the U.S. We have finalized the formulation of ZM-012 as a beef-flavored oral tablet intended for dogs greater
than nine pounds or four kilograms and we completed pilot testing of ZM-012 in the fourth quarter of 2017. In December 2017, we
had a pre-submission meeting with the FDA-CVM to present the regulatory strategy and development plan for ZM-012. Based on the
feedback we received from the FDA-CVM, we are making certain changes to the development plan for ZM-012 which we believe will not
delay its development. We expect to commence a pivotal safety study of ZM-012 in the first half of 2018, which we expect to complete
in the second half of 2018.
Our second drug product candidate is ZM-007, an oral suspension formulation
of metronidazole and a complementary formulation to ZM-012, targeting the treatment of acute diarrhea in small dog breeds and puppies
under nine pounds or four kilograms. An INAD was opened for ZM-007 with the FDA-CVM in October 2016. We have finalized the formulation
and completed pilot testing of ZM-012. We expect to hold a pre-submission meeting in the first half of 2018 with the FDA-CVM specific
to the product development strategy for ZM-007 as a bioequivalent to ZM-012. Drugs that are considered to be bioequivalent are,
for regulatory purposes, essentially the same, meaning the absence of significant difference between the extent and rate of absorption
over the course of a specific period of time at the same dose and under the same conditions. If deemed acceptable by the FDA-CVM,
the implementation of this bioequivalent strategy is contingent on FDA-CVM approval of the new animal drug application (NADA) for
ZM-012. If the FDA-CVM permits us to rely on the bioequivalence of ZM-007 to ZM-012, we anticipate that this regulatory pathway
will conserve significant development costs because a bioequivalence study could replace the need for pivotal safety and efficacy
studies for ZM-007.
Our third drug product candidate is ZM-006, a transdermal gel formulation
of methimazole targeting hyperthyroidism in cats. Hyperthyroidism is one of the most commonly diagnosed endocrine disorders in
middle-aged to older cats according to the American Association of Feline Practitioners. We are investigating ZM-006 pursuant to
an INAD opened with the FDA-CVM in June 2016. The API in ZM-006, methimazole, has been the subject of multiple studies in humans
and has been approved for oral use in humans for decades. Our transdermal gel formulation is intended to provide an alternative
to an oral tablet formulation already approved by the FDA-CVM for cats. We do not believe that the API in ZM-006 is protected by
any patents or other proprietary rights of third parties. ZM-006 is intended for application to the cat’s ear using an applicator
pen. The formulation of ZM-006 has been completed. We expect to complete pilot testing of ZM-006 in the first half of 2018, and
assuming that such pilot testing is successful, we intend to commence and complete a pivotal safety study of ZM-006 in the second
half of 2018.
Our fourth drug product candidate is ZM-011, a transdermal gel formulation
of fluoxetine, most commonly known as Prozac®, its human pharmaceutical brand name. Fluoxetine in pill or compounded form is
frequently prescribed by veterinarians to treat feline behavioral disorders such as inappropriate urination. We are investigating
ZM-011 pursuant to an INAD opened with the FDA-CVM in January 2017. The API, fluoxetine, has been the subject of multiple studies
in humans and has been approved for use in humans for decades. We do not believe that the API in ZM-011 is protected by any patents
or other proprietary rights of third parties. ZM-011 is a transdermal gel formulation intended for application to the cat’s
ear using an applicator pen. The formulation of ZM-011 has been completed. We expect to complete pilot testing of ZM-011 in the
second half of 2018.
License Agreements
In January 2017, we entered into a collaborative research agreement
with Celsee, Inc., or Celsee, a developer of diagnostics for the detection and quantification of cells and other markers. Subsequent
to this agreement, in December 2017, we entered into a license and supply agreement with Celsee for exclusive global rights to
develop and market Celsee’s liquid biopsy platform. The agreement with Celsee covers the development and commercialization
of liquid biopsy assays and related consumables for the detection of cancer in companion animals. We will be responsible for the
clinical development and commercialization of the assays. Celsee will supply us on an exclusive basis with the assays and the consumables
for the products to be developed under the agreement pursuant to a rolling forecast to be provided by us at prices specified in
the agreement. We will be responsible for the marketing and sale of the assays and the related consumables. The agreement, which
is exclusive in the field of veterinary cancer diagnostic applications, has a term of seven years (subject to termination in certain
circumstances) and automatically renews for additional one-year terms thereafter.
We have agreed to pay Celsee up-front fees of $500,000 and to issue
to Celsee unregistered common shares having a value of $250,000, consisting of an aggregate of 112,314 common shares to be issued
at an ascribed price of $2.2259. Celsee is entitled to additional payments totaling up to an additional $1 million, payable 50
percent in cash and 50 percent in additional unregistered common shares, upon the achievement of specified milestones—namely,
completion of product development (in respect of 50 percent of the foregoing cash and share payments) and upon successful completion
of manufacturing milestones (as to the remaining 50 percent of the foregoing cash and share payments). Future issuances of shares
will be subject to TSX-V approval and will be priced relative to market at the time of issuance. Celsee is entitled to certain
registration rights with respect to the common shares issued by us under the agreement.
In April 2016, we entered into a collaboration agreement with CTX
Technology, Inc., or CTX, which has developed a peptide-based skin penetration platform technology for the topical delivery of
a range of APIs. Under this agreement, we have an option to obtain an exclusive worldwide license to use CTX’s technology
platform in animals. In the event that we exercise the option, we would be required to pay CTX a one-time license fee of $20,000
and to pay CTX a royalty in the low single digits on any products that we sell that incorporates their technology. Unless we exercise
our option prior thereto, this agreement will terminate on March 1, 2019.
Research and Development
Together with our strategic partner, we are performing development
work on a liquid biopsy diagnostic platform for potential use in companion animals. Our drug product candidate development programs
focus on the development of product candidates for target indications that have already demonstrated safety and efficacy in humans
and the development of therapeutics based on these drugs for appropriate target indications in companion animals. In addition,
we are investigating the development of alternative drug delivery systems for our drug product candidates. We use various contract
research organizations, or CROs, to assist in performing our research and development activities.
In connection with these activities, we have incurred and will continue
to incur significant research and development expenses. Our research and development expenses were $2,751,326 for the year ended
December 31, 2017 and $1,518,589 for the year ended December 31, 2016.
Sales and Marketing
We intend to commercialize any product candidate for which we receive
regulatory approval in the United States with a direct sales force. We intend to sell products directly to veterinarians, who typically
mark up the diagnostics and therapeutics that they prescribe for pet owners. We believe that veterinarians are self-motivated to
prescribe innovative therapeutics that are safe, effective, and supported by reliable clinical data and regulatory approval in
order to improve the health of companion animals, while also generating additional revenue.
We will focus on marketing directly to both reference labs and the
end user, veterinarians. It is common utility for veterinarians to send diagnostic samples to reference labs for analysis. Our
strategic plan will be to sell the ZM-017 diagnostic equipment to a reference lab(s), while driving utilization of the test with
the end user, veterinary community/market, back to the lab.
We also intend to selectively utilize distributors, which we believe
will enable us to expand our commercial reach to a majority of all veterinarians in our chosen markets. We believe that we can
compete effectively with a combination of our own direct sales force and complementary distributors.
To support our marketing efforts, we introduced a unique “Voice
of the Vet™” program in the fourth quarter of 2016 to gather insights and better understand the needs of veterinarians
and their practices, and to gauge interest for potential future product offerings, while building brand awareness as a valued veterinary
partner. Our Voice of the Vet™ program allows veterinarians, practice managers and veterinary technicians to participate
in conversations where they can share ideas and experiences with each other, as well as with us through an interactive platform.
As part of our commercialization strategy, we also plan to participate in large veterinary meetings and to establish partnerships
with leading veterinary colleges.
Manufacturing
We have no internal manufacturing capabilities for our diagnostic
and therapeutic product candidates.
Under our license and supply agreement, Celsee is responsible for
the manufacture and supply of the CTC platform technology and consumables to us. Celsee has primary responsibility for assuring
that all products will be manufactured in accordance with applicable laws and meet all agreed upon specifications.
To ensure a dependable and high quality supply of the APIs for our
pilot studies and pivotal trials, we rely on cGMP-compliant contract manufacturers. Because the APIs in our drug product candidates
are used in human drugs that are no longer subject to patent protection, we believe that there are multiple contract manufacturers
for our drug product candidates that have demonstrated the ability to provide high-quality formulated products more cost effectively
than we could on our own. We believe that the contract manufacturers of our trial supplies will be able to provide commercial supplies
of any of our drug product candidates that are approved for marketing.
While we and our contract manufacturers have historically been able
to obtain supplies of the APIs for development of our drug product candidates, neither we nor our contract manufacturers have long-term
supply agreements with the API manufacturers. We also have no agreements for commercial-scale supply of the API or manufacture
of any of our drug product candidates.
Intellectual Property
We intend to rely primarily upon a combination of in-licensing exclusive
rights, regulatory exclusivity, proprietary know-how, and confidentiality agreements to protect our diagnostic assays, product
formulations, processes, methods and other technologies and to preserve any trade secrets and operate without infringing on the
proprietary rights of other parties, both in the United States and in other countries. We currently have no issued patents.
Because our drug product candidates are based on approved human drugs
that no longer are subject to patent protection, there is little, if any, composition-of-matter patent protection available for
the API in these product candidates. Where feasible, however, we intend to pursue the broadest intellectual property protection
possible for our compounds and any proprietary technology through enhanced formulations of our drug product candidates. However,
even intellectual property protection, if available, may not afford us with complete protection against competitors.
We depend upon the skills, knowledge and experience of our management
personnel, as well as that of our other employees, advisors, consultants and contractors, none of which are patentable. To help
protect our know-how, and any inventions for which patents may be difficult to obtain or enforce, we require all of our employees,
consultants, advisors and other contractors to enter into customary confidentiality and inventions agreements that prohibit the
disclosure of confidential information and, where applicable, require disclosure and assignment to us of the ideas, developments,
discoveries and inventions important to our business.
Competition
Diagnostics
Our potential competitors include large human pharmaceutical and
medical diagnostics companies, small businesses focused on animal health, and reference laboratory services provided by academic
institutions and in-clinic product providers. These competitors include Idexx Laboratories, Inc., Antech Diagnostics, a unit of
VCA Inc., Abaxis, Inc., Heska Corporation and Zoetis Inc.
Therapeutics
If our drug product candidate is the first one approved by the FDA-CVM
for use in animals, it may be eligible for between three and seven years of regulatory exclusivity in the United States, depending
on the type of product and its intended use. However, while there are fewer competitors in the pet therapeutics industry than in
the human pharmaceutical industry, the development and commercialization of new animal health medicines is highly competitive,
and we expect competition from major pharmaceutical, biotechnology and specialty animal health medicine companies.
Our potential competitors include large animal health companies,
which currently derive a significant portion of their revenue from livestock medications. Large animal health companies include
Merck Animal Health, the animal health division of Merck & Co., Inc.; Elanco, the animal health division of Eli Lilly and Company;
Bayer Animal Health, the animal health division of Bayer AG; Novartis Animal Health, the animal health division of Novartis AG;
Boehringer Ingelheim Animal Health, the animal health division of Boehringer Ingelheim GmbH; and Zoetis, Inc., as well as European
companies such as Virbac S.A., Vetoquinol S.A., and Dechra Pharmaceuticals PLC. We are also aware of several smaller early stage
companies that are developing products for use in the pet therapeutics market, including Kindred Biosciences, Inc., Aratana Therapeutics,
Inc., Parnell Pharmaceuticals Holdings Ltd., and Jaguar Animal Health, Inc. Our drug product candidates will also face competition
from medicines and products approved for use in humans that are used off-label for pets. Private organizations, academic institutions
and government agencies conducting animal health product research are also considered potential competitors.
General
Many of our competitors and potential competitors have substantially
more financial, technical, and human resources than we do. Many also have far more experience in the development, manufacture,
regulation and worldwide commercialization of animal diagnostics and animal health medicines, including pet therapeutics. We also
expect to compete with academic institutions, governmental agencies and private organizations that are conducting research in the
fields of animal diagnostics and animal health medicines. If such competing products achieve regulatory approval and commercialization
prior to our product candidates, or if our intellectual property protection and efforts to obtain regulatory exclusivity fail to
provide us with exclusive marketing rights for some of our products, we may be unable to effectively compete in the markets in
which we participate.
Government Regulation
Diagnostic Product Candidates
Our diagnostic product candidates may be subject to regulatory review
by the USDA-CVB and/or post-marketing oversight by the USDA-CVB or FDA-CVM. Generally speaking, full diagnostic kits aimed at the
detection or diagnosis of an infectious disease in animals, including the materials required for testing along with instructions
for use and interpretation of results, used at the point-of-care, including in-office diagnostic tests, may be subject to pre-market
regulatory review and approval by the USDA-CVB. The USDA-CVB’s review process for diagnostics is subject to some variability
based on the type of diagnostic kit being reviewed, however, the USDA-CVB will generally review the results of specific tests that
are required to be conducted in accordance with the USDA-CVB’s testing criteria. These include diagnostic sensitivity/specificity
studies, conducted using a large number of samples of U.S. origin, reproducibility/repeatability/suitability studies used to evaluate
test kits under field conditions in participating laboratories and ruggedness studies in which manufacturers measure the ruggedness
or robustness of the diagnostic test kits based on the capacity of the assay to remain unaffected by small variations in or deviations
from the instructions for use (for example, not allowing the samples to reach the designated temperature). Diagnostic products
and testing kits that do not claim to detect or diagnose an infectious disease and that are not designed for use at the point-of-care
are generally subject only to post-marketing oversight by the FDA-CVM or the USDA-CVB. While the sale of these products does not
require premarket approval by the FDA-CVM and does not subject us to the FDA-CVM’s cGMP requirements, these products must
not be adulterated, mislabeled or misbranded under the Federal Food, Drug and Cosmetic Act, or the FDC Act, and are subject to
post-marketing review.
Drug Product Candidates
The FDA-CVM regulates animal pharmaceuticals under the FDC Act. In
order to obtain regulatory approval to market a drug product candidate in the U.S., an applicant must demonstrate that the product
candidate is safe, effective and produced by a consistent method of manufacture. Post-approval monitoring of products is required
by law, with reports being provided to the FDA-CVM's Surveillance and Compliance group. Reports of product quality defects, adverse
events or unexpected results are required in accordance with the law.
Prior to commencing testing of a drug product candidate, an applicant
is required to open an INAD with the FDA-CVM. Formulation work and pilot testing occurs once the INAD is opened. This is followed
by a pre-submission conference with the FDA-CVM to discuss and agree on a proposed development plan, including the design of pivotal
safety and clinical trials that would support approval of a new animal drug application, or NADA.
Early pilot studies may be conducted in laboratory animals to establish
clinical endpoints and the dose range for a new drug product candidate. Data on how well the drug is absorbed when dosed by different
routes of administration and the relationship of the dose to the effectiveness are studied.
During development, the applicant will usually submit a proposed
pivotal trial protocol to the FDA-CVM for review and concurrence prior to conducting the trial. The applicant must gather and submit
data on manufacturing, safety and effectiveness to the FDA-CVM for review, which will be conducted according to timelines specified
in the Animal Drug User Fee Act, or ADUFA. ADUFA also imposes certain fees including a sponsor fee of $75,150 per year, an application
fee of $238,100 per product candidate submission, and certain administrative application and manufacturing fees imposed per product
candidate per year based on sales.
The pivotal clinical trial must be conducted with the formulation
of the drug product candidate that is intended to be commercialized, and is a multi-site, randomized, controlled study, generally
with a placebo control. To reduce bias in the study, individuals doing the assessment are not told whether the subject is in the
group receiving the treatment being tested or the placebo group.
Once all data have been submitted and reviewed for each technical
section - safety, effectiveness and chemistry, manufacturing and controls, or CMC - the FDA-CVM issues a “technical section
complete letter” as each section review is completed, and when all three letters have been issued, the applicant prepares
a draft of the Freedom of Information Summary, the proposed labeling, and all other relevant information, and submits these for
FDA review. An administrative NADA is a NADA that is submitted after all of the technical sections that fulfill the requirements
for the approval of the new drug product candidate have been reviewed by FDA-CVM and FDA-CVM has issued a technical section complete
letter for each of those technical sections. Although this process is not required and submission of a non-administrative NADA
is also acceptable, we plan to take advantage of the administrative NADA process to obtain a timelier phased review. Because FDA-CVM
has already reviewed the individual technical sections before the administrative NADA is filed, FDA-CVM is committed under ADUFA
to reviewing and acting on 90% of administrative NADAs within 60 days after submission. The FDA-CVM user fee goal is to review
and act on 90% of non-administrative NADAs within 180 days after submission. After approval, we will be required to collect reports
of adverse events and submit them on a regular basis to the FDA.
Other Regulatory Considerations
Regulatory rules relating to human food safety, food additives, or
drug residues in food will not apply to our product candidates because our product candidates are not intended for use in food
animals or food production animals.
Advertising and promotion of animal health products is controlled
by regulations in the United States. These rules generally restrict advertising and promotion to those claims and uses that have
been reviewed and authorized by the FDA-CVM.
Any drug product candidate, if approved, may eventually face generic
competition in the United States. In the United States, a generic animal drug may be approved pursuant to an Abbreviated New Animal
Drug Application, or ANADA. Instead of demonstrating the drug’s safety and effectiveness in the target species as required
in a NADA, a generic applicant must only show that the proposed generic product is the same as, and bioequivalent to, the approved
brand name product. However, if any of our drug product candidates is the first one approved by the FDA-CVM for use in animals,
it will be eligible for between three and seven years of regulatory exclusivity in the United States, depending on the type of
product and its intended use.
We will be required to conduct post-approval monitoring of any approved
product and to submit reports of product quality defects, adverse events or unexpected results, and be subject to regulatory inspection
from time to time. Safety, quality, or efficacy concerns can lead to product recalls, withdrawals or suspended or declining sales,
as well as product liability and other claims.
Employees
As of December 31, 2017, we had 20 employees, including one employee
who is a doctor of veterinary medicine. Of our employees, four are engaged in research and development activities, five are engaged
in business development and marketing activities, and eleven are engaged in corporate and administrative activities. None of our
employees are represented by labor unions or covered by collective bargaining agreements.
Properties
Our corporate headquarters is located in Ann Arbor, Michigan, where
we lease approximately 7,900 square feet pursuant to a lease that expires February 2022. Our research and development laboratory
is also located in Ann Arbor, Michigan, where we lease approximately 4,800 square feet pursuant to a lease that expires in August
2018. We have the option to extend that lease for three additional years. We believe that our facilities are sufficient for our
existing and expected future needs.
Legal Proceedings
We are not currently a party to any material legal proceedings.
Corporate Information
Zomedica Pharmaceuticals Corp. (formerly, Wise Oakwood Ventures Inc.)
was originally incorporated as Wise Oakwood Ventures Inc. on January 7, 2013 under the
Business Corporations Act
(Alberta).
On October 28, 2013, we completed our initial public offering in Canada and became classified as a Capital Pool Company, as defined
under the rules of the TSX Venture Exchange, or TSX-V. On April 21, 2016, we changed our name to Zomedica Pharmaceuticals Corp.
and consolidated our common shares on a one-for-two and one-half (2½) basis. ZoMedica Pharmaceuticals Inc., or ZoMedica
Inc., was incorporated on May 14, 2015 under the
Canada Business Corporations Act
. On April 21, 2016, we completed a qualifying
transaction, or the Qualifying Transaction, under TSX-V Policy 2.4 –
Capital Pool Companies
, consisting of a three-cornered
amalgamation among our company, ZoMedica Inc. and our wholly-owned subsidiary. Under the Qualifying Transaction, ZoMedica Inc.
and our subsidiary were amalgamated to form Zomedica Pharmaceuticals Ltd., or Zomedica Ltd. As consideration for the amalgamation,
shareholders of ZoMedica Inc. became the owners of 97.6% (non-diluted) of our common shares, and ZoMedica Ltd. became our wholly-owned
subsidiary. Subsequent to the Qualifying Transaction, Zomedica Ltd. was vertically amalgamated into our company. We have one wholly-owned
subsidiary, Zomedica Pharmaceuticals, Inc., a Delaware company. ZoMedica Inc. entered into the Qualifying Transaction in order
to accomplish the following:
|
·
|
Enable its shareholders to own shares in a company that was publicly traded on the TSX-V;
|
|
·
|
Expand its shareholder base to include the public shareholders of Wise Oakwood; and
|
|
·
|
Obtain access to the cash resources raised by Wise Oakwood in its initial public offering.
|
On November 10, 2017, our shares were approved for listing on the
NYSE American under the symbol “ZOM”. On November 20, 2017 the U.S. Securities and Exchange Commission declared our
registration statement on Form S-1 effective. Our common shares commenced trading on the NYSE American on November 21, 2017.
Our principal executive offices are located at 100 Phoenix Drive,
Suite 190, Ann Arbor, MI 48108, and our telephone number is (734) 369-2555. Our website address is www.zomedica.com. The information
contained in, or accessible through, our website is not part of the registration statement of which this prospectus forms a part.
MANAGEMENT
Executive Officers and Directors
The following table sets forth the name, age, position and tenure
of each of our directors and executive officers as of February 27, 2018:
Name
|
Age
|
Position
|
Gerald Solensky Jr.
|
44
|
Chairman of the Board, President and Chief Executive Officer
|
Shameze Rampertab
|
51
|
Chief Financial Officer, Corporate Secretary and Director
|
Stephanie Morley
|
42
|
Chief Operations Officer and Vice President of Product Development
|
Robert DiMarzo
|
61
|
Executive Vice President of Global Strategy
|
Bruk Herbst
|
48
|
Chief Commercial Officer
|
James LeBar
(1)(2)(3)
|
65
|
Director
|
Rodney Williams
(1)(2)(3)
|
56
|
Director
|
Jeffrey Rowe
(1)(3)
|
62
|
Director
|
Thomas Robitaille
(1)(2)
|
55
|
Director
|
Jane Eagleson
(3)
|
66
|
Director
|
_________________________________________________________________
(1)
|
|
Member of the Audit Committee
|
(2)
|
|
Member of the Compensation Committee
|
(3)
|
|
Member of the Nominating and Corporate Governance Committee
|
Management
Gerald Solensky Jr.
is the founder of our business. He has
been our President and Chief Executive Officer since May 2015. He has been the Chairman of our board of directors since May 2016.
From 2013 to 2015, Mr. Solensky worked on developing our business model, authored a consumer financial education program and completed
over 800 hours of observation time with a board-certified veterinary surgeon to garner a more complete understanding of our veterinary
customers and their associated needs. From 2010 to 2013, he was a consultant for business turnarounds and capital raising. We selected
Mr. Solensky to serve on and lead our board of directors due to his track-record building successful operations within start-up,
turnaround and rapid-change environments.
Shameze Rampertab, CPA, CA
has been our Chief Financial Officer
since March 2016. In April 2016, he took on the roles of Corporate Secretary and Director. Mr. Rampertab acted as an independent
consultant for a number of companies, including us, in respect of which he provided general financial advisory and accounting services
prior to his appointment as Chief Financial Officer, from November 2015 to March 2016. He was the Chief Financial Officer of multiple
publicly-traded health care companies including Profound Medical Corp. from October 2014 to November 2015 and Intellipharmaceutics
International Inc. from October 2010 to October 2014. Mr. Rampertab is a chartered professional accountant and chartered accountant
with twenty years of experience in capital markets, strategic planning and analysis. He holds an MBA from McMaster University and
a Bachelor’s degree in molecular genetics and molecular biology from the University of Toronto. We selected Mr. Rampertab
to serve on our board of directors due to his strong experience in the financial, medical and scientific arenas.
Stephanie Morley, DVM
has been our Chief Operations Officer
and Vice President of Product Development since July 2017. From October 2015 until July 2017, she served as our Chief Operating
Officer. Prior thereto, from July 2015 until October 2015, Dr. Morley was a consultant for us providing strategic and tactical
support. From December 2013 to August 2015 Dr. Morley served as Associate Director of Business Development with the University
of Michigan Medical School. From April 2006 to August 2013 Dr. Morley held several positions of increasing responsibility with
MPI Research, a contract research organization, including Vice President of Operations. Dr. Morley is a trained veterinarian, having
earned her DVM degree from Michigan State University. After earning her DVM degree, Dr. Morley was a practicing veterinarian with
Oakwood Animal Hospital in Kalamazoo, MI and Adobe Animal Medical Center in Albuquerque, NM where she assumed dual roles of both
clinical practitioner and operations management.
Robert DiMarzo
has been our Executive Vice President of Global
Strategy since February 2017. Mr. DiMarzo was intermittently a Principal Consultant with DiMarzo Business Consulting from November
2007 to February 2017, including advising our company. From August 2015 through January 2016, Mr. DiMarzo was Vice President of
Commercial Development and Product Category Management with the global animal health group at Henry Schein, Inc. Prior to that,
he was Executive Chairman of the U.S. animal health distributor Ivesco Holdings, LLC from April 2010 to October 2013. Before that,
Mr. DiMarzo was Executive Vice President of Sales and Marketing for the veterinary diagnostic startup Scandinavian Micro Biodevices
from July 2008 to April 2010. From 1992 to 2007 Mr. DiMarzo held several director-level and executive leadership position with
Pfizer Animal Health, including President of U.S. Operations.
Bruk Herbst
has been our Chief Commercial Officer since July
2017. From October 2015 to December 2016 Mr. Herbst was the Executive Senior Vice President of Sales and Marketing at i4C Innovations
Inc. d/b/a Voyce, an animal health and wellness company. From October 2007 to September 2015, he served as Executive Senior Director
and Head of U.S. Sales at IDEXX Laboratories, Inc, a developer, manufacturer and distributor of products and services for the companion
animal veterinary and other markets, where he was responsible for in-clinic and reference lab diagnostics, point of care, information
technologies and digital radiology. From January 1999 to October 2007 Mr. Herbst also held commercial leadership roles in patient
monitoring, pharmacy and diagnostics with Omnicare Specialty Care Group and Life Systems. He holds a Bachelor of Science degree
in business from the University of Arizona.
Non-Management Directors
James LeBar
has been a Director and the Chairman of our Compensation
Committee since April 2016. Mr. LeBar also served as a director on the board of Zomedica Pharmaceuticals, Inc. from May 2015 until
the completion of our Qualifying Transaction in April 2016. From March 2011 until his retirement in January 2016, Mr. LeBar served
as a turnaround consultant for Nationwide Placement Inc., a specialized health training company. We selected Mr. LeBar to serve
on our board of directors due to his experience as an entrepreneur and executive leader, an expert in building and operating start-up
companies and establishing corporate structures for profitability and success.
Rodney Williams
,
MBA
has served as a Director and
the Chair of our Corporate Governance Committee (now called the Nominating and Corporate Governance Committee) since April 2016.
He is currently employed as Corporate Global Vice President Portfolio and Services for publicly-traded Align Technologies (ALGN)
as of February 1, 2017. Previously, Mr. Williams was an entrepreneur-in-residence with PTV Healthcare Capital, a private equity
investment firm and he has been with PTV since October 2015. Prior to PTV, he was President and CEO of Heart Rhythm Society Consulting
Services from January 2013 through August 2015. From January 2008 through January 2013, Mr. Williams served as Senior Vice President
of Global Product Planning and Marketing at St. Jude Medical Inc. Mr. Williams also served in commercial leadership roles in sales
and marketing at GE Healthcare, Johnson and Johnson, and Bausch & Lomb. Mr. Williams earned both his MBA and Bachelor of Science
degrees from the University of Southern California and attended the General Management Executive Leadership Program at The Wharton
School of Business. We selected Mr. Williams to serve on our board of directors due to his experience with both large and small-cap
medical technology and related health care companies and his global commercialization expertise.
Jeffrey Rowe
has served as a Director and the Chairman of
our Audit Committee since April 2016. Until his retirement in October 2015, Mr. Rowe served as Executive Vice President and a Director
of Diplomat Pharmacy, Inc., the largest independent specialty pharmacy company in the U.S. During his tenure with Diplomat, the
company grew from a single location with less than $5 million in revenue, to sixteen locations and $3 billion in sales, and became
publicly traded on the New York Stock Exchange. Prior to his career with Diplomat, Mr. Rowe owned two successful community pharmacies
in Genesee County, Michigan. He holds a Bachelor of Pharmacy degree from Ferris State University. We selected Mr. Rowe to serve
on our board of directors due to his financial expertise and his extensive experience in pharmaceutical operations, the specialty
pharmacy industry and fundamental business strategies involving accreditation, contracting, cybersecurity and regulation, combined
with an expertise in compounding and integrative medicine.
Thomas Robitaille
has been a Director since October 2016.
Mr. Robitaille is an independent management consultant specialized in animal health. From February 2016 to April 2017, he was the
Vice President of Veterinary Channel Development at Blue Buffalo Company, a premium, all-natural pet food company. From October
2006 to October 2015, Mr. Robitaille was the Director of the Americas for the animal health pharmaceutical company Vetoquinol SA
Inc. As the Director of the Americas he managed affiliated companies and regional distributors in Canada, the United States, Mexico
and Brazil. He was responsible for veterinary pharmaceutical operations in the United Kingdom, Ireland, Belgium, and the Netherlands
as Managing Director and also served as Director of International Development, where he contributed to an increase in sales and
profit for in Eastern Europe, Asia Pacific, Africa, and Latin America. He has a Master of Business Administration degree from the
University of Warwick and Bachelor of Science degree from Concordia University. We selected Mr. Robitaille to serve on our board
of directors due to his lengthy experience in the animal health industry and his skills in the areas of product development, sales
and marketing and mergers and acquisitions.
Jane Eagleson,
has been a Director since October 2016. Dr.
Eagleson is a veterinarian with more than 30 years of experience in animal health pharmaceutical development. She has owned Bleecker
Street Consulting, a consulting firm specializing in global animal health pharmaceutical product development strategy since January
2013. From November 2014 until the company’s acquisition by Zoetis Inc. in July 2017, she served as Vice President of Clinical
and Regulatory Affairs at Nexvet US, Inc., a veterinary biotherapeutics company, where she was responsible for the clinical and
regulatory phases of global biopharmaceutical product development. From September 2007 through December 2012, Dr. Eagleson was
the General Manager of Research & Development and subsequently the Head of Growth Strategies for Argenta Limited, a specialist
animal health contract manufacturing organization based on Auckland, New Zealand, through December 2010 and New Jersey thereafter.
At Argenta, Dr. Eagleson was responsible for the management of a subsidiary of the company, Alcherabio, an animal health clinical
contract research organization in New Jersey, the development staff in New Zealand and the overall management of Argenta’s
strategic plans. She has a Master of Veterinary Science in immunology from Massey University and Bachelor of Veterinary Science
(U.S. DVM equivalent) from the University of Sydney. She has also authored a number of publications in peer reviewed journals.
We selected Dr. Eagleson to serve on our board of directors due to her in depth knowledge of the animal health industry and regulatory
agencies in developed markets including the United States, European Union and Oceania.
Board Composition
Our board of directors currently consists of seven members. Our
bylaws provide that our directors will hold office until the close of the first annual meeting of shareholders following his or
her election unless the director is elected for a stated term. Our board of directors is responsible for the business and affairs
of our company and considers various matters that require its approval.
Our board of directors is comprised of a majority of directors who
are “independent” (as discussed below), and the Board has established an Audit Committee, a Compensation Committee
and a Nominating and Corporate Governance Committee. We have adopted charters for our each of these committees and a code of ethics
and business conduct, or Code of Ethics. Our Code of Ethics is available on our website at www.zomedica.com. The committee charters
are also available for review on our website.
Director Independence
Our board of directors has determined that all of our directors,
other than Messrs. Solensky and Rampertab, are “independent,” as defined under the NYSE American. For purposes of the
NYSE American rules, an independent director means a person other than an executive officer or employee of our company or any other
individual having a relationship which, in the opinion of our board of directors, would interfere with the exercise of independent
judgment in carrying out the responsibilities of a director, subject to certain additional limitations. Such directors are
also deemed to be “independent” under applicable Canadian securities laws.
Code of Ethics
Our board of directors has adopted the Code of Ethics, which applies
to all officers, directors and employees. Our Code of Ethics is available on our website at www.zomedica.com. Information contained
in, or accessible through, our website does not constitute part of this Form 10-K. We intend to disclose any amendments to our
Code of Ethics, or waivers of its requirements, on our website or in our filings under the Exchange Act.
Board Committees
Our board of directors has three standing committees: the Audit
Committee, the Compensation Committee and the Nominating and Corporate Governance Committee. All of our committee members are “independent,”
as defined under the NYSE American rules and for purposes of Canadian securities laws.
Each of our committee charters is available on our website at www.zomedica.com.
Audit Committee
Our audit committee is currently comprised of four members, Mr.
Rowe (Chairman), Mr. Williams, Mr. LeBar and Mr. Robitaille. Each member of our audit committee is a non-employee member of our
board of directors. We have designated Mr. Rowe as our “audit committee financial expert,” as defined under Item 407
of Regulation S-K. All of the members of our audit committee are “independent” members of our board of directors, as
required by the NYSE American rules and Canadian securities laws.
The purpose of our audit committee of our board of directors is
to oversee (i) the integrity of our company’s financial statements, our company’s accounting and financial reporting
processes and financial statement audits; (ii) our company’s compliance with applicable legal and regulatory requirements;
(iii) our company’s systems of internal control over financial reporting and disclosure controls and procedures; (iv) the
independent auditor’s engagement, qualifications, performance, compensation and independence; (v) review of related party
transactions; and (vi) compliance with the company’s corporate policies. The audit committee’s function is one of oversight,
whereas the planning and conduct of the audit is the responsibility of the independent auditor, and the financial statements are
the responsibility of the company’s management.
Each member of the audit committee has experience reviewing financial
statements and dealing with related accounting and auditing issues and is “financially literate” within the meaning
of Canadian securities laws.
The audit committee has the sole authority to pre-approve all audit
and permitted non-audit services provided by the independent auditor.
Compensation Committee
Our compensation committee is currently comprised of three members,
Mr. LeBar (Chairman), Mr. Williams and Mr. Robitaille. All of the members of our compensation committee are “independent”
directors, as defined under the NYSE American rules and for purposes of Canadian securities laws.
The purpose of our compensation committee is to (i) make recommendations
to our board of directors relating to evaluation and compensation of our executives, (ii) oversee incentive, equity-based and other
compensatory plans in which executive officers and key employees of our company participate, (iii) review and participate in determining
director compensation and (iv) prepare any report on executive compensation required by the rules and regulations of the Commission
and the listing standards of NYSE American.
Nominating and Corporate Governance Committee
Our nominating and corporate governance committee is currently comprised
of four members, Mr. Williams (Chairman), Mr. LeBar, Mr. Rowe and Dr. Eagleson. All of the members of our corporate governance
committee are “independent” directors, as defined under the NYSE American rules and for the purposes of Canadian securities
laws.
The purpose of our nominating and corporate governance committee
of our board of directors is to carry out the responsibilities delegated by the board of directors relating to the our director
nominations process, developing and maintaining our company’s corporate governance policies, and any related matters required
by the federal securities laws or by the applicable listing rules of the NYSE American.
Board Leadership Structure and Role in Risk Oversight
Although we have not adopted a formal policy on whether the Chairman
and Chief Executive Officer positions should be separate or combined, we have determined that it is in our best interests and the
best interests of our shareholders to combine these roles. Mr. Solensky currently serves as our Chief Executive Officer and Chairman
of our board of directors. Due to our small size and our early development stage, we believe it is currently most effective to
have the Chairman and Chief Executive Officer positions combined.
Our board of directors is primarily responsible for overseeing our
risk management processes. The board of directors receives and reviews periodic reports from management, auditors, legal counsel,
and others, as considered appropriate regarding our assessment of risks. The board of directors focuses on the most significant
risks facing our general risk management strategy, and us and also ensures that risks undertaken by us are consistent with the
board’s appetite for risk. While the board oversees our risk management, management is responsible for day-to-day risk management
processes. We believe that this division of responsibilities is the most effective approach for addressing the risks facing us
and that our board leadership structure supports this approach.
EXECUTIVE AND DIRECTOR
COMPENSATION
The following table shows the compensation for each of the years
ended December 31, 2017 and December 31, 2016 awarded to or earned by our principal executive officer and our two other most highly
compensated executive officers who were serving as executive officers as of December 31, 2017. The persons listed in the following
table are referred to herein as the “named executive officers.”
|
|
|
|
Salary
|
|
Bonus
|
|
Option
|
|
All Other
|
|
Total
|
Name and Principal Position
|
|
|
|
($)
|
|
($)
|
|
Awards(4)
|
|
Compensation(5)
|
|
($)
|
|
|
|
|
|
|
|
|
($)
|
|
($)
|
|
|
Gerald Solensky Jr.
(1)
|
|
2017
|
|
285,000
|
|
30,000
|
|
-
|
|
24,000
|
|
339,000
|
Chairman of the Board, President and Chief Executive Officer
|
|
2016
|
|
252,918
|
|
40,000
|
|
323,501
|
|
900
|
|
617,319
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Stephanie Morley
(2)
|
|
2017
|
|
187,500
|
|
30,000
|
|
272,089
|
|
12,000
|
|
501,589
|
Chief Operations Officer and Vice President of Product Development
|
|
2016
|
|
175,001
|
|
40,000
|
|
250,306
|
|
-
|
|
465,307
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Robert DiMarzo
(3)
|
|
2017
|
|
188,125
|
|
18,000
|
|
287,064
|
|
67,958
|
|
561,147
|
Executive Vice President of Global Strategy
|
|
2016
|
|
-
|
|
-
|
|
34,053
|
|
25,000
|
|
59,053
|
__________________
(1)
Mr. Solensky entered into an employment
agreement in December 2016 which was amended in August 2017 pursuant to which he receives an annual salary of $285,000 and a monthly
car allowance of $2,000. Mr. Solensky received a grant of options to purchase 950,000 common shares at an exercise price of $1.19
in 2016.
(2)
Dr. Morley entered into an employment agreement
with us in October 2015 pursuant to which she receives an annual salary of $150,000 per annum, which was increased to $200,000
effective July 2017. Effective in July 2017, Dr. Morley also receives a monthly allowance of $2,000 for vehicle and tax preparation.
Dr. Morley received a grant of options to purchase 1,100,000 common shares at an exercise price of $0.20 in 2016, a grant of options
to purchase 600,000 common shares at an exercise price of $1.19 in 2016, and a grant of options to purchase 500,000 common shares
at an exercise price of $2.18.
(3)
Mr. DiMarzo began serving as a consultant
in October 2016 and received consulting fees of $50,958 in cash and options to purchase 100,000 common shares at an exercise price
of $1.19. He was appointed Executive Vice President of Global Strategy of Zomedica Pharmaceuticals, Inc. in February 2017. Mr.
DiMarzo entered into an employment agreement with us in February 2017 pursuant to which he receives an annual salary of $215,000
and a monthly allowance of $4,000 for vehicle, insurance and tax preparation. Mr. DiMarzo received a grant of options to purchase
500,000 common shares at an exercise price of $1.19 in 2017 and a grant of options to purchase 250,000 common shares at an exercise
price of $2.18 in 2017.
(4)
Represents the aggregate grant date fair
value for grants made in 2017 and 2016, respectively, computed in accordance with FASB ASC Topic 718. The assumptions we used
in valuing options are described in Note 10 to our financial statements included in this prospectus.
(5)
All Other Compensation represents
consulting fees and monthly allowances.
Employment and Consulting Agreements
Gerald Solensky Jr.
In December 2016, we entered into an employment agreement with Mr.
Solensky, which was amended in August 2017 pursuant to which Mr. Solensky serves as our President and Chief Executive Officer.
Mr. Solensky’s amended employment agreement has an unspecified term and provides him with an annual base salary of $285,000
plus quarterly bonuses and participation in our employee benefit plan. In addition, we agreed to pay Mr. Solensky a $2,000 monthly
car allowance and four weeks of paid vacation. Pursuant to Mr. Solensky’s amended employment agreement, any options granted
to him will be subject to accelerated vesting upon a change of control, a resolution of our board in anticipation of a change of
control, our termination of his employment without cause or his resignation for good reason. Mr. Solensky’s employment agreement
also includes customary non-solicitation, confidentiality and assignment of inventions provisions. If we terminate Mr. Solensky’s
employment without cause or he resigns for good reason, we are required to pay him twelve months base salary and any quarterly
bonus allocable or payable prior to termination.
Stephanie Morley
In connection with her appointment as Chief Operations Officer and
Vice President of Product Development, effective July 1, 2017, we entered into an employment agreement with Dr. Morley that superseded
and replaced her earlier employment agreement with us. The agreement is effective for a period of one year and automatically extends
for one year terms unless either party elects to terminate it. Dr. Morley’s employment agreement provides her with an annual
base salary of $200,000 and quarterly bonuses upon the achievement of certain specified objectives. In addition, we agreed to pay
Dr. Morley a $2,000 monthly allowance in respect of the following items: (i) vehicle and (ii) tax preparation. Dr. Morley is entitled
to three weeks paid vacation time. We granted Dr. Morley options to purchase 500,000 common shares at an exercise price of $2.20
per share and, under her employment agreement, Dr. Morley is eligible to receive additional options to purchase 500,000 common
shares in the fourth quarter of 2017. All such grants will have an exercise price of not less than fair market value on the date
of grant. Pursuant to Dr. Morley’s employment agreement, any options granted to her will be subject to accelerated vesting
upon our termination of Dr. Morley’s employment without cause. Dr. Morley’s employment agreement also includes customary
non-solicitation, confidentiality and assignment of inventions provisions. In the event that Dr. Morley has a “separation
from service” within the meaning of Section 409A of the Internal Revenue Code of 1986, as amended, or the Code, Dr. Morley
would have the right to exercise all of her options, and we would be required to pay her a lump sum equal to 12 months of her base
salary and any quarterly bonus allocable or payable prior to the date of termination.
Robert DiMarzo
Effective February 1, 2017, we entered into an employment agreement
with Robert DiMarzo. Mr. DiMarzo serves as our Executive Vice President of Global Strategy. The agreement is effective for a period
of one year and automatically extends for one year terms unless either party elects to terminate it. Mr. DiMarzo’s employment
agreement provides for an annual base salary of $215,000. In addition, Mr. DiMarzo is eligible to receive up to four quarterly
bonuses totaling $36,000 upon the achievement of certain specified objectives. In addition, we agreed to pay Mr. DiMarzo a $4,000
monthly allowance in respect of the following items: (i) vehicle; (ii) insurance (medical, dental, vision) premiums; and (iii)
tax preparation. Mr. DiMarzo is entitled to three weeks paid vacation time, and five business days’ vacation during the period
between December 25 and December 31 of each year. We granted Mr. DiMarzo options to purchase 500,000 common shares at an exercise
price of $1.20 per common share and, under his employment agreement, he is eligible to receive additional options to purchase 250,000
common shares upon the six month anniversary upon achievement of six month performance objectives, and to receive further options
to purchase 250,000 common shares upon the twelve month anniversary upon achievement of twelve month performance objectives. All
such grants will have an exercise price of not less than fair market value on the date of grant. Pursuant to Mr. DiMarzo’s
employment agreement, any options granted to him will be subject to accelerated vesting upon our termination of Mr. DiMarzo’s
employment without cause or resignation by Mr. DiMarzo for good reason. Mr. DiMarzo’s employment agreement also includes
customary non-solicitation, confidentiality and assignment of inventions provisions. If we terminate Mr. DiMarzo’s employment
other than for cause or Mr. DiMarzo resigns for good reason, we are required to pay Mr. DiMarzo twelve months base salary and any
quarterly bonus amounts payable.
Outstanding Equity Awards at Fiscal Year End
The following table sets forth certain information, on an award-by-award
basis, concerning outstanding equity awards for each named executive officer as of December 31, 2017.
|
|
Option awards
|
|
|
|
Stock awards
|
|
Name
|
|
Number of
securities
underlying
unexercised
options (#)
exercisable
|
|
|
Number of
securities
underlying
options (#)
unexercisable
|
|
|
Equity
incentive plan
awards:
Number of
securities
underlying
unexercised
unearned
options (#)
|
|
|
Option
exercise
price ($)
|
|
|
Option
expiration
date
|
|
|
Number
of shares
or units
of stock
that have
not vested (#)
|
|
|
Market
Value of
shares of
units of
stock that
have not
vested ($)
|
|
|
Equity
incentive
plan awards:
Number of
unearned
shares, units
or other
rights that
have not
vested (#)
|
|
|
Equity
incentive
plan awards:
Market or
payout value
of unearned
shares, units
or other
rights that
have not
vested ($)
|
|
Jerry Solensky Jr.
(2)
|
|
|
200,000
|
|
|
|
-
|
|
|
|
-
|
|
|
|
1.19
|
|
|
12/21/2018
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
Dr. Stephanie Morley
(1)
|
|
|
1,100,000
|
|
|
|
-
|
|
|
|
-
|
|
|
|
0.20
|
|
|
4/21/2018
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
Dr. Stephanie Morley
(2)
|
|
|
600,000
|
|
|
|
-
|
|
|
|
-
|
|
|
|
1.19
|
|
|
12/21/2018
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
Dr. Stephanie Morley
(4)
|
|
|
500,000
|
|
|
|
-
|
|
|
|
-
|
|
|
|
2.18
|
|
|
8/14/2019
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
Robert DiMarzo
(2)
|
|
|
100,000
|
|
|
|
-
|
|
|
|
-
|
|
|
|
1.19
|
|
|
12/21/2018
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
Robert DiMarzo
(3)
|
|
|
500,000
|
|
|
|
-
|
|
|
|
-
|
|
|
|
1.19
|
|
|
2/24/2019
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
Robert DiMarzo
(4)
|
|
|
250,000
|
|
|
|
-
|
|
|
|
-
|
|
|
|
2.18
|
|
|
8/14/2019
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
__________________
(1) Stock options vest immediately upon issue, with an issue date
of March 28, 2016, and expire on April 21, 2018.
|
(2) Stock options vest immediately upon issue, with an issue date of December 21,
2016, and expire on December 21, 2018.
|
(3) Stock options vest immediately upon issue, with an issue date of February 24,
2017, and expire on February 24, 2019.
|
(4) Stock options vest immediately upon issue, with an issue date of August 14, 2017,
and expire on August 14, 2019.
|
Equity Compensation Plan Information
The following table provides information, as of December 31, 2017,
with respect to all compensation arrangements maintained by us, including individual compensation arrangements, under which shares
are authorized for issuance.
Plan Category
|
|
Number of Securities
to be issued upon
outstanding options
rights (a)
|
|
Weighted-average
exercise price
outstanding options
and rights (b)
|
|
Number of securities
remaining available for future
issuance under equity
compensation plans (excluding
securities reflected in columns
(a)) (c)
|
Equity compensation plans approved by shareholders
|
|
|
8,080,000
|
|
|
$
|
0.96
|
|
|
|
942,586
|
|
Equity compensation plans not approved by shareholders
|
|
|
Nil
|
|
|
|
N/A
|
|
|
|
Nil
|
|
Total
|
|
|
8,080,000
|
|
|
$
|
0.96
|
|
|
|
942,586
|
|
Stock Option Plans
As of December 31, 2015, Zomedica Pharmaceuticals Corp (formerly,
Wise Oakwood Ventures Inc.), had a shareholder-approved option plan, or the WOW Plan, pursuant to which options to purchase 200,000
common shares were outstanding. The terms of the WOW Plan were substantially similar to those of our current Stock Option Plan.
In connection with the Qualifying Transaction, these options were consolidated into options to purchase 80,000 common shares of
Zomedica Pharmaceuticals Corp. and fully exercised and the WOW Plan was terminated.
In April 2016, concurrent with the completion of the Qualifying
Transaction, we adopted a new equity stock option plan, the Stock Option Plan. The Stock Option Plan was approved by our shareholders.
The purpose of the Stock Option Plan is to attract and retain employees, consultants, officers and directors to our company and
to motivate them to advance the interests of our company by affording them with the opportunity, through share options, to acquire
an equity interest in our company and benefit from its growth.
Administration
. The Stock Option Plan is administered by
our board of directors. Our board of directors may grant options to purchase shares of our common shares or such other shares as
may substitute therefore in the capital of Zomedica Pharmaceuticals Corp. Our board of directors also has authority to determine
the terms and conditions of each award, prescribe, amend and rescind rules and regulations relating to the Stock Option Plan, and
amend the terms of awards (provided that no amendment may materially prejudice the rights of a participant without consent such
participant’s consent). Our board of directors may delegate authority to a committee of our directors or to an officer. Our
board or directors may terminate the Stock Option Plan.
Eligibility
. Persons eligible to receive awards under the
Stock Option Plan include any person who is an employee, officer, director or consultant provided that any consultant has performed
and/or continues to perform services for our company under a written agreement and on an ongoing basis or is expected to provide
a service to our company.
Shares Subject to the Stock Option Plan
. The aggregate number
of shares of common shares available for issuance in connection with options and awards granted under the Stock Option Plan is
ten percent of the total number of issued and outstanding common shares calculated on a non-diluted basis. If any award of options
granted under the Stock Option Plan expires or terminates without having been fully exercised, that number of common shares shall
become available for the purpose of future grants under the Stock Option Plan.
Terms and Conditions of Options
. Our board of directors will
determine the exercise price of options granted under the Stock Option Plan. The exercise price of stock options may not be less
than that from time to time permitted under the rules of any stock exchange on which the common shares are then listed. In addition,
the exercise price of an option must be paid in cash.
The number of common shares subject to each option shall be determined
by our board of directors with the following limitations. The number of common shares reserved for issuance to any one individual,
consultant, person conducting investor relations or insider (as defined in the
Securities Act
(Alberta)) in a 12 month period
may not exceed 5%, 2%, 2% and 10%, respectively, of the issued and outstanding common shares at the time of the grant.
No option may be exercisable for more than ten years from the date
of grant. Options granted under the Stock Option Plan will be exercisable at such time or times as our board of directors prescribes
at the time of grant. Options shall only be exercised by the participant as long as the optionee remains or was within the last
ninety days an employee, officer, director or consultant, if the optionee dies, within one year of the optionee's death or if an
optionee is engaged in investor relations activities, within 30 days of being so engaged by our company.
All benefits, rights and options accruing under the Stock Option
Plan are non-transferrable and non-assignable unless specifically provided in the grant. During the lifetime of a participant,
any options granted under the Stock Option Plan may only be exercised by the participant and in the event of the death of a participant,
by the person or persons to whom the participant's rights under the option pass by the participant's will or applicable law.
Effect of Certain Corporate Transactions
. In the event of
a sale by our company of all or substantially all of its assets or in the event of a change of control (as defined in the Stock
Option Plan) of our company, each participant shall be entitled to exercise, in whole or in part, the options granted to such participant
under the Stock Option Plan, either during the term of the option or within ninety days after the date of the sale or change of
control, whichever first occurs.
Director Compensation
We have not established a formal compensation policy for our outside
directors. We did not compensate our outside directors for their service in 2017.
SECURITY OWNERSHIP OF
CERTAIN BENEFICIAL OWNERS AND MANAGEMENT
The table below sets forth certain information
with respect to beneficial ownership of our securities as of February 27, 2018 by:
|
·
|
each person known by us to be the beneficial owner of more than 5% of our issued and outstanding common shares;
|
|
·
|
each of our executive officers and directors; and
|
|
·
|
all executive officers and directors as a group.
|
The number of shares beneficially owned by each
shareholder is determined in accordance with SEC rules. Under these rules, beneficial ownership includes any shares as to which
a person has sole or shared voting power or investment power. Percentage ownership is based on 90,449,869 common shares outstanding
on February 27, 2018. In computing the number of shares beneficially owned by a person and the percentage ownership of that person,
common shares subject to stock options, warrants or other rights held by such person that are currently convertible or exercisable
or will become convertible or exercisable within 60 days of February 27, 2018 are considered outstanding, although these shares
are not considered outstanding for purposes of computing the percentage ownership of any other person.
Unless otherwise stated, the address of each
5% or greater beneficial holder is c/o Zomedica Pharmaceuticals Corp., 100 Phoenix Drive, Suite 190, Ann Arbor, Michigan 48108.
We believe, based on information provided to us, that each of the shareholders listed below has sole voting and investment power
with respect to the shares beneficially owned by the shareholder unless noted otherwise, subject to community property laws where
applicable.
|
|
Beneficial Ownership
|
|
|
Number of Shares
Beneficially Owned
|
|
Percent of Total
Outstanding
Common Shares
|
Name and Address of Beneficial Owner:
|
|
|
|
|
|
|
|
|
Gerald Solensky Jr.
(1)
|
|
|
38,151,100
|
|
|
|
42.1
|
%
|
Jeffrey Rowe
(2)
|
|
|
12,240,480
|
|
|
|
13.5
|
%
|
Stephanie Morley
(3)
|
|
|
3,060,580
|
|
|
|
3.3
|
%
|
Shameze Rampertab
(4)
|
|
|
1,093,000
|
|
|
|
1.2
|
%
|
Robert DiMarzo
(5)
|
|
|
984,880
|
|
|
|
1.1
|
%
|
Bruk Herbst
(6)
|
|
|
203,000
|
|
|
|
*
|
|
James LeBar
(7)
|
|
|
420,000
|
|
|
|
*
|
|
Rodney Williams
(8)
|
|
|
380,000
|
|
|
|
*
|
|
Jane Eagleson
(9)
|
|
|
100,000
|
|
|
|
*
|
|
Thomas Robitaille
(10)
|
|
|
100,000
|
|
|
|
*
|
|
All executive officers and directors as a group (ten persons)
(11)
|
|
|
56,733,040
|
|
|
|
59.3
|
%
|
*
|
Less than one percent.
|
(1)
|
Includes options to purchase 200,000 common shares.
|
(2)
|
Includes 11,120,000 shares are held in the Rowe Family GST Trust,
664,480 shares held by the Jeffrey M. Rowe U/T/A dated November 5, 2004 (the “Jeffrey M. Rowe Living Trust”) and
181,000 shares held by Mr. Rowe through his IRA. Mr. Rowe’s sister, Michele Ramo, serves as trustee to the Rowe Family
GST Trust, with Mr. Rowe’s oversight and Mr. Rowe serves as trustee to the Jeffrey M. Rowe Living Trust. Mr. Rowe exclusively
makes all investment decisions on behalf of this trust. Mr. Rowe also has options to purchase 275,000 common shares.
|
(3)
|
Includes options to purchase 2,200,000 common shares.
Includes 5,000 common shares held by Dr. Morley’s children.
|
(4)
|
Includes options to purchase 750,000 common shares. Includes 3,000 common shares held by Mr. Rampertab’s
children.
|
(5)
|
Includes options to purchase 850,000 common shares.
|
(6)
|
Includes options to purchase 200,000 common shares. Includes
3,000 common shares held by Mr. Herbst’s children.
|
(7)
|
Includes options to purchase 200,000 common shares.
|
(8)
|
Includes 40,000 shares held by Entrust Group Inc. FBO Rodney
James Williams IRA and options to purchase 340,000 common shares.
|
(9)
|
Includes options to purchase 85,000 common shares.
|
(10)
|
Includes options to purchase 100,000 common shares.
|
(11)
|
In the aggregate, this includes options to purchase 5,200,000 common shares.
|
SELLING SHAREHOLDERS
The table below sets forth, as of February 27, 2018, the following
information regarding the selling shareholders:
|
•
|
the number of common shares beneficially owned by each selling shareholder prior to this offering;
|
|
•
|
the number of common shares to be offered by each selling shareholder in this offering;
|
|
•
|
the number of common shares to be beneficially owned by each selling shareholder assuming the sale of all of the common shares covered by this prospectus; and
|
|
•
|
the percentage of our issued and outstanding common shares to be owned by each selling shareholder assuming
the sale of all of the common shares covered by this prospectus based on the number of common shares issued and outstanding as
of February 27, 2018.
|
All information with respect to the common share ownership of the
selling shareholders has been furnished by or on behalf of the selling shareholders. We believe, based on information supplied
by the selling shareholders, that except as may otherwise be indicated in the footnotes to the table below, the selling shareholders
have sole voting and dispositive power with respect to the common shares reported as beneficially owned by them. Because the selling
shareholders identified in the table may sell some or all of the common shares owned by them and covered by this prospectus, and
because there are currently no agreements, arrangements or understandings with respect to the sale of any of the common shares,
no estimate can be given as to the number of common shares available for resale hereby that will be held by the selling shareholders
upon termination of this offering. In addition, the selling shareholders may have sold, transferred or otherwise disposed of, or
may sell, transfer or otherwise dispose of, at any time and from time to time, the common shares they hold in transactions exempt
from the registration requirements of the Securities Act after the date on which they provided the information set forth in the
table below. We have, therefore, assumed for the purposes of the following table, that the selling shareholders will sell all of
the common shares owned beneficially by them that are covered by this prospectus, but will not sell any other common shares that
they presently own. Except as described below under “Relationships with Selling Shareholders,” none of the selling
shareholders has held any position or office, or has otherwise had a material relationship, with us or any of our subsidiaries
within the past three years other than as a result of the ownership of our common shares or other securities.
Name of Selling Shareholder
|
|
Shares
Beneficially
Owned prior to
Offering
|
|
Shares
Offered by this
Prospectus
|
|
Shares
Beneficially
Owned after
Offering
|
|
Percentage
of Shares
Beneficially
Owned
After
Offering
|
Gerald Solensky Jr.
(1)
|
|
|
38,151,100
|
|
|
|
37,201,100
|
|
|
|
950,000
|
|
|
|
1.1
|
%
|
The Rowe Family GST Trust
(2)
|
|
|
11,120,000
|
|
|
|
11,120,000
|
|
|
|
-
|
|
|
|
-
|
|
David Sikkema
|
|
|
4,465,600
|
|
|
|
4,456,600
|
|
|
|
9,000
|
|
|
|
*
|
|
Clinton Starrs
|
|
|
3,815,699
|
|
|
|
3,815,699
|
|
|
|
-
|
|
|
|
-
|
|
Jeffrey T. Pinkston
|
|
|
2,595,800
|
|
|
|
2,595,800
|
|
|
|
-
|
|
|
|
-
|
|
William Carpenter MacArthur
(3)
|
|
|
2,675,740
|
|
|
|
1,374,740
|
|
|
|
1,301,000
|
|
|
|
1.4
|
%
|
Stephanie Laine Morley
(4)
|
|
|
3,060,580
|
|
|
|
855,580
|
|
|
|
2,205,000
|
|
|
|
2.4
|
%
|
Gerald Solensky Sr.
|
|
|
1,297,900
|
|
|
|
1,297,900
|
|
|
|
-
|
|
|
|
-
|
|
Helen D. Starman
(5)
|
|
|
4,096,925
|
|
|
|
30,186
|
|
|
|
669,084
|
|
|
|
*
|
|
Equidebt LLC
(6)
|
|
|
3,578,259
|
|
|
|
3,381,475
|
|
|
|
196,784
|
|
|
|
*
|
|
Damon Granger
|
|
|
632,483
|
|
|
|
632,483
|
|
|
|
-
|
|
|
|
-
|
|
Lisa D. VanGilder Trust
(7)
|
|
|
603,726
|
|
|
|
603,726
|
|
|
|
-
|
|
|
|
-
|
|
Linda D. Becker Living Trust
(8)
|
|
|
556,000
|
|
|
|
556,000
|
|
|
|
-
|
|
|
|
-
|
|
Name of Selling Shareholder
|
|
Shares
Beneficially
Owned prior to
Offering
|
|
Shares
Offered by this
Prospectus
|
|
Shares
Beneficially
Owned after
Offering
|
|
Percentage
of Shares
Beneficially
Owned
After
Offering
|
Trevis J. Burbach
|
|
|
556,000
|
|
|
|
556,000
|
|
|
|
-
|
|
|
|
-
|
|
William K. Becker Living Trust
(9)
|
|
|
556,000
|
|
|
|
556,000
|
|
|
|
-
|
|
|
|
-
|
|
Russell H. VanGilder Jr. Trust
(10)
|
|
|
431,233
|
|
|
|
431,233
|
|
|
|
-
|
|
|
|
-
|
|
Kevin Lewis
|
|
|
414,970
|
|
|
|
389,370
|
|
|
|
25,600
|
|
|
|
*
|
|
Robert K. Martin
|
|
|
389,370
|
|
|
|
389,370
|
|
|
|
-
|
|
|
|
-
|
|
Daniel T. Hibma
|
|
|
405,500
|
|
|
|
389,200
|
|
|
|
16,300
|
|
|
|
*
|
|
Peter A. Levine and Marion V. Day, JTWROS
|
|
|
421,450
|
|
|
|
333,600
|
|
|
|
87,850
|
|
|
|
*
|
|
Radical Capital Ltd.
(11)
|
|
|
325,400
|
|
|
|
325,400
|
|
|
|
-
|
|
|
|
-
|
|
Russell H. VanGilder III
|
|
|
280,301
|
|
|
|
280,301
|
|
|
|
-
|
|
|
|
-
|
|
Barbara Ruth Levine
(12)
|
|
|
203,000
|
|
|
|
203,000
|
|
|
|
-
|
|
|
|
-
|
|
Henry Vander Goot
|
|
|
278,000
|
|
|
|
278,000
|
|
|
|
-
|
|
|
|
-
|
|
Joel Yale Hechtman
|
|
|
278,000
|
|
|
|
278,000
|
|
|
|
-
|
|
|
|
-
|
|
David Stowell Jr.
(13)
|
|
|
296,580
|
|
|
|
259,580
|
|
|
|
37,000
|
|
|
|
*
|
|
Joshua Edward Schuyler
|
|
|
259,580
|
|
|
|
259,580
|
|
|
|
-
|
|
|
|
-
|
|
Great Lakes Investment Company
(14)
|
|
|
227,446
|
|
|
|
227,446
|
|
|
|
-
|
|
|
|
-
|
|
Entrust Group FBO Rodney James Williams IRA
(15)
|
|
|
40,000
|
|
|
|
40,000
|
|
|
|
-
|
|
|
|
-
|
|
Julie K. Tittl
|
|
|
172,493
|
|
|
|
172,493
|
|
|
|
-
|
|
|
|
-
|
|
Russell H. VanGilder III 2010 Grantor Trust
(16)
|
|
|
172,493
|
|
|
|
172,493
|
|
|
|
-
|
|
|
|
-
|
|
Erica D. Sandusky 2010 Grantor Trust
(16)
|
|
|
129,370
|
|
|
|
129,370
|
|
|
|
-
|
|
|
|
-
|
|
William C. Ogle Trust
(17)
|
|
|
129,370
|
|
|
|
129,370
|
|
|
|
-
|
|
|
|
-
|
|
Kevin J. Weatherwax
|
|
|
111,300
|
|
|
|
111,200
|
|
|
|
100
|
|
|
|
*
|
|
Jamie L. VanGilder 2009 Trust
(16)
|
|
|
107,808
|
|
|
|
107,808
|
|
|
|
-
|
|
|
|
-
|
|
Bruce A. Burskey
|
|
|
159,846
|
|
|
|
86,246
|
|
|
|
73,600
|
|
|
|
*
|
|
Erica D. Sandusky 2009 Trust #1
(16)
|
|
|
86,246
|
|
|
|
86,246
|
|
|
|
-
|
|
|
|
-
|
|
Russell H. VanGilder IV 2009 Trust
(16)
|
|
|
86,246
|
|
|
|
86,246
|
|
|
|
-
|
|
|
|
-
|
|
Tiffany R. King 2009 Trust
(16)
|
|
|
86,246
|
|
|
|
86,246
|
|
|
|
-
|
|
|
|
-
|
|
Jeffrey M. Rowe U/T/A dated November 5, 2004
(18)
|
|
|
664,480
|
|
|
|
664,480
|
|
|
|
-
|
|
|
|
-
|
|
Wickfield Properties LLC
(19)
|
|
|
47,866
|
|
|
|
47,866
|
|
|
|
-
|
|
|
|
-
|
|
RJB SEP LLC
(20)
|
|
|
43,123
|
|
|
|
43,123
|
|
|
|
-
|
|
|
|
-
|
|
Michelle M. Hayosh
(21)
|
|
|
80,186
|
|
|
|
30,186
|
|
|
|
50,000
|
|
|
|
*
|
|
Bernard Jay Alpern
|
|
|
21,561
|
|
|
|
21,561
|
|
|
|
-
|
|
|
|
-
|
|
Kristen Grace Boozman
|
|
|
21,561
|
|
|
|
21,561
|
|
|
|
-
|
|
|
|
-
|
|
Robert W. DiMarzo
(22)
|
|
|
984,880
|
|
|
|
134,880
|
|
|
|
850,000
|
|
|
|
1.1
|
%
|
Jane Eagleson
(23)
|
|
|
100,000
|
|
|
|
15,000
|
|
|
|
85,000
|
|
|
|
*
|
|
Matthew M. Wittbrodt
|
|
|
59,347
|
|
|
|
59,347
|
|
|
|
-
|
|
|
|
-
|
|
Daniel B. Carroll
|
|
|
893,133
|
|
|
|
893,133
|
|
|
|
-
|
|
|
|
-
|
|
Mark Edward Letavis
|
|
|
223,283
|
|
|
|
223,283
|
|
|
|
-
|
|
|
|
-
|
|
HPH Phoenix LLC
(24)
|
|
|
588,403
|
|
|
|
588,403
|
|
|
|
-
|
|
|
|
-
|
|
5KP, LLC
(25)
|
|
|
9,052
|
|
|
|
9,052
|
|
|
|
-
|
|
|
|
-
|
|
Tim Turczyn
|
|
|
218,243
|
|
|
|
218,243
|
|
|
|
-
|
|
|
|
-
|
|
(1)
|
Includes options to purchase 200,000 common shares not being offered in this prospectus.
|
(2)
|
Michele Ramo is a trustee and shares voting and dispositive power with Jeffrey. Rowe over the shares held by The Rowe Family GST Trust.
|
(3)
|
Includes options to purchase 1,300,000 common shares. Includes 1,000 shares held by Dr. MacArthur’s child.
|
(4)
|
Includes options to purchase 2,200,000 common shares. Includes 5,000 shares held by Dr. Morley’s children.
|
(5)
|
Ms. Starman is a natural person with voting and dispositive power over an additional 397,300 common shares in her own name; Ms. Starman is also the beneficial owner of an additional 4,066,739 shares, consisting of 3,578,259 common shares held by Equidebt LLC, of which 3,381,475 common shares are being offered in this prospectus , 47,866 common shares held by and being offered by Wickfield Properties LLC and 75,000 common shares held by Ms. Starman’s children; at the entity level, Bradley J. Hayosh and Jeffrey S. Starman have voting and dispositive power over an aggregate 3,429,341 shares, while Ms. Starman and Mr. Hayosh share ownership of both Equidebt LLC and Wickfield Properties LLC.
|
(6)
|
Bradley J. Hayosh and Jeffrey S. Starman share voting and dispositive power over the shares held by Equidebt LLC, while Equidebt LLC is co-owned by Mr. Hayosh and Helen D. Starman. Mr. Hayosh and Mr. Starman also share voting and dispositive power over 47,866 common shares held and being offered by Wickfield Properties LLC, while Wickfield Properties LLC is co-owned by Mr. Hayosh and Ms. Starman. Ms. Starman is a natural person with voting and dispositive power over an additional 427,486 common shares held in her own name and over an additional 75,000 common shares held by her children.
|
(7)
|
Lisa D. VanGilder is a natural person with voting and dispositive power of the shares held by the Lisa D. VanGilder Trust.
|
(8)
|
Linda D. Becker is a trustee with voting and dispositive power over the shares held by the Linda D. Becker Living Trust.
|
(9)
|
William K. Becker is a trustee with voting and dispositive power over the shares held by the William K. Becker Living Trust.
|
(10)
|
Russell H. VanGilder Jr. is a natural person with voting and dispositive power of the shares held by the Russell H. VanGilder Jr. Trust.
|
(11)
|
Marcus New is a natural person with voting and dispositive power over the shares held by Radical Capital Ltd.
|
(12)
|
Peter Arthur Levine has a power of attorney with voting and dispositive power over the shares held by Barbara Ruth Levine.
|
(13)
|
Includes options to purchase 35,000 common shares and 2,000 common shares held by Mr. Stowell’s children.
|
(14)
|
Thomas Carrigan is a natural person with voting and dispositive power over the shares held by Great Lakes Investment Company.
|
(16)
|
Includes options to purchase 340,000 common shares held by Rodney Williams in his individual capacity.
|
(16)
|
Lisa D. VanGilder is a trustee with voting and dispositive power of the shares held by: the Erica D. Sandusky 2009 Trust #1, the Erica D. Sandusky 2010 Grantor Trust, the Jamie L. VanGilder 2009 Trust, the Russell H. VanGilder III 2010 Grantor Trust, the Russell H. VanGilder IV 2009 Trust and the Tiffany R. King 2009 Trust.
|
(17)
|
William C. Ogle is a natural person with voting and dispositive power over the shares held by the William C. Ogle Trust.
|
(18)
|
Jeffrey Rowe is a trustee with voting and dispositive power over the shares held by Jeffrey M. Rowe Living
Trust.
|
(19)
|
Bradley J. Hayosh and Jeffrey S. Starman share voting and dispositive power over the shares held by Wickfield Properties LLC, while Wickfield Properties LLC is co-owned by Mr. Hayosh and Helen D.Starman. Mr. Hayosh and Mr. Starman also share voting and dispositive power over 47,866 common shares held and being offered by Equidebt LLC, while Equidebt LLC is co-owned by Mr. Hayosh and Ms. Starman. Ms. Starman is a natural person with voting and dispositive power over an additional 31,686 common shares held in her own name.
|
(20)
|
Robert J. Burskey is a natural person with voting and dispositive power over the shares held by RJB SEP LLC.
|
(21)
|
Includes 50,000 common shares held by Ms. Hayosh’s children.
|
(22)
|
Includes options to purchase 850,000 common shares.
|
(23)
|
Includes options to purchase 85,000 common shares.
|
(24)
|
Jeffrey S. Starman is a natural person with voting and dispositive power over the common shares held by HPH Phoenix LLC.
|
(25)
|
Darrell L. Pursell, Jr. is the member manager of 5KP, LLC and has voting and dispositive power over the common shares held by 5KP, LLC.
|
Relationships with Selling Shareholders
As discussed elsewhere in this prospectus. Messrs. Rowe and Solensky
are members of our board of directors and Dr. MacArthur was a member of our board of directors until June 2017. Mr. Solensky is
also our President and Chief Executive Officer and Mr. MacArthur was our Chief Medical Officer and Director of Research and Development
prior to his retirement effective July 1, 2017. Ms. Morley is our Chief Operations Officer and Vice President of Product Development.
Mr. DiMarzo is our Executive Vice President of Global Strategy. Mr. Gerald Solensky, Sr. is the father of Mr. Solensky.
The selling shareholders received their common shares (other than those
common shares acquired through the exercise of options to purchase our common shares) in a series of private placement transactions
conducted in 2015, 2016 and 2017 by us and ZoMedica Pharmaceuticals Inc. (prior to the Qualifying Transaction) in Canada and the
United States in which we offered our common shares for sale pursuant to certain exemptions from the registration requirements
of the Securities Act.
See “Certain Relationships and Related Party Transactions –
Equidebt Working Capital Facility” for additional information relating to transactions with Equidebt LLC, one of our shareholders.
CERTAIN RELATIONSHIPS
AND RELATED PARTY TRANSACTIONS
Other than compensation arrangements for our named executive officers
and directors, we describe below each transaction or series of transactions, since January 1, 2017, to which we were a party or
will be a party, in which:
|
•
|
the amounts involved exceeded or will exceed $120,000; and
|
|
•
|
any of our directors, executive officers or holders of more than 5% of our common shares, or any member of the immediate family of the foregoing persons, had or will have a direct or indirect material interest.
|
Compensation arrangements for our named executive officers and directors are
described elsewhere in this prospectus.
Equidebt Working Capital Facility
On September 1, 2017, Equidebt LLC, or Equidebt, one of our shareholders,
entered into a Loan Agreement, or the Loan Agreement, with Mr. Solensky pursuant to which Equidebt agreed to provide Mr. Solensky
with an unsecured line of credit in the amount of $5,000,000 for the purpose of enabling Mr. Solensky to exercise options to purchase
up to 950,000 common shares expiring on December 21, 2018 and to purchase additional common shares from us from time to time,
or the line of credit. Amounts borrowed under the line of credit were to bear interest at a rate of 14% per annum payable at maturity.
In addition, Mr. Solensky was required to pay Equidebt a monthly maintenance fee of $6,250 per month payable at maturity. All
amounts borrowed under the line of credit were to become due and payable on September 1, 2022. Upon the occurrence of an Event
of Default (defined in the Loan Agreement to include Mr. Solensky’s failure to make payments under the line of credit or
his other indebtedness when due, the occurrence of certain insolvency events relating to Mr. Solensky or the occurrence of a substantial
change in the existing or prospective financial condition or net worth of Mr. Solensky which Equidebt determines to be materially
adverse), Equidebt had the right to declare all amounts outstanding under the line of credit immediately due and payable. We were
not a party to the line of credit, which was full recourse against Mr. Solensky.
As
a result of discussions with the NYSE American in connection with our application to list our common shares, we restructured and
replaced the line of credit. Accordingly, on October 17, 2017, we entered into a Loan Agreement, or the Working Capital Loan Agreement,
with Equidebt pursuant to which Equidebt agreed to provide us with a five-year $5,000,000 unsecured working capital line of credit,
or the working capital line of credit. Amounts borrowed under the working capital line of credit bear interest at a rate of 14%
per annum payable at maturity. All amounts borrowed under the line of credit become due and payable on October 17, 2022. Upon
the occurrence of an Event of Default (defined in the Working Capital Loan Agreement to include our failure to make payments under
the working capital line of credit or our other indebtedness when due, the occurrence of certain insolvency events relating to
us, Equidebt has the right to declare all amounts outstanding under the working capital line of credit immediately due and payable.
The working capital line of credit is unsecured; however Mr. Solensky has personally guaranteed our obligations under the working
capital line of credit. In connection with the establishment of the working capital line of credit, the line of credit provided
by Equidebt to Mr. Solensky was cancelled without further liability or obligation of either party.
DESCRIPTION OF SHARE CAPITAL
General
The following is a summary of the rights of our common shares and
preferred shares as set forth in our company Articles (as amended) and By-laws, which are included as exhibits to the registration
statement relating to this offering filed by us with the SEC. This summary does not purport to be complete and is qualified in
its entirety by the full text of our aforementioned constating documents.
Our authorized capital consists of an unlimited number of common
shares without nominal or par value and an unlimited number of preferred shares without nominal or par value, which are issuable
in series.
As of December 31, 2017, 90,225,869 common shares were issued and
outstanding as fully paid and non-assessable shares. No preferred shares had been issued as of that date and accordingly, none
were issued and outstanding. In addition, as of December 31, 2017, we had outstanding options to purchase an aggregate of 8,080,000
common shares outstanding with a weighted average exercise price of $0.96 per share.
Common Shares
The holders of the common shares are entitled to receive notice of
and attend any meeting of our shareholders and are entitled to cast one vote for each common share held. Subject to any rights,
privileges, restrictions and conditions which may apply to any series of preferred shares that are issued, holders of our common
shares are entitled to receive dividends, if, as and when declared by the board of directors. On the winding-up, liquidation or
dissolution of our company or upon the happening of any other event giving rise to a distribution of our assets other than by way
of dividend amongst our shareholders for the purposes of winding-up our affairs, subject to any rights, privileges, restrictions
and conditions which may have been determined by the directors to attach to any series of preferred shares, the holders of all
common shares shall be entitled to participate
pari passu
.
Preferred Shares
Our directors may at any time issue any preferred shares in one or
more series, each series to consist of such number of shares as may be determined by the directors. The directors may determine
at the time of issuance the designation, rights, privileges, restrictions and conditions attaching to the shares of each series.
Holders of preferred shares shall have no right to receive notice
of or to be present at or vote either in person or by proxy, at any general meeting of our shareholders by virtue of or in respect
of their holding of preferred shares.
Stock Options
Our company has in place a “rolling” stock option plan
that allows for the reservation of a maximum of 10% of our issued and outstanding shares at the time of the stock option grant,
with vesting restrictions at the discretion of our directors. The purpose of our stock option plan is to attract and retain employees,
consultants, officers and directors and to motivate them to advance the interests of our company by affording them with the opportunity,
through share options, to acquire an equity interest in our company and benefit from its growth.
Under our stock option plan, our board of directors is authorized
to grant, in its absolute discretion, stock options to directors, officers, employees or consultants on such terms, limitations,
conditions and restrictions as it deems necessary and advisable, subject to the following terms and regulatory approvals:
|
1.
|
The maximum number of common shares reserved for issuance under our stock option plan, together with all previously established or proposed share compensation arrangements, will be 10% of the issued and outstanding common shares as at the date of the grant of the stock option.
|
|
2.
|
The number of common shares subject to each option shall be determined by our board of directors provided that:
|
|
a.
|
the number of common shares reserved for issuance to any one individual in a 12 month period does not exceed 5% of the issued and outstanding common shares at the time of the grant;
|
|
b.
|
the number of options granted to any one consultant in a 12 month period does not exceed 2% of the issued and outstanding common shares of the at the time of the grant;
|
|
c.
|
the aggregate number of options granted to any person conducting investor relations activities in any 12 month period does not exceed 2% of the issued and outstanding common shares at the time of grant; and
|
|
d.
|
the grant to insiders in a 12 month period of a number of options does not exceed 10% of the issued and outstanding common shares at the time of the grant.
|
|
3.
|
The exercise price of an option may not be set less than the closing market price during the trading day immediately preceding the date of grant of the option less any discount allowed by the TSX-V. However, if the options are granted within ninety days of a public distribution by prospectus, then the minimum exercise price shall be the greater of the aforementioned price and the per share price paid by the public investors for shares acquired in the distribution.
|
|
4.
|
The options may be exercisable for a period of up to five years.
|
|
5.
|
The options shall be non-assignable, and non-transferable (subject to options being exercisable by the optionee’s heirs or administrator).
|
|
6.
|
The options shall only be exercised by the optionee as long as:
|
|
a.
|
the optionee remains an eligible person pursuant to the option plan; or
|
|
b.
|
within a period of not more than 90 days after ceasing to be an eligible person; or
|
|
c.
|
if the optionee dies, within one year of the optionee’s death; or
|
|
d.
|
if an optionee is engaged in investor relations activities, within 30 days of being so engaged by our company.
|
Action Necessary to Change the Rights of Holders of Our Shares
Under the ABCA, a company can amend its articles and governing documents
via a special resolution of its shareholders. A “
special resolution”
is a resolution passed by a majority
of not less than two-thirds of the votes cast by the shareholders who voted in respect of that resolution or signed by all the
shareholders entitled to vote on that resolution. Items that can be amended via special resolution include (but are not limited
to): a change in our name; changing any maximum number of shares that we are authorized to issue; creating new classes of shares;
reducing or increasing our stated capital; changing the designation of our shares to add, change or remove any rights, privileges,
restrictions and conditions, including rights to accrued dividends, in respect of all or any of our shares, whether issued or unissued;
dividing a class of shares, whether issued or unissued, into series and fixing the number of shares in each series and the rights,
privileges, restrictions and conditions thereof; authorizing the directors to divide any class of unissued shares into series and
to fix the number of shares in each series and the rights, privileges, restrictions and conditions thereof; authorizing the directors
to change the rights, privileges, restrictions and conditions attached to unissued shares of any series; or adding, changing or
removing restrictions on the issue, transfer or ownership of shares.
Shareholder Meetings
Under the ABCA: (1) Zomedica must hold an annual meeting of shareholders
not later than 15 months after holding the last preceding annual meeting; (2) the directors may at any time call a special meeting
of shareholders; and (3) the holders of not less than 5% of the issued shares of Zomedica that carry the right to vote at a meeting
sought to be held may requisition the directors to call a meeting of shareholders for the purposes stated in the requisition. The
most recent annual meeting of our shareholders was held on April 21, 2016.
The ABCA requires that notice of the time and place of a meeting
of shareholders shall be sent not less than 21 days and not more than 50 days before the meeting: (1) to each shareholder on record
that is entitled to vote at the meeting; (2) to each director; and (3) to the auditor of Zomedica.
Zomedica also complies with certain continuous disclosure obligations
of a reporting issuer in Canada respecting shareholder meetings, in addition to the rules and policies of the TSX-V.
Listing
Our common shares are listed on the NYSE American and the TSX-V under
the symbol “ZOM.”
Transfer Agent and Registrar
The transfer agent and registrar for our common shares is AST Trust Company (Canada) 1 Toronto Street, Suite
1200, Toronto, Ontario M5C 2VC, telephone (416) 682-3844.
Our co-transfer agent is American Stock Transfer & Trust Company.
MATERIAL UNITED STATES
FEDERAL INCOME TAX CONSIDERATIONS
The following summary describes the material U.S. federal income
tax consequences to U.S. Holders (as defined below) of acquiring, owning, and disposing of our common shares acquired pursuant
to this prospectus. This summary does not discuss any tax consequences applicable to the selling shareholders. Each selling shareholder
should consult its own tax advisor regarding the tax consequences of the resale of common shares.
Scope of this Summary
Tax Consequences Not Addressed
This summary does not address all potential U.S. federal income
tax considerations that may be relevant to a particular U.S. Holder. In addition, this summary does not take into account the
individual facts and circumstances that may affect the U.S. federal income tax consequences to a particular U.S. Holder, including
specific tax consequences under an applicable income tax treaty. Accordingly, this summary is not intended to be, and should not
be construed as, legal or U.S. federal income tax advice with respect to any U.S. Holder. This summary does not address any U.S.
federal alternative minimum, U.S. federal estate and gift, U.S. state and local, or non-U.S. tax considerations. Except as specifically
set forth below, this summary does not discuss tax reporting requirements that may be applicable to any particular U.S. Holder.
Each prospective U.S. Holder should consult its own tax advisors regarding the tax consequences of acquiring, owning, and disposing
of our common shares acquired pursuant to this prospectus.
Authorities
This summary is based upon the provisions of the Code, the United States Treasury Regulations (whether
final, temporary, or proposed) promulgated thereunder, the Convention Between Canada and the United States of America with Respect
to Taxes on Income and on Capital, signed September 26, 1980, as amended (the “Canada-U.S. Tax Convention”), and administrative
rulings and judicial decisions interpreting the Code and the United States Treasury Regulations, all as currently in effect, and
all subject to differing interpretations or change, possibly on a retroactive basis. We have not sought, and will not seek, a ruling
from the IRS regarding any matter discussed herein, and no assurance can be given that the IRS would not assert, or that a court
would not sustain, a position that is different from, and contrary to, the positions taken in this summary.
U.S. Holders
For purposes of this summary, the term “U.S. Holder”
means a beneficial owner of common shares acquired pursuant to this prospectus that is for U.S. federal income tax purposes:
|
•
|
an individual who is a citizen or resident of the United States (as determined under U.S. federal income tax rules);
|
|
•
|
a corporation (or other entity treated as a corporation for U.S. federal income tax purposes) created or organized in or under the laws of the United States or of any political subdivision of the United States;
|
|
•
|
an estate, the income of which is subject to U.S. federal income taxation regardless of its source; or
|
|
•
|
a trust that (i) is subject to the primary supervision of a court within the United States and the control of one or more U.S. persons for all substantial decisions or (ii) has a valid election in effect under applicable United States Treasury Regulations to be treated as a U.S. person.
|
An individual may be a resident for U.S. federal income tax purposes
in any calendar year if the individual was present in the United States for at least 31 days in that calendar year and for an aggregate
of at least 183 days during the three-year period ending with the current calendar year. For purposes of this calculation, all
of the days present in the current year, one-third of the days present in the immediately preceding year, and one-sixth of the
days present in the second preceding year are counted. Residents are taxed for U.S. federal income tax purposes as if they were
U.S. citizens.
Non-U.S. Holders Not Addressed
For purposes of this summary, a “non-U.S.
Holder” is a beneficial owner of common shares that is not a U.S. Holder and is not a partnership for U.S. federal income
tax purposes. This summary does not address the U.S. federal income tax consequences to non-U.S. Holders of acquiring, owning,
and disposing of common shares. Each prospective investor should consult a professional tax advisor with respect to the U.S. federal
income, U.S. alternative minimum, U.S. federal estate and gift, U.S. state and local, and non-U.S. tax consequences of acquiring,
owning, and disposing of our common shares.
Certain U.S. Holders Not Addressed
This summary does not address the U.S. federal
income tax considerations applicable U.S. Holders that are subject to special provisions under the Code, including, but not limited
to, U.S. Holders that:
|
•
|
are tax-exempt organizations, qualified retirement plans, individual retirement accounts, or other tax-deferred accounts;
|
|
•
|
are financial institutions, underwriters, insurance companies, real estate investment trusts, or regulated investment companies;
|
|
•
|
are broker-dealers, dealers, or traders in securities or currencies that elect to apply a mark-to-market accounting method;
|
|
•
|
have a “functional currency” other than the U.S. dollar;
|
|
•
|
own common shares as part of a straddle, hedging transaction, conversion transaction, constructive sale,
or other arrangement involving more than one position;
|
|
•
|
acquired common shares in connection with the exercise of employee stock options or otherwise as compensation for services;
|
|
•
|
hold common shares other than as a capital asset within the meaning of section 1221 of the Code (generally, property held for investment purposes);
|
|
•
|
are partnerships or other “pass-through” entities for U.S. federal income tax purposes (or investors in such partnerships or entities);
|
|
•
|
own, have owned, or will own (directly, indirectly, or by attribution) 10% or more of the total combined
voting power or total value of the outstanding shares of our company;
|
|
•
|
are U.S. expatriates or former long-term residents of the United States;
|
|
•
|
have been, are, or will be residents or deemed to be residents in Canada for purposes of the Income Tax Act (Canada) (the “Tax Act”);
|
|
•
|
use or hold, will use or hold, or that are or will be deemed to use or hold common shares in connection with carrying on a business in Canada;
|
|
•
|
are persons whose common shares constitute “taxable Canadian property” under the Tax Act; or
|
|
•
|
have a permanent establishment in Canada for the purposes of the Canada-U.S. Tax Convention.
|
U.S. Holders that are subject to special provisions
under the Code, including, but not limited to, U.S. Holders described immediately above, should consult their own tax advisors
regarding the U.S. federal income, U.S. federal alternative minimum, U.S. federal estate and gift, U.S. state and local, and non-U.S.
tax consequences of acquiring, owning, and disposing of our common shares.
The following summary is not a substitute
for careful tax planning and advice. U.S. Holders of common shares are urged to consult their own tax advisors concerning the
U.S. federal income tax consequences of the issues discussed herein, in light of their particular circumstances, as well as any
considerations arising under the laws of any foreign, state, local, or other taxing jurisdiction.
PFIC Status and Related Tax Consequences
Status as a PFIC
We believe we were classified as a PFIC during our taxable year ended
2017, and based on current business plans and financial expectations, we believe we will continue to be a PFIC for the current
and future taxable years. As a result, certain potentially adverse rules may affect the U.S. federal income tax consequences to
a U.S. Holder of acquiring, owning, and disposing of our common shares. No opinion of legal counsel or ruling from the IRS concerning
our status as a PFIC has been obtained or is currently planned to be requested. The determination of whether any corporation was,
or will be, a PFIC for a taxable year depends, in part, on the application of complex U.S. federal income tax rules, which are
subject to differing interpretations. In addition, whether any corporation will be a PFIC for any taxable year depends on the assets
and income of such corporation calculated on an annual basis and, as a result, cannot be predicted with certainty as of the date
of this prospectus. Each U.S. Holder should consult its own tax advisors regarding the PFIC status of our company.
A foreign corporation generally will be classified as a PFIC under
Section 1297 of the Code in any taxable year in which either:
|
•
|
at least 75% of its gross income is “passive income”, or the PFIC Income Test; or
|
|
•
|
at least 50% of the gross value of its assets is attributable to assets that produce, or are held for the production of, passive income, based on the quarterly average of the fair market value of such assets, or the PFIC Asset Test.
|
For this purpose, passive income generally includes, among other
things, dividends, interest, rents, royalties, gains from the disposition of passive assets and gains from commodities and securities
transactions. Passive assets include cash and liquid securities, even if used as working capital.
If our company is a PFIC for any taxable year during which a U.S.
Holder owns common shares, such U.S. Holder will be subject to different taxation rules with respect to an investment in our common
shares depending on whether such U.S. Holder makes an election to treat our company as a “qualified electing fund”
under Section 1295 of the Code, or a QEF Election or makes a mark-to-market election under Section 1296 of the Code, or a Mark-to-Market
Election. A U.S. Holder that does not make either election is referred to in this summary as a “Non-Electing U.S. Holder.”
Default PFIC Rules
A Non-Electing U.S. Holder will be subject to the rules of Section
1291 of the Code.
Distributions are divided into two categories, “excess distributions”
and others. An excess distribution is the amount received in a taxable year that exceeds 125% of the average annual distributions
paid on our common shares in the three preceding taxable years.
Any gain realized on the sale, exchange or other disposition of our
common shares is also considered an excess distribution.
Under these rules:
|
•
|
the excess distribution is allocated ratably over the holding period (on a daily basis) for the common shares;
|
|
•
|
the amount allocated to prior taxable years is subject to tax at the highest rate of tax applicable to ordinary income in each such year;
|
|
•
|
an interest charge for the deemed tax deferral is imposed with respect to the resulting tax attributable to each such prior taxable year. A taxpayer that is not a corporation must treat any such interest paid as “personal interest,” which is not deductible; and
|
|
•
|
the amount allocated to the current taxable year is taxed as ordinary income and would not be “qualified dividend income” or long-term capital gain (see “General Rules Applicable to the Ownership and Disposition of Common Shares – Distributions on Common Shares” below).
|
In addition, if a Non-Electing U.S. Holder who is an individual dies
while owning our common shares the Non-Electing U.S. Holder’s successor would be ineligible to receive a step-up in tax basis
of the common shares.
To the extent a distribution on our common shares does not constitute
an excess distribution to a Non-Electing U.S. Holder, such Non-Electing U.S. Holder generally will be required to include the amount
of such distribution in gross income as a dividend to the extent of our current or accumulated earnings and profits (as determined
for U.S. federal income tax purposes) that are not allocated to excess distributions, and will not be eligible for the reduced
rates applicable to “qualified dividend income” with respect to such distribution.
Although a determination as to our PFIC status will be made annually,
an initial determination that we are a PFIC will generally apply for subsequent years to a Non-Electing U.S. Holder who held common
shares while we are a PFIC, whether or not we meet the PFIC Income Test or PFIC Asset Test in those subsequent years. Non-Electing
U.S. Holders are encouraged to consult their tax advisors regarding the application of the PFIC rules to their specific situation.
QEF Election
A U.S. Holder that makes a timely and effective QEF Election with
respect to our common shares, referred to in this disclosure as an “Electing U.S. Holder,” will not be subject to the
default PFIC tax, or Section 1291, and interest charge rules (or the denial of basis step-up at death) discussed above with respect
to such shares. Instead, an Electing U.S. Holder must include in income such shareholder’s pro rata share of our ordinary
earnings and net capital gain, if any, for our taxable year that ends with or within the taxable year of the Electing U.S. Holder.
The amount so included in income generally will be treated as ordinary income to the extent of such Electing U.S. Holder’s
allocable share of the PFIC’s ordinary earnings and as long-term capital gain to the extent of such Electing U.S. Holder’s
allocable share of the PFIC’s net capital gains. No portion of any such inclusion of ordinary earnings will be eligible to
be treated as “qualified dividend income.” If an Electing U.S. Holder is an individual, any such net capital gain inclusions
would be eligible for taxation at the preferential capital gain tax rates. Such income inclusions generally will be treated as
income from sources outside the United States for foreign tax credit purposes.
An Electing U.S. Holder will be subject to U.S. federal income tax
on such income inclusions for each taxable year in which we are a PFIC, regardless of whether such amounts are actually distributed
to such Electing U.S. Holder. However, an Electing U.S. Holder may, subject to certain limitations, elect to defer payment of current
U.S. federal income tax on such amounts, subject to an interest charge. If an Electing U.S. Holder is an individual, any such interest
will be treated as non-deductible “personal interest.”
Any net operating loss or net capital loss of a PFIC will not pass
through to the Electing U.S. Holder and will not offset any ordinary earnings or net capital gain of a PFIC recognized by Electing
U.S. Holders in subsequent years (although such losses would ultimately reduce the gain, or increase the loss, recognized by the
Electing U.S. Holder on its disposition of the common shares).
An Electing U.S. Holder generally (i) may receive a tax-free distribution
from our company to the extent that such distribution represents earnings and profits of our company that were previously included
in income by the Electing U.S. Holder because of such QEF Election and (ii) will adjust such Electing U.S. Holder’s tax basis
in the common shares to reflect the amount included in income or allowed as a tax-free distribution because of such QEF Election.
In addition, an Electing U.S. Holder generally will recognize capital gain or loss on the sale, exchange, or other taxable disposition
of common shares.
A U.S. Holder may make a timely QEF Election with respect to its
ownership of our common shares by filing one copy of IRS Form 8621, including a PFIC Annual Information Statement, to a timely
filed United States federal income tax return for the first year in which it holds our common shares. If a U.S. Holder does not
make a timely and effective QEF Election for the first year in the U.S. Holder’s holding period for the common shares, the
U.S. Holder may still be able to make a timely and effective QEF Election in a subsequent year if such U.S. Holder meets certain
requirements and makes a “purging election” pursuant to Section 1291(d) of the Code recognizing gain as if its common
shares were sold for their fair market value on the day the QEF Election is effective (which will be taxed under the default rules
of Section 1291 of the Code discussed above). If a U.S. Holder makes a QEF Election but does not make a “purging election,”
then such U.S. Holder shall not be subject to the QEF Election rules and shall continue to be subject to tax under the rules of
Section 1291 discussed above with respect to its common shares. If a U.S. Holder owns PFIC stock indirectly through another PFIC,
separate QEF Elections must be made for the PFIC in which the U.S. Holder is a direct shareholder and the subsidiary PFIC for the
QEF rules to apply to both PFICs.
A QEF Election will apply to the taxable year for which such QEF
Election is timely made and to all subsequent taxable years, unless such QEF Election is invalidated or terminated or the IRS consents
to revocation of such QEF Election. If a U.S. Holder makes a QEF Election and, in a subsequent taxable year we cease to be a PFIC,
the QEF Election will remain in effect (although it will not be applicable) during those taxable years in which we are not a PFIC.
Accordingly, if we become a PFIC in another subsequent taxable year, the QEF Election will be effective and the Electing U.S. Holder
will be subject to the QEF rules described above during any subsequent taxable year in which the Company qualifies as a PFIC.
Each U.S. Holder should consult its own tax advisors regarding tax
consequences of a QEF Election with respect to us and any subsidiary PFIC.
Mark-to-Market Election
Alternatively, if our common shares are “marketable stock,”
a U.S. Holder generally would be permitted to make a Mark-to-Market Election. Generally, stock will be considered “marketable
stock” if it is “regularly traded” on a “qualified exchange” within the meaning of applicable United
States Treasury Regulations. A class of stock is “regularly traded” on an exchange during any calendar year in which
such class of stock is traded, other than in
de minimis
quantities, on at least 15 days during each calendar quarter. A
“qualified exchange” includes: (i) a national securities exchange that is registered with the Securities and Exchange
Commission, (ii) the national market system established pursuant to section 11A of the Securities and Exchange Act of 1934, or
(iii) a foreign securities exchange that is regulated or supervised by a governmental authority of the country in which the market
is located, provided that (a) such foreign exchange has trading volume, listing, financial disclosure, and surveillance requirements,
and meets other requirements and the laws of the country in which such foreign exchange is located, together with the rules of
such foreign exchange, ensure that such requirements are actually enforced and (b) the rules of such foreign exchange effectively
promote active trading of listed stocks.
If a Mark-to-Market Election is made, the U.S. Holder generally would
include as ordinary income in each taxable year the excess, if any, of the fair market value of the common shares at the end of
the taxable year over such U.S. Holder’s adjusted tax basis in the common shares. The U.S. Holder would also be permitted
an ordinary loss in respect of the excess, if any, of the U.S. Holder’s adjusted tax basis in the common shares over their
fair market value at the end of the taxable year, but only to the extent of the net amount previously included in income as a result
of the Mark-to-Mark Election. A U.S. Holder’s tax basis in the common shares would be adjusted to reflect the amount included
in gross income or allowed as a deduction because of the Mark-to-Market Election. Gain realized on the sale, exchange, or other
disposition of the common shares would be treated as ordinary income, and any loss realized on the sale, exchange, or other disposition
of the common shares would be treated as ordinary loss to the extent that such loss does not exceed the net mark-to-market gains
previously included in income by the U.S. Holder. Losses that exceed this limitation are subject to the rules generally applicable
to losses provided in the Code and Treasury Regulations (see “General Rules Applicable to the Ownership and Disposition of
Common Shares – Sale or Other Taxable Disposition of Common Shares” below). Amounts treated as ordinary income are
not eligible for the preferential tax rates applicable to “qualified dividend income” or long-term capital gains.
A U.S. Holder makes a Mark-to-Market Election by attaching a completed
IRS Form 8621 to a timely filed United States federal income tax return. A Mark-to-Market Election applies to the taxable year
in which such Mark-to-Market Election is made and to each subsequent taxable year, unless the common shares cease to be marketable
stock or the IRS consents to revocation of such election. If a U.S. Holder does not make a Mark-to-Market Election beginning in
the first taxable year of such U.S. Holder’s holding period for the common shares for which we are a PFIC and such U.S. Holder
has not made a timely QEF Election, the rules of Section 1291 of the Code discussed above will apply to certain dispositions of,
and distributions on, the common shares. Each U.S. Holder should consult its own tax advisors regarding the availability of, and
procedure for making, a Mark-to-Market Election.
Although a U.S. Holder may be eligible to make a Mark-to-Market
Election with respect to the common shares, no such election may be made with respect to the stock of any subsidiary PFIC that
a U.S. Holder is treated as owning, because such stock is not marketable. Hence, the Mark-to-Market Election will not be effective
to avoid the application of the default rules of Section 1291 of the Code described above with respect to deemed dispositions
of subsidiary PFIC stock or excess distributions from a subsidiary PFIC to its shareholder.
Other PFIC Rules
Under Section 1291(f) of the Code, the IRS has issued proposed Treasury
Regulations that, subject to certain exceptions, would cause a U.S. Holder that had not made a timely QEF Election to recognize
gain (but not loss) upon certain transfers of common shares that would otherwise be tax-deferred (e.g., gifts and exchanges pursuant
to corporate reorganizations). However, the specific U.S. federal income tax consequences to a U.S. Holder may vary based on the
manner in which common shares are transferred.
Certain additional adverse rules may apply with respect to a U.S.
Holder if we are a PFIC, regardless of whether such U.S. Holder makes a QEF Election. For example, under Section 1298(b)(6) of
the Code, a U.S. Holder that uses our common shares as security for a loan will, except as may be provided in Treasury Regulations,
be treated as having made a taxable disposition of such common shares. Special rules also apply to the amount of foreign tax credit
that a U.S. Holder may claim on a distribution from a PFIC. In addition, if a U.S. Holder owns common shares during any taxable
year that we are treated as a PFIC, it will be required to file IRS Form 8621 (regardless of whether a QEF or Mark-to-Market Election
is made). There are certain
de minimis
exceptions to this requirement.
Lastly, if we are not treated as a PFIC, and you paid taxes as if
we were a PFIC, then you may be able to claim a refund for taxes you paid in excess of the taxes you actually owed. If you do not
timely make such a refund claim, then your refund will be disallowed and you will bear more taxes than you actually owe.
The rules dealing with PFICs and with the QEF and Mark-to-Market
Election are very complex and are affected by various factors in addition to those described above. Prospective investors should
consult their own tax advisors regarding the application of the PFIC rules to our common shares, the availability and advisability
of making a QEF or Mark-to-Market Election and the application of the reporting rules to your particular situation.
General Rules Applicable to the Ownership and Disposition of Common Shares
The following discussion describes the general rules applicable to
the ownership and disposition of the common shares but is subject in its entirety to the special rules described above under the
heading “PFIC Status and Related Tax Consequences.”
Distributions on Common Shares
The gross amount of any distribution (including amounts, if any,
withheld in respect of Canadian withholding tax) actually or constructively received by a U.S. Holder with respect to our common
shares will be taxable to the U.S. Holder as a dividend to the extent of our current or accumulated earnings and profits as determined
under U.S. federal income tax principles. Distributions to a U.S. Holder in excess of earnings and profits will be treated first
as a return of capital that reduces a U.S. Holder’s tax basis in such common shares (thereby increasing the amount of gain
or decreasing the amount of loss that a U.S. Holder would recognize on a subsequent disposition of our common shares), and then
as gain from the sale or exchange of such common shares (see “Sale or Other Taxable Disposition of Common Shares”).
The amount of any distribution of property other than cash will be the fair market value of that property on the date of distribution.
In the event we make distributions to holders of common shares, we may or may not calculate our earnings and profits under U.S.
federal income tax principles. If we do not do so, any distribution may be required to be regarded as a dividend, even if that
distribution would otherwise be treated as a non-taxable return of capital or as capital gain. The amount of the dividend will
generally be treated as foreign-source dividend income to U.S. Holders.
Non-corporate U.S. Holders, including individuals, will generally
be eligible for the preferential U.S. federal rate on “qualified dividend income,” provided that we are a “qualified
foreign corporation,” the stock on which the dividend is paid is held for a minimum holding period, and other requirements
are satisfied. A “qualified foreign corporation” includes a foreign corporation that is not a PFIC in the year of the
distribution or in the prior taxable year and that is eligible for the benefits of an income tax treaty with the United States
that contains an exchange of information provision and has been determined by the United States Treasury Department to be satisfactory
for purposes of the legislation (such as the Canada-U.S. Tax Convention).
Distributions to U.S. Holders generally will not be eligible for
the “dividends received deduction” generally allowed to U.S. corporations in respect of dividends received from other
U.S. corporations.
Sale or Other Taxable Disposition of Common Shares
Upon the sale, exchange, or other taxable disposition of common shares,
a U.S. Holder generally will recognize gain or loss equal to the difference between the amount realized upon the sale, exchange,
or other disposition and such U.S. Holder's tax basis in such common shares sold or otherwise disposed of. If the U.S. holder receives
Canadian dollars in the transaction, the amount realized will be the U.S. dollar value of the Canadian dollars received, which
is determined for cash basis taxpayers on the settlement date for the transaction and for accrual basis taxpayers on the trade
date (although accrual basis taxpayers can also elect the settlement date). A U.S. Holder’s tax basis in common shares generally
will be such holder’s U.S. dollar cost for such common shares. Gain or loss recognized on such sale or other disposition
generally will be long-term capital gain or loss if, at the time of the sale or other disposition, the common shares have been
held for more than one year.
Preferential tax rates currently apply to long-term capital gain
of a U.S. Holder that is an individual, estate, or trust. There are currently no preferential tax rates for long-term capital gain
of a corporate U.S. Holder. Deductions for capital losses are subject to significant limitations under the Code. The gain or loss
will generally be U.S.-source gain or loss for foreign tax credit purposes.
Additional Considerations
Additional Medicare Tax on Net Investment Income
Certain U.S. Holders that are individuals, estates, or trusts (other
than trusts that are exempt from tax) are subject to a tax of 3.8% on “net investment income” (or undistributed “net
investment income,” in the case of estates and trusts) for each taxable year, with such tax applying to the lesser of such
income or the excess of such person’s adjusted gross income (with certain adjustments) over a specified amount. Net investment
income includes dividends on the common shares and net gains from the disposition of the common shares.
Further, excess distributions treated as dividends, gains treated
as excess distributions under the PFIC rules discussed above, and mark-to-market inclusions and deductions are all included in
the calculation of net investment income. United States Treasury Regulations provide, subject to the election described in the
following paragraph, that solely for purposes of this additional tax, distributions of previously taxed income will be treated
as dividends and included in net investment income subject to the additional 3.8% tax. Additionally, to determine the amount of
any capital gain from the sale or other taxable disposition of common shares that will be subject to the additional tax on net
investment income, a U.S. Holder who has made a QEF Election will be required to recalculate its basis in the common shares excluding
QEF basis adjustments. Alternatively, a U.S. Holder may make an election which will be effective with respect to all interests
in a PFIC for which a QEF Election has been made and which is held in that year or acquired in future years. Under this election,
a U.S. Holder pays the additional 3.8% tax on QEF income inclusions and on gains calculated after giving effect to related tax
basis adjustments.
U.S. Holders that are individuals, estates, or trusts should consult
their own tax advisors regarding the applicability of this tax to any of their income or gains in respect of the common shares.
Receipt of Foreign Currency
The amount of any distribution paid to a U.S. Holder in foreign
currency, or on the sale, exchange, or other taxable disposition of common shares, generally will be equal to the U.S. dollar
value of such foreign currency based on the exchange rate applicable on the date of receipt (regardless of whether such foreign
currency is converted into U.S. dollars at that time). If the foreign currency received is not converted into U.S. dollars on
the date of receipt, a U.S. Holder will have a tax basis in the foreign currency equal to its U.S. dollar value on the date of
receipt. Any U.S. Holder who converts or otherwise disposes of the foreign currency after the date of receipt may have a foreign
currency exchange gain or loss that would be treated as ordinary income or loss, and generally will be U.S. source income or loss
for foreign tax credit purposes. Different rules apply to U.S. Holders who use the accrual method of tax accounting. Each U.S.
Holder should consult its own U.S. tax advisors regarding the U.S. federal income tax consequences of receiving, owning, and disposing
of foreign currency.
Foreign Tax Credit
Subject to the PFIC rules discussed above, a U.S. Holder that pays
(whether directly or through withholding) Canadian income tax with respect to dividends paid on the common shares generally will
be entitled, at the election of such U.S. Holder, to receive either a deduction or a credit for such Canadian income tax paid.
Generally, a credit will reduce a U.S. Holder’s U.S. federal income tax liability on a dollar-for-dollar basis, whereas a
deduction will reduce a U.S. Holder’s income that is subject to U.S. federal income tax. This election is made on a year-by-year
basis and applies to all creditable foreign taxes paid (whether directly or through withholding) by a U.S. Holder during a year.
Complex limitations apply to the foreign tax credit, including the
general limitation that the credit cannot exceed the proportionate share of a U.S. Holder’s U.S. federal income tax liability
that such U.S. Holder’s “foreign source” taxable income bears to such U.S. Holder’s worldwide taxable income.
In applying this limitation, a U.S. Holder’s various items of income and deduction must be classified, under complex rules,
as either “foreign source” or “U.S. source.” Generally, dividends paid by a foreign corporation (including
constructive dividends) should be treated as foreign source for this purpose, and gains recognized on the sale of stock of a foreign
corporation by a U.S. Holder should be treated as U.S. source for this purpose, except as otherwise provided in an applicable income
tax treaty, and if an election is properly made under the Code. However, the amount of a distribution with respect to the common
shares that is treated as a “dividend” may be lower for U.S. federal income tax purposes than it is for Canadian federal
income tax purposes, resulting in a reduced foreign tax credit allowance to a U.S. Holder. In addition, this limitation is calculated
separately with respect to specific categories of income. The foreign tax credit rules are complex, and each U.S. Holder should
consult its own U.S. tax advisors regarding the foreign tax credit rules.
Information Reporting and Backup Withholding
Under U.S. federal income tax law, certain categories of U.S. Holders
must file information returns with respect to their investment in, or involvement in, a foreign corporation. For example, certain
U.S. Holders who hold certain “specified foreign financial assets” that exceed certain thresholds are required to report
information relating to such assets. The definition of “specified foreign financial assets” generally includes not
only financial accounts maintained in foreign financial institutions, but also, unless held in accounts maintained by a financial
institution, any stock or security issued by a non-U.S. person, any financial instrument or contract held for investment that has
an issuer or counterparty other than a U.S. person, and any interest in a foreign entity. U.S. Holders may be subject to these
reporting requirements unless their common shares are held in an account at certain financial institutions. Significant penalties
may apply for failure to satisfy applicable reporting obligations.
Distributions paid with respect to common shares and proceeds from
a sale, exchange, or redemption of common shares made within the United States or through certain U.S.-related financial intermediaries
may be subject to information reporting to the IRS and possible U.S. backup withholding (at a rate of 24%). Backup withholding
will not apply, however, to a U.S. Holder who furnishes a correct U.S. taxpayer identification number and makes any other required
certification on IRS Form W-9 or that is a corporation or other entity that is otherwise exempt from backup withholding. Each U.S.
Holder should consult its own tax advisors regarding the application of the U.S. information reporting and backup withholding rules.
Backup withholding is not an additional tax. Amounts withheld as backup withholding may be credited against a holder’s U.S.
federal income tax liability, and such holder may obtain a refund of any excess amounts withheld under the backup withholding rules
by filing an appropriate claim for refund with the IRS and furnishing any required information in a timely manner.
The discussion of reporting requirements set forth above is not intended
to constitute a complete description of all reporting requirements that may apply to a U.S. Holder. A failure to satisfy certain
reporting requirements may result in an extension of the time period during which the IRS can assess a tax and, under certain circumstances,
such an extension may apply to assessments of amounts unrelated to any unsatisfied reporting requirement. U.S. Holders should consult
with their own tax advisors regarding their reporting obligations, if any, as a result of their acquisition, ownership, or disposition
of our common shares.
CERTAIN CANADIAN INCOME
TAX CONSIDERATIONS
The following is, as of the date of this prospectus, a summary of
the principal Canadian federal income tax considerations pursuant to the Income Tax Act (Canada) and the regulations thereunder
(the “Tax Act”) that generally apply to the acquisition, holding and disposition of common shares by a person who is
neither resident nor deemed to be resident in Canada for purposes of the Tax Act, is a resident of the U.S. for purposes of the
Canada - U.S. Income Tax Convention (“Treaty”) and acquires a beneficial interest in the common shares (a “U.S.
Holder”).
This summary applies only to a U.S. Holder who, at all relevant times,
for purposes of the Tax Act:
|
•
|
holds the common shares as capital property;
|
|
•
|
does not, and is not deemed to, use or hold the common shares in the course of carrying on a business in Canada;
|
|
•
|
deals at arm’s length and is not affiliated with us; and
|
|
•
|
is a “qualifying person” or otherwise entitled to benefits under the Treaty.
|
Special rules, which are not discussed in this summary, may apply
to a U.S. Holder that is an insurer that carries on an insurance business in Canada and elsewhere.
This summary is based on the current provisions of the Tax Act, all
specific proposals to amend the Tax Act publicly announced by or on behalf of the Minister of Finance (Canada) prior to the date
hereof (“Tax Proposals”), and an understanding of the current administrative policies and assessing practices of the
Canada Revenue Agency (the “CRA”) made publicly available prior to the date hereof. This summary assumes the Tax Proposals
will be enacted in the form proposed, however, no assurance can be given that the Tax Proposals will be enacted in the form proposed,
or at all. Except for the Tax Proposals, this summary does not take into account or anticipate any changes in law or administrative
policies or assessing practices of the CRA, whether by legislative, governmental or judicial action, nor does it take into account
other federal or any provincial, territorial or foreign income tax legislation or considerations, which may differ significantly
from those discussed herein.
This summary is not exhaustive of all possible Canadian federal
income tax considerations that apply to an investment in common shares. Moreover, the income and other tax consequences of acquiring,
holding or disposing of common shares will vary depending on an investor’s particular circumstances. Accordingly, this summary
is of a general nature only and is not intended to be, nor should it be construed to be, legal or tax advice to any investor. Consequently,
investors should consult their own tax advisors for advice with respect to the income tax consequences of an investment in common
shares based on their particular circumstances.
Dividends on Common Shares
Dividends paid or credited on the common shares (or deemed to be
paid or credited on the common shares) to a U.S. Holder will generally be subject to Canadian withholding tax at the rate of 15%.
Dispositions of Common Shares
A U.S. Holder will not be subject to tax under the Tax Act on any
capital gain realized on a disposition or deemed disposition of common shares (other than a disposition to us, unless purchased
by us in the open market in the manner in which shares are normally purchased by any member of the public in the open market, in
which case other considerations may arise), unless the common shares are “taxable Canadian property” of the U.S. Holder
for purposes of the Tax Act and the U.S. Holder is not entitled to relief under the Treaty.
Generally, the common shares will not constitute “taxable Canadian
property” of a U.S. Holder at a particular time provided that the common shares are listed at that time on a “designated
stock exchange” for purposes of the Tax Act (which currently includes the TSX-V and NYSE American), unless at any particular time
during the 60-month period that ends at that time both of the following are true:
1. (a) the U.S. Holder, (b) persons with whom the U.S. Holder does
not deal with at arm’s length (for purposes of the Tax Act), (c) partnerships in which the U.S. Holder or a person described
in (b) holds an interest directly or indirectly through one or more partnerships, or (d) any combination of (a) to (c) owned 25%
or more of the issued shares of any class or series of our capital stock; and
2. more than 50% of the fair market value of the common shares was
derived directly or indirectly from one or any combination of: (a) real or immovable properties situated in Canada, (b) “Canadian
resource properties” (as defined in the Tax Act), (c) “timber resource properties” (as defined in the Tax Act),
and (d) options in respect of, or interests in, or for civil law rights in, property in any of the foregoing whether or not the
property exists.
Notwithstanding the foregoing, in certain circumstances set out in
the Tax Act, common shares may be deemed to be taxable Canadian property. U.S. Holders whose common shares may constitute taxable
Canadian property should consult their own tax advisors.
PLAN OF DISTRIBUTION
The selling shareholders, which, as used herein, includes donees,
pledgees, transferees or other successors-in-interest selling common shares or interests in common shares received after the date
of this prospectus from a selling shareholder as a gift, pledge, partnership distribution or other transfer, may, from time to
time, sell, transfer or otherwise dispose of any or all of their common shares or interests in their common shares on any stock
exchange, market or trading facility on which the shares are traded or in private transactions. These dispositions may be at fixed
prices, at prevailing market prices at the time of sale, at prices related to the prevailing market price, at varying prices determined
at the time of sale, or at negotiated prices.
The selling shareholders may use any one or more of the following
methods when disposing of shares or interests therein:
•
|
ordinary brokerage transactions and transactions in which the broker-dealer solicits purchasers;
|
|
|
•
|
block trades in which the broker-dealer will attempt to sell the shares as agent, but may position and resell a portion of the block as principal to facilitate the transaction;
|
|
|
•
|
purchases by a broker-dealer as principal and resale by the broker-dealer for its account;
|
|
|
•
|
an exchange distribution in accordance with the rules of the applicable exchange;
|
|
|
•
|
privately negotiated transactions;
|
|
|
•
|
short sales effected after the date the registration statement of which this prospectus is a part is declared effective by the SEC;
|
|
|
•
|
through the writing or settlement of options or other hedging transactions, whether through an options exchange or otherwise;
|
|
|
•
|
broker-dealers may agree with the selling shareholders to sell a specified number of such shares at a stipulated price per share;
|
|
|
•
|
a combination of any such methods of sale; and
|
|
|
•
|
any other method permitted by applicable law.
|
The selling shareholders may, from time to time, pledge or grant
a security interest in some or all of the common shares owned by them and, if they default in the performance of their secured
obligations, the pledgees or secured parties may offer and sell the common shares, from time to time, under this prospectus, or
under an amendment to this prospectus under Rule 424(b)(3) or other applicable provision of the Securities Act amending the list
of selling shareholders to include the pledgee, transferee or other successors in interest as selling shareholders under this prospectus.
The selling shareholders also may transfer the common shares in other circumstances, in which case the transferees, pledgees or
other successors in interest will be the selling beneficial owners for purposes of this prospectus.
In connection with the sale of our common shares or interests therein,
the selling shareholders may enter into hedging transactions with broker-dealers or other financial institutions, which may in
turn engage in short sales of the common shares in the course of hedging the positions they assume. The selling shareholders may
also sell our common shares short and deliver these securities to close out their short positions, or loan or pledge the common
shares to broker-dealers that in turn may sell these securities. The selling shareholders may also enter into option or other transactions
with broker-dealers or other financial institutions or the creation of one or more derivative securities which require the delivery
to such broker-dealer or other financial institution of common shares offered by this prospectus, which shares such broker-dealer
or other financial institution may resell pursuant to this prospectus (as supplemented or amended to reflect such transaction).
The aggregate proceeds to the selling shareholders from the sale
of the common shares offered by them will be the purchase price of the common shares less discounts or commissions, if any. Each
of the selling shareholders reserves the right to accept and, together with their agents from time to time, to reject, in whole
or in part, any proposed purchase of common shares to be made directly or through agents. We will not receive any of the proceeds
from this offering.
The selling shareholders also may resell all or a portion of the
common shares in open market transactions in reliance upon Rule 144 under the Securities Act, provided that they and we meet the
criteria and conform to the requirements of that rule, including the requirements applicable to former shell companies.
The selling shareholders and any underwriters, broker-dealers or
agents that participate in the sale of the common shares or interests therein may be “underwriters” within the meaning
of Section 2(a)(11) of the Securities Act. Any discounts, commissions, concessions or profit they earn on any resale of the shares
may be underwriting discounts and commissions under the Securities Act. Selling shareholders who are “underwriters”
within the meaning of Section 2(a)(11) of the Securities Act will be subject to the prospectus delivery requirements of the Securities
Act.
To the extent required, the common shares to be sold, the names of
the selling shareholders, the respective purchase prices and public offering prices, the names of any agents, dealer or underwriter,
any applicable commissions or discounts with respect to a particular offer will be set forth in an accompanying prospectus supplement
or, if appropriate, a post-effective amendment to the registration statement that includes this prospectus.
In order to comply with the securities laws of some states, if applicable,
the common shares may be sold in these jurisdictions only through registered or licensed brokers or dealers. In addition, in some
states the common shares may not be sold unless it has been registered or qualified for sale or an exemption from registration
or qualification requirements is available and is complied with.
We have advised the selling shareholders that the anti-manipulation
rules of Regulation M under the Exchange Act may apply to sales of shares in the market and to the activities of the selling shareholders
and their affiliates. In addition, to the extent applicable we will make copies of this prospectus (as it may be supplemented or
amended from time to time) available to the selling shareholders for the purpose of satisfying the prospectus delivery requirements
of the Securities Act. The selling shareholders may indemnify any broker-dealer that participates in transactions involving the
sale of the shares against certain liabilities, including liabilities arising under the Securities Act.
LEGAL MATTERS
The validity of the common shares offered hereby has been passed
upon for us by Tingle Merrett LLP, Calgary, Alberta, Canada. Partners and associates of Tingle Merrett LLP own or exert control
or direction over an aggregate of 1,000,000 common shares and options to acquire an aggregate of 300,000 common shares. Lowenstein
Sandler LLP, New York, New York has acted as our United States counsel in connection with this offering. Lowenstein Sandler LLP
owns 43,613 common shares.
EXPERTS
The consolidated financial statements of Zomedica Pharmaceuticals
Corp. as of and for the years ended December 31, 2017 and 2016 included in this prospectus have been audited by MNP LLP, independent
registered public accounting firm, as stated in their report included in this prospectus. Such consolidated financial statements
have been so included in reliance upon the report of such firm given upon their authority as experts in accounting and auditing.
WHERE YOU CAN FIND MORE
INFORMATION
We have filed with the SEC a registration
statement on Form S-1 under the Securities Act with respect to the common shares offered by this prospectus. This prospectus does
not contain all of the information set forth in the registration statement and its exhibits, certain portions of which are omitted
as permitted by the rules and regulations of the SEC. For further information pertaining to us and our common shares, we refer
you to the registration statement, including its exhibits and the financial statements, notes and schedules filed as a part of
that registration statement. Statements contained in this prospectus regarding the contents of any contract or other document referred
to in those documents are not necessarily complete, and in each instance we refer you to the copy of the contract or other document
filed as an exhibit to the registration statement or other document. Each of these statements is qualified in all respects by this
reference.
You may read and copy the registration
statement and its exhibits and schedules at the SEC’s public reference room at 100 F Street, N.E., Washington, D.C. 20549.
You also may obtain information on the operation of the public reference room by calling the commission at 1-800-SEC-0330. The
SEC maintains a web site at www.sec.gov that contains reports, proxy and information statements and other information regarding
registrants, such as Zomedica Pharmaceuticals Corp., that file electronically with the SEC.
We are subject to the information and
reporting requirements of the Exchange Act and, in accordance with this law, file periodic reports, proxy statements and other
information with the SEC. These periodic reports, proxy statements and other information are available for inspection and copying
at the SEC’s public reference facilities and the website of the SEC referred to above. We also maintain a website at www.zomedica.com.
You may access these materials free of charge as soon as reasonably practicable after they are electronically filed with, or furnished
to, the SEC. Information contained in, or accessible through, our website does not constitute part of this prospectus.
INDEX TO FINANCIAL STATEMENTS
Zomedica Pharmaceuticals Corp.
Consolidated financial statements
For the years ended December 31, 2017
and 2016
(Expressed in United States Dollars, except
as otherwise noted)
Report of the Independent Registered Public Accounting Firm
To the Shareholders of Zomedica Pharmaceuticals Corp.:
Opinion on the Consolidated Financial Statements
We have audited the accompanying consolidated
financial statements of Zomedica Pharmaceuticals Corp. (the “Company”), which comprise the consolidated balance sheets
as at December 31, 2017 and 2016, and the consolidated statements of operations and comprehensive loss, changes in equity and cash
flows for the years then ended, and the related notes, comprising a summary of significant accounting policies and other explanatory
information (collectively referred to as the consolidated financial statements).
In our opinion, the consolidated financial
statements present fairly, in all material respects, the consolidated financial position of the Company as at December 31, 2017
and 2016, and its consolidated financial performance and its consolidated cash flows for the years then ended in conformity with
accounting principles generally accepted in the United States of America.
Basis for Opinion
Management’s Responsibility for the Consolidated Financial
Statements
Management is responsible for the preparation
and fair presentation of these consolidated financial statements in accordance with accounting principles generally accepted in
the United States of America, and for such internal control as management determines is necessary to enable the preparation of
consolidated financial statements that are free from material misstatement, whether due to error or fraud.
Auditor’s Responsibility
Our responsibility is to express an opinion
on these consolidated financial statements based on our audits. We conducted our audits in accordance with Canadian generally accepted
auditing standards and the standards of the Public Company Accounting Oversight Board (United States) (“PCAOB”). Those
standards require that we plan and perform the audits to obtain reasonable assurance about whether the consolidated financial statements
are free from material misstatement, whether due to error or fraud. Those standards also require that we comply with ethical requirements,
including independence. We are required to be independent with respect to the Company in accordance with the ethical requirements
that are relevant to our audits of the consolidated financial statements in Canada, the U.S. federal securities laws and the applicable
rules and regulations of the Securities and Exchange Commission and the PCAOB. We are a public accounting firm registered with
the PCAOB.
An audit includes performing procedures
to assess the risks of material misstatements of the consolidated financial statements, whether due to error or fraud, and performing
procedures to respond to those risks. Such procedures include obtaining and examining, on a test basis, audit evidence regarding
the amounts and disclosures in the consolidated financial statements. The procedures selected depend on our judgment, including
the assessment of the risks of material misstatement of the consolidated financial statements, whether due to error or fraud. In
making those risk assessments, we consider internal control relevant to the entity’s preparation and fair preparation of
the consolidated financial statements in order to design audit procedures that are appropriate in the circumstances, but not for
the purpose of expressing an opinion on the effectiveness of the entity’s internal control. The Company is not required to
have, nor were we engaged to perform, an audit of its internal control over financial reporting. Accordingly, we express no such
opinion.
An audit also includes evaluating the appropriateness
of accounting policies and principles used and the reasonableness of accounting estimates made by management, as well as evaluating
the overall presentation of the consolidated financial statements.
We believe that the audit evidence we have
obtained in our audits is sufficient and appropriate to provide a reasonable basis for our audit opinion.
/s/ MNP LLP
|
|
We have served as the Company's auditor since 2015.
|
February 28, 2018
|
|
Chartered Professional Accountants
|
Toronto, Ontario
|
|
Licensed Public Accountants
|
Zomedica Pharmaceuticals Corp.
Consolidated Balance Sheets
As at December 31, 2017 and 2016
(Stated in United States dollars)
|
|
Note
|
|
December 31,
2017
|
|
|
December 31,
2016
|
|
|
|
|
|
|
|
|
|
|
Assets
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Current assets:
|
|
|
|
|
|
|
|
|
|
|
Cash and cash equivalents
|
|
|
|
$
|
3,448,147
|
|
|
$
|
3,226,680
|
|
Prepaid expenses and deposits
|
|
5
|
|
|
786,273
|
|
|
|
332,611
|
|
Trade and other receivable
|
|
|
|
|
28,272
|
|
|
|
18,921
|
|
|
|
|
|
|
4,262,692
|
|
|
|
3,578,212
|
|
|
|
|
|
|
|
|
|
|
|
|
Prepaid expenses and deposits
|
|
5
|
|
|
566,832
|
|
|
|
690,374
|
|
Property and equipment
|
|
6
|
|
|
371,157
|
|
|
|
289,034
|
|
Intangible assets
|
|
7
|
|
|
15,141
|
|
|
|
17,938
|
|
|
|
|
|
$
|
5,215,822
|
|
|
$
|
4,575,558
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Liabilities and shareholders' equity
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Current liabilities:
|
|
|
|
|
|
|
|
|
|
|
Accounts payable and accrued liabilities
|
|
|
|
$
|
828,737
|
|
|
$
|
734,431
|
|
Shareholder loans payable
|
|
18
|
|
|
-
|
|
|
|
6,726
|
|
|
|
|
|
|
828,737
|
|
|
|
741,157
|
|
|
|
|
|
|
|
|
|
|
|
|
Shareholders' equity:
|
|
|
|
|
|
|
|
|
|
|
Capital stock
|
|
|
|
|
|
|
|
|
|
|
Authorized
|
|
|
|
|
|
|
|
|
|
|
Unlimited common shares without par value
|
|
|
|
|
|
|
|
|
|
|
Issued and outstanding
|
|
|
|
|
|
|
|
|
|
|
90,225,869 common shares (2016 - 83,964,569)
|
|
9
|
|
|
18,244,659
|
|
|
|
10,189,973
|
|
Additional paid-in capital
|
|
10
|
|
|
1,768,526
|
|
|
|
1,205,456
|
|
Accumulated deficit
|
|
|
|
|
(15,626,100
|
)
|
|
|
(7,561,028
|
)
|
|
|
|
|
|
4,387,085
|
|
|
|
3,834,401
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$
|
5,215,822
|
|
|
$
|
4,575,558
|
|
Signed on behalf of the Board:
“Gerald Solensky”
|
|
“Jeff Rowe”
|
Chairman of the Board
|
|
Director
|
The accompanying notes are an integral part
of these consolidated financial statements.
Zomedica Pharmaceuticals Corp.
Consolidated statements of operations and comprehensive loss
For the years ended December 31, 2017 and 2016
(Stated in United States dollars)
|
|
Note
|
|
December 31,
2017
|
|
|
December 31,
2016
|
|
|
|
|
|
|
|
|
|
|
Expenses:
|
|
|
|
|
|
|
|
|
|
|
Research and development
|
|
15
|
|
$
|
2,751,326
|
|
|
$
|
1,518,589
|
|
General and administrative
|
|
15
|
|
|
3,946,270
|
|
|
|
2,916,604
|
|
Professional fees
|
|
15
|
|
|
1,294,044
|
|
|
|
1,245,182
|
|
Amortization
|
|
7
|
|
|
2,797
|
|
|
|
2,690
|
|
Depreciation
|
|
6
|
|
|
89,613
|
|
|
|
43,131
|
|
Loss from operations
|
|
|
|
|
8,084,050
|
|
|
|
5,726,196
|
|
Gain on settlement of liabilities
|
|
|
|
|
(5,000
|
)
|
|
|
-
|
|
Foreign exchange (gain) loss
|
|
|
|
|
(13,978
|
)
|
|
|
14,296
|
|
Loss before income taxes
|
|
|
|
|
8,065,072
|
|
|
|
5,740,492
|
|
Income tax expense
|
|
11
|
|
|
-
|
|
|
|
-
|
|
Net loss and comprehensive loss
|
|
|
|
$
|
8,065,072
|
|
|
$
|
5,740,492
|
|
|
|
|
|
|
|
|
|
|
|
|
Weighted average number of common shares - basic and diluted
|
|
|
|
|
87,400,255
|
|
|
|
80,158,312
|
|
|
|
|
|
|
|
|
|
|
|
|
Loss per share - basic and diluted
|
|
|
|
$
|
(0.09
|
)
|
|
$
|
(0.07
|
)
|
Nature of operations and going concern
(Note 1)
Commitments and contingencies (Note 12)
The accompanying notes are an integral part
of these consolidated financial statements.
Zomedica Pharmaceuticals Corp.
Consolidated statements of shareholders’ equity
For the years ended December 31, 2017 and 2016
(Stated in United States dollars)
|
|
Note
|
|
Number of
common
stock
|
|
|
Capital
stock
|
|
|
Additional
paid-in
capital
|
|
|
Accumulated
deficit
|
|
|
Total
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Balance at December 31, 2015
|
|
|
|
|
77,370,716
|
|
|
$
|
5,214,691
|
|
|
$
|
19,890
|
|
|
$
|
(1,820,536
|
)
|
|
$
|
3,414,045
|
|
Stock issuance due to recapitalization, net of cost
|
|
19
|
|
|
1,900,000
|
|
|
|
196,534
|
|
|
|
-
|
|
|
|
-
|
|
|
|
196,534
|
|
Stock issuance for financing, net of cost
|
|
9
|
|
|
4,133,853
|
|
|
|
4,717,570
|
|
|
|
-
|
|
|
|
-
|
|
|
|
4,717,570
|
|
Stock issuance for services
|
|
9
|
|
|
80,000
|
|
|
|
15,741
|
|
|
|
-
|
|
|
|
-
|
|
|
|
15,741
|
|
Excess of purchase price over net asset value
|
|
19
|
|
|
-
|
|
|
|
-
|
|
|
|
(272,354
|
)
|
|
|
-
|
|
|
|
(272,354
|
)
|
Stock-based compensation
|
|
10
|
|
|
-
|
|
|
|
-
|
|
|
|
1,467,934
|
|
|
|
-
|
|
|
|
1,467,934
|
|
Stock issued due to exercise of options
|
|
10
|
|
|
480,000
|
|
|
|
45,437
|
|
|
|
(10,014
|
)
|
|
|
-
|
|
|
|
35,423
|
|
Net loss
|
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
(5,740,492
|
)
|
|
|
(5,740,492
|
)
|
Balance at December 31, 2016
|
|
|
|
|
83,964,569
|
|
|
$
|
10,189,973
|
|
|
$
|
1,205,456
|
|
|
$
|
(7,561,028
|
)
|
|
$
|
3,834,401
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Stock issuance for services
|
|
|
|
|
155,927
|
|
|
|
275,131
|
|
|
|
-
|
|
|
|
-
|
|
|
|
275,131
|
|
Stock-based compensation
|
|
10
|
|
|
-
|
|
|
|
-
|
|
|
|
849,679
|
|
|
|
-
|
|
|
|
849,679
|
|
Stock issuance for financing, net of cost
|
|
9
|
|
|
4,405,373
|
|
|
|
6,513,424
|
|
|
|
-
|
|
|
|
-
|
|
|
|
6,513,424
|
|
Stock issued due to exercise of options
|
|
10
|
|
|
1,700,000
|
|
|
|
1,266,131
|
|
|
|
(286,609
|
)
|
|
|
-
|
|
|
|
979,522
|
|
Net loss
|
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
(8,065,072
|
)
|
|
|
(8,065,072
|
)
|
Balance at December 31, 2017
|
|
|
|
|
90,225,869
|
|
|
$
|
18,244,659
|
|
|
$
|
1,768,526
|
|
|
$
|
(15,626,100
|
)
|
|
$
|
4,387,085
|
|
The accompanying notes are an integral part
of these consolidated financial statements.
Zomedica Pharmaceuticals Corp.
Consolidated statements of cash flows
For the years ended December 31, 2017 and 2016
(Stated in United States dollars)
|
|
Note
|
|
2017
|
|
|
2016
|
|
|
|
|
|
|
|
|
|
|
Cash flows used in operating activities:
|
|
|
|
|
|
|
|
|
|
|
Net loss
|
|
|
|
$
|
(8,065,072
|
)
|
|
$
|
(5,740,492
|
)
|
Adjustments for
|
|
|
|
|
|
|
|
|
|
|
Depreciation
|
|
6
|
|
|
89,613
|
|
|
|
43,131
|
|
Amortization
|
|
7
|
|
|
2,797
|
|
|
|
2,690
|
|
Stock issued for services
|
|
9
|
|
|
275,131
|
|
|
|
15,741
|
|
Stock-based compensation
|
|
10
|
|
|
849,679
|
|
|
|
1,467,934
|
|
Change in non-cash operating working capital
|
|
|
|
|
|
|
|
|
|
|
Trade and other receivable
|
|
|
|
|
(9,351
|
)
|
|
|
(21,031
|
)
|
Prepaid expenses
|
|
|
|
|
(205,143
|
)
|
|
|
7,393
|
|
Deposits
|
|
|
|
|
(124,977
|
)
|
|
|
(890,142
|
)
|
Accounts payable and accrued liabilities
|
|
|
|
|
94,306
|
|
|
|
552,608
|
|
|
|
|
|
|
(7,093,017
|
)
|
|
|
(4,562,168
|
)
|
|
|
|
|
|
|
|
|
|
|
|
Cash flows from financing activities:
|
|
|
|
|
|
|
|
|
|
|
Cash proceeds from financing
|
|
9
|
|
|
6,570,000
|
|
|
|
4,755,586
|
|
Cash paid on stock issuance costs
|
|
|
|
|
(56,576
|
)
|
|
|
(115,635
|
)
|
Cash received from stock option exercises
|
|
|
|
|
979,522
|
|
|
|
35,423
|
|
Cash received on amalgamation
|
|
19
|
|
|
-
|
|
|
|
108,966
|
|
Repayments (advances) of shareholder loan
|
|
|
|
|
(6,726
|
)
|
|
|
2,013
|
|
|
|
|
|
|
7,486,220
|
|
|
|
4,786,353
|
|
|
|
|
|
|
|
|
|
|
|
|
Cash flows used in investing activities:
|
|
|
|
|
|
|
|
|
|
|
Investment in intangibles
|
|
7
|
|
|
-
|
|
|
|
(9,611
|
)
|
Investment in property and equipment
|
|
6
|
|
|
(171,736
|
)
|
|
|
(231,604
|
)
|
|
|
|
|
|
(171,736
|
)
|
|
|
(241,215
|
)
|
|
|
|
|
|
|
|
|
|
|
|
Increase (decrease) in cash and cash equivalents during the year
|
|
|
|
|
221,467
|
|
|
|
(17,030
|
)
|
|
|
|
|
|
|
|
|
|
|
|
Cash and cash equivalents, beginning of year
|
|
|
|
|
3,226,680
|
|
|
|
3,243,710
|
|
|
|
|
|
|
|
|
|
|
|
|
Cash and cash equivalents, end of year
|
|
|
|
$
|
3,448,147
|
|
|
$
|
3,226,680
|
|
The accompanying notes are an integral part
of these consolidated financial statements.
Zomedica Pharmaceuticals Corp.
Notes to the consolidated financial statements
For the years ended December 31, 2017 and 2016
(Stated in United States dollars)
|
1. Nature of operations and going concern
Zomedica Pharmaceuticals Corp. ("Zomedica"
or the “Company”) was incorporated on January 7, 2013 under the
Business Corporations Act
(Alberta) as Wise
Oakwood Ventures Inc. (“WOW”) and was classified as a capital pool company, as defined in Policy 2.4 of the TSX Venture
Exchange. ZoMedica Pharmaceuticals Inc. was incorporated on May 14, 2015 under the Canada Business Corporations Act.
On April 21, 2016, the Company closed its
qualifying transaction (“Transaction”), consisting of the acquisition of ZoMedica Pharmaceuticals Inc. (“ZoMedica”)
pursuant to a three-cornered amalgamation, whereby ZoMedica was amalgamated with 9674128 Canada Inc. (which was wholly-owned by
WOW) and common shares and options of the Company were issued to former holders of ZoMedica securities as consideration. The amalgamated
company changed its name to Zomedica Pharmaceuticals Ltd. and WOW subsequently changed its name to Zomedica Pharmaceuticals Corp.
Prior to completion of the Transaction, WOW consolidated its common shares on the basis of the one post-consolidation common share
for every 2.5 pre-consolidation common shares. The Transaction constituted WOW’s qualifying transaction under TSX Venture
Exchange Policy 2.4 –
Capital Pool Companies
. The shares of Zomedica Pharmaceuticals Corp. began trading on the TSX
Venture Exchange under the new symbol “ZOM” on Monday, May 2, 2016. On June 21, 2016, the Company filed Articles of
Amalgamation and vertically amalgamated with its wholly-owned subsidiary, Zomedica Pharmaceuticals Ltd.
Zomedica has one corporate subsidiary,
Zomedica Pharmaceuticals, Inc., a Delaware company whose results and operations are included in these consolidated financial statements.
The Company is a biopharmaceutical company targeting health and wellness solutions for the companion pet through a ground-breaking
approach that focuses on the needs of the veterinarians themselves. Zomedica's head office is located at 100 Phoenix Drive, Suite
190, Ann Arbor, MI 48108 and its registered office is located at Suite 1250, 639 – 5th Avenue S.W., Calgary, Alberta T2P
0M9.
On November 20, 2017, Zomedica announced
that its registration statement on Form S-1 was declared effective by the U.S. Securities and Exchange Commission (SEC) and on
November 21, 2017, the Company’s common shares began trading on the NYSE under the symbol “ZOM”.
Going concern
The consolidated financial statements are
prepared on a going concern basis, which assumes that the Company will be able to meet its obligations and continue its operations
for the next twelve months.
The accounting policies set out below have
been applied consistently in the consolidated financial statements.
Basis of consolidation
These consolidated financial statements
include the accounts of the Company and its wholly owned operating subsidiary, ZoMedica Pharmaceuticals Inc.
All inter-company accounts and transactions
have been eliminated on consolidation.
Zomedica Pharmaceuticals Corp.
Notes to the consolidated financial statements
For the years ended December 31, 2017 and 2016
(Stated in United States dollars)
|
3.
|
Significant accounting policies
|
Use of estimates
The preparation of the consolidated financial
statements in conformity with accounting principles generally accepted in the United States of America (“U.S. GAAP”)
requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure
of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenue and
expenses during the period. Actual results could differ from those estimates.
Areas where significant judgment is involved
in making estimates are: the fair values of financial assets and liabilities; the determination of fair value of stock-based compensation;
the useful lives of property and equipment; and forecasting future cash flows for assessing the going concern assumption.
Basis of measurement
The consolidated financial statements have
been prepared on the historical cost basis except as otherwise noted.
Functional and reporting currencies
The Company’s and subsidiary’s
functional currency, as determined by management, is US dollars, which is also the Company’s reporting currency.
The accounting policies set out below have
been applied consistently to all periods and companies presented in the consolidated financial statements.
Cash and cash equivalents
The Company considers all highly liquid
securities with an original maturity of three months or less to be cash equivalents. Cash and cash equivalents comprises cash on
hand and cash held in trust related to share issuances. The cash held in trust is readily available to the Company and is classified
as current.
The financial risks associated with these
instruments are minimal and the Company has not experienced any losses from investments in these securities. The carrying amount
of cash and cash equivalents approximates its fair value due to its short-term nature.
Property and equipment
Property and equipment are carried at historical
cost less accumulated depreciation and any accumulated impairment losses. Each component of an item of property and equipment with
a cost that is significant in relation to the total cost of the item is depreciated separately. Maintenance and repair expenditures
that do not improve or extend the life are expensed in the period incurred.
Depreciation is recognized so as to write
off the cost or valuation of assets (other than land) less their residual values over their useful lives, using the straight-line
method. The estimated useful lives, residual values and depreciation methods are reviewed at the end of each year, with the effect
of any changes in estimate accounted for on a prospective basis.
Zomedica Pharmaceuticals Corp.
Notes to the consolidated financial statements
For the years ended December 31, 2017 and 2016
(Stated in United States dollars)
|
|
3.
|
Significant accounting policies (continued)
|
Property and equipment (continued)
An item of property and equipment is derecognized
upon disposal or when no future economic benefits are expected to arise from the continued use of the asset. Any gain or loss arising
on the disposal or retirement of an item of property, plant and equipment is determined as the difference between the sales proceeds
and the carrying amount of the asset and is recognized in profit or loss.
Estimated useful lives for the principal
asset categories are as follows:
Computer equipment (years)
|
|
3
|
|
Furniture and equipment (years)
|
5
|
-
|
7
|
Laboratory equipment (years)
|
5
|
-
|
7
|
Leasehold improvements
|
|
Over shorter of estimated
useful life and lease term
|
|
Impairment of long-lived assets
Long-lived assets are reviewed for impairment
when events or circumstances indicate that the carrying value of an asset may not be recoverable. For assets that are to be held
and used, impairment is recognized when the sum of estimated undiscounted cash flows associated with the asset or group of assets
is less than its carrying value. If impairment exists, an adjustment is made to write the asset down to its fair value, and a loss
is recorded as the difference between the carrying value and fair value.
Research and development
Research and development costs related
to continued research and development programs are expensed as incurred in accordance with ASC topic 730.
Share issue costs
Share issue costs are recorded as a reduction
of the proceeds from the issuance of capital stock.
Translation of foreign currencies
In respect of other transactions denominated
in currencies other than the Company and its wholly owned operating subsidiaries’ functional currencies, the monetary assets
and liabilities are translated at the period end rates. Revenue and expenses are translated at rates of exchange prevailing on
the transaction dates. All of the exchange gains or losses resulting from these other transactions are recognized in the consolidated
statements of operations and comprehensive loss.
Stock-based compensation
The Company measures the cost of equity-settled
transactions by reference to the fair value of the equity instruments at the date at which they are granted if the fair value of
the goods or services received by the Company cannot be reliably estimated.
Zomedica Pharmaceuticals Corp.
Notes to the consolidated financial statements
For the years ended December 31, 2017 and 2016
(Stated in United States dollars)
|
|
3.
|
Significant accounting policies (continued)
|
Stock-based compensation (continued)
The Company calculates stock-based compensation
using the fair value method, under which the fair value of the options at the grant date is calculated using the Black-Scholes
Option Pricing Model, and subsequently expensed over the vesting period of the option. The provisions of the Company's stock-based
compensation plans do not require the Company to settle any options by transferring cash or other assets, and therefore the Company
classifies the awards as equity. Stock-based compensation expense recognized during the period is based on the value of stock-based
payment awards that are ultimately expected to vest.
The Company estimates forfeitures at the
time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates.
Loss per share
Basic loss per share (“EPS”)
is computed by dividing the loss attributable to common shareholders by the weighted average number of common shares outstanding.
Diluted EPS reflects the potential dilution that could occur from common shares issuable through the exercise or conversion of
stock options, restricted stock awards, warrants and convertible securities. In certain circumstances, the conversion of options
are excluded from diluted EPS if the effect of such inclusion would be anti-dilutive.
The dilutive effect of stock options is
determined using the treasury stock method. Stock options to purchase common shares of the Company during fiscal 2017 and 2016
were not included in the computation of diluted EPS because the Company has incurred a loss for the year ended December 31, 2017
and 2016 as the effect would be anti-dilutive.
Comprehensive loss
The Company follows ASC topic 220. This
statement establishes standards for reporting and display of comprehensive (loss) income and its components. Comprehensive loss
is net loss plus certain items that are recorded directly to shareholders' equity. The Company has no other comprehensive loss
items.
Intangible assets
Intangible assets with finite useful lives
that are acquired separately are carried at cost less accumulated amortization and accumulated impairment losses. Amortization
is recognized on a straight-line basis over their estimated useful lives. The estimated useful lives and amortization methods are
reviewed at the end of each year, with the effect of any changes in estimate being accounted for on a prospective basis. Intangible
assets with indefinite useful lives that are acquired separately are carried at cost less accumulated impairment losses.
Computer software (years)
|
3
|
Trademarks (years)
|
15
|
Zomedica Pharmaceuticals Corp.
Notes to the consolidated financial statements
For the years ended December 31, 2017 and 2016
(Stated in United States dollars)
|
|
3.
|
Significant accounting policies (continued)
|
Fair value measurement
Under ASC topic 820, fair value is defined
as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants
at the measurement date (i.e., an exit price). ASC topic 820 establishes a hierarchy for inputs to valuation techniques used in
measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that
the most observable inputs be used when available. Observable inputs are inputs that reflect assumptions market participants would
use in pricing the asset or liability developed based on market data obtained from sources independent of the Company. Unobservable
inputs are inputs that reflect the Company's own assumptions about the assumptions market participants would use in pricing the
asset or liability developed based on the best information available in the circumstances. There are three levels to the hierarchy
based on the reliability of inputs, as follows:
|
l
|
Level 1 - Observable
inputs that reflect quoted prices (unadjusted) for identical assets or liabilities in active markets.
|
|
l
|
Level 2 - Inputs
other than quoted prices included in Level 1 that are observable for the asset or liability, either directly or indirectly. Level
2 inputs include quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets
and liabilities in markets that are not active.
|
|
l
|
Level 3 - Unobservable
inputs for the asset or liability.
|
The degree of judgment exercised by the
Company in determining fair value is greatest for instruments categorized in Level 3.
Income taxes
The Company accounts for income taxes in
accordance with Accounting Standard Codification 740, Income Taxes ("ASC 740"), on a tax jurisdictional basis. The Company
files income tax returns in the United States and its subsidiary files income tax returns in Canada and the Province of Ontario.
Deferred tax assets and liabilities are
recognized for the expected future tax consequences of temporary differences between the tax bases of assets and liabilities and
their financial statement reported amounts using enacted tax rates and laws in effect in the year in which the differences are
expected to reverse. A valuation allowance is provided against deferred tax assets when it is determined to be more likely than
not that the deferred tax asset will not be realized.
The Company assesses the likelihood of
the financial statement effect of a tax position that should be recognized when it is more likely than not that the position will
be sustained upon examination by a taxing authority based on the technical merits of the tax position, circumstances, and information
available as of the reporting date. The Company is subject to examination by taxing authorities in jurisdictions such as the United
States and Canada. Management does not believe that there are any uncertain tax positions that would result in an asset or liability
for taxes being recognized in the accompanying consolidated financial statements. The Company recognizes tax-related interest and
penalties, if any, as a component of income tax expense.
ASC 740 prescribes recognition threshold
and measurement attributes for the financial statement recognition and measurement of a tax position taken or expected to be taken
in a tax return. ASC 740 also provides guidance on de-recognition, classification, interest and penalties, accounting in periods,
disclosure and transition. At December 31, 2017 and 2016, the Company has not taken any tax positions that would require disclosure
under ASC 740.
Zomedica Pharmaceuticals Corp.
Notes to the consolidated financial statements
For the years ended December 31, 2017 and 2016
(Stated in United States dollars)
|
|
3.
|
Significant accounting policies (continued)
|
Segmented reporting
The Company currently operates as a single
segment. Its principal business relates to the discovery, development and commercialization of innovative pharmaceuticals for the
companion pet.
Future accounting pronouncements
In May 2014, the Financial Accounting Standards
Board ("FASB") issued Accounting Standards Update (“ASU”) No. 2014-09, Revenue from Contracts with Customers,
requiring an entity to recognize the amount of revenue to which it expects to be entitled for the transfer of promised goods or
services to customers. The updated standard will replace most existing revenue recognition guidance in U.S. GAAP when it becomes
effective. In March 2016, the FASB issued ASU No. 2016-08 to clarify the implementation guidance on considerations of whether an
entity is a principal or an agent, impacting whether an entity reports revenue on a gross or net basis. In April 2016, the FASB
issued ASU No. 2016-10 to clarify guidance on identifying performance obligations and the implementation guidance on licensing.
In May 2016, the FASB issued amendments ASU No. 2016-11 and 2016-12 to amend certain aspects of the new revenue guidance (including
transition, collectability, noncash consideration and the presentation of sales and other similar taxes) and provided certain practical
expedients. The guidance is effective for annual reporting periods beginning after December 15, 2017 (including interim reporting
periods). Early adoption is permitted but not before the annual reporting period (and interim reporting period) beginning January
1, 2017. Entities have the option of using either a full retrospective or a modified approach to adopt the guidance. The Company
is in the process of evaluating the amendments to determine if they have a material impact on the Company’s financial position,
results of operations, cash flows or disclosures.
In January 2016, the FASB issued ASU No.
2016-01, which makes limited amendments to the guidance in U.S. GAAP on the classification and measurement of financial instruments.
The new standard significantly revises an entity’s accounting related to (1) the classification and measurement of investments
in equity securities and (2) the presentation of certain fair value changes for financial liabilities measured at fair value. It
also amends certain disclosure requirements associated with the fair value of financial instruments. ASU No. 2016-01 is effective
for fiscal years beginning after December 15, 2017, and interim periods within those annual periods. The Company is in the process
of evaluating the amendments to determine if they have a material impact on the Company’s financial position, results of
operations, cash flows or disclosures.
In February 2016, the FASB issued new guidance,
ASU No. 2016-02, Leases (Topic 842). The main difference between current U.S. GAAP and the new guidance is the recognition of lease
liabilities based on the present value of remaining lease payments and corresponding lease assets for operating leases under current
U.S. GAAP with limited exception. Additional qualitative and quantitative disclosures are also required by the new guidance. Topic
842 is effective for annual reporting periods (including interim reporting periods) beginning after December 15, 2018. Early adoption
is permitted. The Company is in the process of evaluating the amendments to determine if they have a material impact on the Company’s
financial position, results of operations, cash flows or disclosures.
In August 2016, the FASB issued ASU 2016-15,
Statement of Cash Flows (Topic 230) Classification of Certain Cash Receipts and Cash Payments, which will make eight targeted changes
to how cash receipts and cash payments are presented and classified in the Statement of Cash Flows. ASU 2016-15 will be effective
on May 1, 2018 and will require adoption on a retrospective basis unless it is impracticable to apply, in which case the Company
would be required to apply the amendments prospectively as of the earliest date practicable. The Company is in the process of evaluating
the amendments to determine if they have a material impact on the Company’s financial position, results of operations, cash
flows or disclosures.
Zomedica Pharmaceuticals Corp.
Notes to the consolidated financial statements
For the years ended December 31, 2017 and 2016
(Stated in United States dollars)
|
|
3.
|
Significant accounting policies (continued)
|
Future accounting pronouncements (continued)
In August 2016, the FASB issued ASU 2017-01
that changes the definition of a business to assist entities with evaluating when a set of transferred assets and activities is
a business. The guidance requires an entity to evaluate if substantially all of the fair value of the gross assets acquired is
concentrated in a single identifiable asset or a group of similar identifiable assets; if so, the set of transferred assets and
activities is not a business. ASU 2017-01 also requires a business to include at least one substantive process and narrows the
definition of outputs by more closely aligning it with how outputs are described in ASC 606.1. ASU 2017-01 is effective for public
business entities for fiscal years beginning after December 15, 2017, and interim periods within those years. Early adoption is
permitted. The Company is in the process of evaluating the amendments to determine if they have a material impact on the Company’s
financial position, results of operations, cash flows or disclosures.
In May 2017, FASB issued ASU 2017-09 in
relation to Compensation —Stock Compensation (Topic 718), Modification Accounting. The amendments provide guidance about
which changes to the terms or conditions of a share-based payment award require an entity to apply modification accounting in Topic
718. The amendments are effective for all entities for annual periods, and interim periods within those annual periods, beginning
after December 15, 2017. Early adoption is permitted, including adoption in any interim period, for (1) public business entities
for reporting periods for which financial statements have not yet been issued and (2) all other entities for reporting periods
for which financial statements have not yet been made available for issuance. The amendments should be applied prospectively to
an award modified on or after the adoption date. The Company is in the process of evaluating the amendments to determine if they
have a material impact on the Company’s financial position, results of operations, cash flows or disclosures.
4.
|
Critical accounting judgments and key sources of estimation uncertainty
|
The preparation of financial statements
requires management to make judgments, estimates and assumptions that affect the application of policies and reported amounts of
assets and liabilities, and revenue and expenses. The estimates and associated assumptions are based on historical experience and
various other factors that are believed to be reasonable under the circumstances, the results of which form the basis of making
the judgments about carrying values of assets and liabilities that are not readily apparent from other sources. Actual results
may differ from these estimates.
The estimates and underlying assumptions
are reviewed on an ongoing basis. Revisions to accounting estimates are recognized in the period in which the estimate is revised
if the revision affects only that period or in the period of the revision and further periods if the review affects both current
and future periods.
Critical areas of estimation and judgements
in applying accounting policies include the following:
Going concern
These consolidated financial statements
have been prepared in accordance with U.S GAAP on a going concern basis, which assumes the realization of assets and discharge
of liabilities in the normal course of business within the foreseeable future. Management uses judgment in determining assumptions
for cash flow projections, such as anticipated financing, anticipated sales and future commitments to assess the Company’s
ability to continue as a going concern. A critical judgment is that the Company continues to raise funds going forward and satisfy
their obligations as they become due.
Zomedica Pharmaceuticals Corp.
Notes to the consolidated financial statements
For the years ended December 31, 2017 and 2016
(Stated in United States dollars)
|
|
4.
|
Critical accounting judgments and key sources of estimation uncertainty (continued)
|
Useful lives of property and equipment
As described in Note 3 above, the Company
reviews the estimated useful lives of property and equipment with definite useful lives at the end of each year and assesses whether
the useful lives of certain items should be shortened or extended, due to various factors including technology, competition and
revised service offerings. During the year ended December 31, 2017 and 2016, the Company was not required to adjust the useful
lives of any assets based on the factors described above.
Deferred income taxes
The calculation of deferred income taxes
is based on assumptions which are subject to uncertainty as to timing and which tax rates are expected to apply when temporary
differences reverse. Deferred tax recorded is also subject to uncertainty regarding the magnitude of non-capital losses available
for carry forward and of the balances in various tax pools. By their nature, these estimates are subject to measurement uncertainty,
and the effect on the financial statements from changes in such estimates in future period could be material. Deferred tax assets
are recognized to the extent that it is probable that they will be able to be utilized against future taxable income. Deferred
tax assets are reviewed at each balance sheet date and adjusted to the extent that it is no longer probable that the related tax
benefit will be realized.
Stock-based payments
The Company estimates the fair value of
convertible securities such as options using the Black-Scholes option-pricing model which requires significant estimation around
assumptions and inputs such as expected term to maturity, expected volatility and expected dividends.
5.
|
Prepaid expenses and deposits
|
The Company entered into a lease agreement
with Wickfield Phoenix LLC effective on August 23, 2016. The Company prepaid the full outstanding balance of $801,973 on August
26, 2016 and recorded the prepaid rent due within a year as current. As at December 31, 2017, the Company has classified $155,220
as a current asset in the consolidated balance sheet (December 31, 2016 - $160,395).
Zomedica Pharmaceuticals Corp.
Notes to the consolidated financial statements
For the years ended December 31, 2017 and 2016
(Stated in United States dollars)
|
6.
|
Property and equipment
|
|
|
Computer
equipment
|
|
|
Furniture and
equipment
|
|
|
Laboratory
equipment
|
|
|
Leasehold
improvements
|
|
|
Total
|
|
Cost
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Balance at December 31, 2015
|
|
$
|
51,795
|
|
|
$
|
7,364
|
|
|
$
|
32,665
|
|
|
$
|
14,735
|
|
|
$
|
106,559
|
|
Additions
|
|
|
9,803
|
|
|
|
-
|
|
|
|
210,864
|
|
|
|
10,937
|
|
|
|
231,604
|
|
Balance at December 31, 2016
|
|
|
61,598
|
|
|
|
7,364
|
|
|
|
243,529
|
|
|
|
25,672
|
|
|
|
338,163
|
|
Additions
|
|
|
89,557
|
|
|
|
68,694
|
|
|
|
2,200
|
|
|
|
11,285
|
|
|
|
171,736
|
|
Balance at December 31, 2017
|
|
|
151,155
|
|
|
|
76,058
|
|
|
|
245,729
|
|
|
|
36,957
|
|
|
|
509,899
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Accumulated depreciation
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Balance at December 31, 2015
|
|
|
3,163
|
|
|
|
438
|
|
|
|
1,578
|
|
|
|
819
|
|
|
|
5,998
|
|
Depreciation
|
|
|
10,695
|
|
|
|
1,052
|
|
|
|
28,205
|
|
|
|
3,179
|
|
|
|
43,131
|
|
Balance at December 31, 2016
|
|
|
13,858
|
|
|
|
1,490
|
|
|
|
29,783
|
|
|
|
3,998
|
|
|
|
49,129
|
|
Depreciation
|
|
|
28,944
|
|
|
|
10,355
|
|
|
|
45,092
|
|
|
|
5,222
|
|
|
|
89,613
|
|
Balance at December 31, 2017
|
|
|
42,802
|
|
|
|
11,845
|
|
|
|
74,875
|
|
|
|
9,220
|
|
|
|
138,742
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net book value as at:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
December 31, 2016
|
|
$
|
47,740
|
|
|
$
|
5,874
|
|
|
$
|
213,746
|
|
|
$
|
21,674
|
|
|
$
|
289,034
|
|
December 31, 2017
|
|
$
|
108,353
|
|
|
$
|
64,213
|
|
|
$
|
170,854
|
|
|
$
|
27,737
|
|
|
$
|
371,157
|
|
|
|
Computer
software
|
|
|
Trademarks
|
|
|
Total
|
|
Cost
|
|
|
|
|
|
|
|
|
|
|
|
|
Balance at December 31, 2015
|
|
$
|
5,143
|
|
|
$
|
6,625
|
|
|
$
|
11,768
|
|
Additions
|
|
|
-
|
|
|
|
9,611
|
|
|
|
9,611
|
|
Balance at December 31, 2016
|
|
|
5,143
|
|
|
|
16,236
|
|
|
|
21,379
|
|
Additions
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
Balance at December 31, 2017
|
|
|
5,143
|
|
|
|
16,236
|
|
|
|
21,379
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Accumulated amortization
|
|
|
|
|
|
|
|
|
|
|
|
|
Balance at December 31, 2015
|
|
|
714
|
|
|
|
37
|
|
|
|
751
|
|
Amortization
|
|
|
1,714
|
|
|
|
976
|
|
|
|
2,690
|
|
Balance at December 31, 2016
|
|
|
2,428
|
|
|
|
1,013
|
|
|
|
3,441
|
|
Amortization
|
|
|
1,715
|
|
|
|
1,082
|
|
|
|
2,797
|
|
Balance at December 31, 2017
|
|
|
4,143
|
|
|
|
2,095
|
|
|
|
6,238
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net book value as at:
|
|
|
|
|
|
|
|
|
|
|
|
|
December 31, 2016
|
|
$
|
2,715
|
|
|
$
|
15,223
|
|
|
$
|
17,938
|
|
December 31, 2017
|
|
$
|
1,000
|
|
|
$
|
14,141
|
|
|
$
|
15,141
|
|
Zomedica Pharmaceuticals Corp.
Notes to the consolidated financial statements
For the years ended December 31, 2017 and 2016
(Stated in United States dollars)
|
On October 18, 2017, the Company entered
into a loan arrangement with a shareholder of the Company, pursuant to which such shareholder has agreed to provide a loan facility
to the Company, whereby the Company may borrow up to $5,000,000, with the proceeds to be used for working capital and general corporate
purposes. The term of the loan facility is five (5) years, with principal and interest payments being due only at the time of maturity.
Under the loan agreement, the Company may borrow in one or more advances, provided however that a minimum amount of $250,000 must
be borrowed at any one time and not more than two advances may occur per month. Interest shall accrue at a rate of fourteen percent
(14%) per annum, payable upon maturity. As of December 31, 2017, no amounts have been borrowed.
The Company
is authorized to issue an unlimited number of common stock, all without par value.
Issued and outstanding common stock:
|
|
Number of
common
stock
|
|
|
Capital
stock
|
|
Balance at December 31, 2015
|
|
|
77,370,716
|
|
|
$
|
5,214,691
|
|
Stock issued to effect the recapitalization (Note 19)
|
|
|
1,900,000
|
|
|
|
196,534
|
|
Stock issued due to option exercises related to amalgamation (Note 10)
|
|
|
80,000
|
|
|
|
22,058
|
|
Stock issued to Everfront Capital Corp
|
|
|
80,000
|
|
|
|
15,741
|
|
Stock issued for financing (i and ii)
|
|
|
4,133,853
|
|
|
|
4,717,570
|
|
Stock issued due to exercise of options (Note 10)
|
|
|
400,000
|
|
|
|
23,379
|
|
Balance at December 31, 2016
|
|
|
83,964,569
|
|
|
|
10,189,973
|
|
Stock issuance for services (iii and iv)
|
|
|
155,927
|
|
|
|
275,131
|
|
Stock issued from financing (v and vi)
|
|
|
4,405,373
|
|
|
|
6,513,424
|
|
Stock issued due to exercise of options (Note 10)
|
|
|
1,700,000
|
|
|
|
1,266,131
|
|
Balance at December 31, 2017
|
|
|
90,225,869
|
|
|
$
|
18,244,659
|
|
|
i)
|
On August 25, 2016, the Company issued 3,342,480 common shares for gross proceeds of $3,875,500.
The Company recorded $29,310 of share issuance costs as an offset to capital stock.
|
|
ii)
|
On December 29, 2016, the Company issued 791,373 common shares for gross proceeds of $880,086.
The Company recorded $8,706 of share issuance costs as an offset to capital stock.
|
|
iii)
|
On March 14, 2017, the Company settled $50,000 of amounts due to a vendor by issuing 43,613 common
shares valued at $45,000 at the date of issuance. The Company recorded a $5,000 gain on the settlement of liabilities.
|
|
iv)
|
On December 22, 2017, the Company issued 112,314 common shares in accordance with a License and Supply Agreement with Celsee,
Inc. and recognized $230,131 as a research and development expense in the consolidated statements of operations and
comprehensive loss.
|
|
v)
|
On April 7, 2017, the Company issued 2,902,682 common shares for gross proceeds of $3,250,000.
The Company recorded $32,754 of share issuance costs as an offset to capital stock.
|
|
vi)
|
On July 28, 2017, the Company issued 1,502,691 common shares for gross proceeds of $3,320,000.
The Company recorded $23,822 of share issuance costs as an offset to capital stock.
|
Zomedica Pharmaceuticals Corp.
Notes to the consolidated financial statements
For the years ended December 31, 2017 and 2016
(Stated in United States dollars)
|
10.
|
Stock-based compensation
|
During the year ended December 31, 2017,
the Company issued 1,815,000 stock options, each option entitling the holder to purchase one common share of the Company. During
the year ended December 31, 2017, an aggregate of 1,700,000 options were exercised.
During the year ended December 31, 2016,
the Company issued 7,375,000 stock options, each option entitling the holder to purchase one common share of the Company. The Company
also had 80,000 options issued as part of the qualifying transaction as disclosed in Note 19. These options were exercised immediately
after the close of the qualifying transaction on April 21, 2016. During the year ended December 31, 2016, 400,000 of additional
options were exercised.
The continuity of stock options are as
follows:
|
|
Number of
Options
|
|
|
Weighted Avg
Exercise Price
(CDN$)
|
|
Balance at December 31, 2015
|
|
|
1,000,000
|
|
|
$
|
0.05
|
|
Options issued
|
|
|
3,500,000
|
|
|
$
|
0.25
|
|
Options issued through amalgamation
|
|
|
80,000
|
|
|
$
|
0.25
|
|
Options exercised on April 21, 2016
|
|
|
(80,000
|
)
|
|
$
|
0.25
|
|
Options exercised on August 15, 2016
|
|
|
(400,000
|
)
|
|
$
|
0.05
|
|
Options issued on December 21, 2016
|
|
|
3,875,000
|
|
|
$
|
1.50
|
|
Balance at December 31, 2016
|
|
|
7,975,000
|
|
|
$
|
0.84
|
|
Stock options exercised on February 21, 2017
|
|
|
(10,000
|
)
|
|
$
|
0.25
|
|
Stock options exercised on February 21, 2017
|
|
|
(400,000
|
)
|
|
$
|
0.05
|
|
Options issued on February 24, 2017
|
|
|
535,000
|
|
|
$
|
1.50
|
|
Stock options exercised on May 8, 2017
|
|
|
(7,060
|
)
|
|
$
|
1.50
|
|
Stock options cancelled on May 17, 2017
|
|
|
(10,000
|
)
|
|
$
|
1.50
|
|
Stock options exercised on May 23, 2017
|
|
|
(80,000
|
)
|
|
$
|
0.25
|
|
Stock options exercised on July 6, 2017
|
|
|
(200,000
|
)
|
|
$
|
0.05
|
|
Stock options exercised on July 17, 2017
|
|
|
(220,000
|
)
|
|
$
|
0.25
|
|
Options issued on August 14, 2017
|
|
|
1,280,000
|
|
|
$
|
2.75
|
|
Stock options exercised on August 29, 2017
|
|
|
(7,940
|
)
|
|
$
|
1.50
|
|
Stock options exercised on December 19, 2017
|
|
|
(25,000
|
)
|
|
$
|
0.25
|
|
Stock options exercised on December 19, 2017
|
|
|
(750,000
|
)
|
|
$
|
1.50
|
|
Balance at December 31, 2017
|
|
|
8,080,000
|
|
|
$
|
1.21
|
|
As at December 31, 2017, details of the
issued and outstanding stock options are as follows:
Grant date
|
|
Exercise
price
(CDN$)
|
|
|
Number of
options issued
and outstanding
|
|
|
Number of
vested options
outstanding
|
|
|
Weighted Avg
Remaining Life
(years)
|
|
March 28, 2016
|
|
$
|
0.25
|
|
|
|
3,165,000
|
|
|
|
3,165,000
|
|
|
|
0.24
|
|
December 21, 2016
|
|
$
|
1.50
|
|
|
|
3,100,000
|
|
|
|
3,100,000
|
|
|
|
0.97
|
|
February 24, 2017
|
|
$
|
1.50
|
|
|
|
535,000
|
|
|
|
535,000
|
|
|
|
1.15
|
|
August 14, 2017
|
|
$
|
2.75
|
|
|
|
1,205,000
|
|
|
|
1,205,000
|
|
|
|
1.62
|
|
August 14, 2017
|
|
$
|
2.75
|
|
|
|
75,000
|
|
|
|
37,500
|
|
|
|
0.62
|
|
Zomedica Pharmaceuticals Corp.
Notes to the consolidated financial statements
For the years ended December 31, 2017 and 2016
(Stated in United States dollars)
|
|
10.
|
Stock-based compensation (continued)
|
The fair value of options granted
during the year ended December 31, 2017 was estimated using the Black-Scholes option pricing model to determine the fair value
of options granted using the following assumptions:
|
|
March 28, 2016
|
|
|
April 21, 2016
|
|
|
December 21, 2016
|
|
Volatility
|
|
|
63
|
%
|
|
|
63
|
%
|
|
|
58
|
%
|
Risk-free interest rate
|
|
|
0.56
|
%
|
|
|
1.12
|
%
|
|
|
0.81
|
%
|
Expected life (years)
|
|
|
2.06
|
|
|
|
1
|
|
|
|
2
|
|
Dividend yield
|
|
|
0
|
%
|
|
|
0
|
%
|
|
|
0
|
%
|
Common share price
|
|
|
CDN $0.20
|
|
|
|
CDN $0.20
|
|
|
|
CDN $1.45
|
|
Strike price
|
|
|
CDN $0.25
|
|
|
|
CDN $0.25
|
|
|
|
CDN $1.50
|
|
Forfeiture rate
|
|
|
nil
|
|
|
|
nil
|
|
|
|
nil
|
|
|
|
February 24, 2017
|
|
|
August 14, 2017
|
|
|
August 14, 2017
|
|
Volatility
|
|
|
59
|
%
|
|
|
59
|
%
|
|
|
83
|
%
|
Risk-free interest rate
|
|
|
0.81
|
%
|
|
|
1.22
|
%
|
|
|
1.22
|
%
|
Expected life (years)
|
|
|
2
|
|
|
|
2
|
|
|
|
1
|
|
Dividend yield
|
|
|
0
|
%
|
|
|
0
|
%
|
|
|
0
|
%
|
Common share price
|
|
|
CDN $1.35
|
|
|
|
CDN $2.40
|
|
|
|
CDN $2.40
|
|
Strike price
|
|
|
CDN $1.50
|
|
|
|
CDN $2.75
|
|
|
|
CDN $2.75
|
|
Forfeiture rate
|
|
|
nil
|
|
|
|
nil
|
|
|
|
nil
|
|
The
Company recorded $849,679 of stock-based compensation for the year ended December 31, 2017 and $1,467,934 of stock-based compensation
for the year ended December 31, 2016. During the year ended December 31, 2017, the Company recorded the cash receipt of $979,522
as capital stock and reclassified $286,609 of stock-based compensation to capital stock due to the exercise of 1,700,000 options
disclosed above. During the year ended December 31, 2016, the Company recorded the cash receipt of $35,423 as capital stock and
reclassified $10,014 of stock-based compensation to capital stock due to the exercise of 480,000 options disclosed above.
Volatility is determined based on volatilities
of comparable companies when the Company does not have its own sufficient trading history. The expected term, which represents
the period of time that options granted are expected to be outstanding, is estimated based on an average of the term of the options.
The risk-free rate assumed in valuing the
options is based on the Canadian treasury yield curve in effect at the time of grant for the expected term of the option. The expected
dividend yield percentage at the date of grant is Nil as the Company is not expected to pay dividends in the foreseeable future.
The Company has estimated its stock option forfeitures to be Nil for the year ended December 31, 2017 and 2016.
Zomedica Pharmaceuticals Corp.
Notes to the consolidated financial statements
For the years ended December 31, 2017 and 2016
(Stated in United States dollars)
|
The
reconciliation of the combined Canadian federal and provincial statutory income tax rate of 27% (2016- 27%) to the effective tax
rate is as follows:
|
|
For the year ended
December 31, 2017
|
|
|
For the year ended
December 31, 2016
|
|
Loss before income taxes
|
|
$
|
(8,065,072
|
)
|
|
$
|
(5,740,492
|
)
|
Expected income tax expense (recovery)
|
|
|
(2,177,570
|
)
|
|
|
(1,549,930
|
)
|
Difference in foreign tax rates
|
|
|
(297,460
|
)
|
|
|
(162,210
|
)
|
Tax rate changes and other adjustments
|
|
|
808,260
|
|
|
|
(43,960
|
)
|
Stock based compensation and non-deductible expenses
|
|
|
236,350
|
|
|
|
398,930
|
|
Change in valuation allowance
|
|
|
1,430,420
|
|
|
|
1,357,170
|
|
Total income tax expense
|
|
$
|
-
|
|
|
$
|
-
|
|
The following
table summarizes the components of deferred tax:
Deferred Tax Assets
|
|
2017
|
|
|
2016
|
|
Property, plant and equipment
|
|
$
|
157,920
|
|
|
$
|
-
|
|
Intangible assets
|
|
|
90
|
|
|
|
104,340
|
|
Intangible assets transferred on amalgamation
|
|
|
-
|
|
|
|
14,980
|
|
Share issuance costs
|
|
|
89,970
|
|
|
|
23,120
|
|
Reserves
|
|
|
14,030
|
|
|
|
7,760
|
|
Non-capital losses carried forward - Canada
|
|
|
1,762,250
|
|
|
|
973,670
|
|
Net operating losses carried forward - US
|
|
|
1,289,100
|
|
|
|
887,890
|
|
Investment Tax Credits
|
|
|
87,200
|
|
|
|
42,200
|
|
Total deferred tax assets
|
|
$
|
3,400,560
|
|
|
$
|
2,053,960
|
|
|
|
|
|
|
|
|
|
|
Deferred Tax Liabilities
|
|
|
|
|
|
|
|
|
Property and equipment
|
|
|
(57,370
|
)
|
|
|
(59,680
|
)
|
Intangible assets
|
|
|
-
|
|
|
|
(520
|
)
|
Total deferred tax liabilities
|
|
$
|
(57,370
|
)
|
|
$
|
(60,200
|
)
|
|
|
|
|
|
|
|
|
|
Valuation allowance
|
|
$
|
3,343,190
|
|
|
$
|
1,993,760
|
|
Net deferred tax asset
|
|
$
|
-
|
|
|
$
|
-
|
|
No deferred tax asset has been recognized,
as it is not more likely than not to be realized. Consequently, a valuation allowance has been applied against the net deferred
tax asset. The Canadian non-capital loss carry forwards expire as noted in the table below.
2035
|
|
|
465,790
|
|
2036
|
|
|
1,945,020
|
|
2037
|
|
|
4,116,040
|
|
|
|
$
|
6,526,850
|
|
Zomedica Pharmaceuticals Corp.
Notes to the consolidated financial statements
For the years ended December 31, 2017 and 2016
(Stated in United States dollars)
|
|
11.
|
Income taxes (continued)
|
The
Company’s US non-operating income tax losses expire as follows:
2035
|
|
|
856,300
|
|
2036
|
|
|
1,484,640
|
|
2037
|
|
|
2,667,240
|
|
|
|
$
|
5,008,180
|
|
12.
|
Commitments and Contingencies
|
Total future annual lease payments for
the premises are as follows:
|
2018
|
|
|
34,784
|
|
|
|
Total
|
|
$
|
34,784
|
|
|
13.
|
Financial instruments
|
The Company follows ASC topic 820, “Fair
Value Measurements” which defines fair value, establishes a framework for measuring fair value, and expands disclosures about
fair value measurements. The provisions of ASC topic 820 apply to other accounting pronouncements that require or permit fair value
measurements. ASC topic 820 defines fair value as the exchange price that would be received for an asset or paid to transfer a
liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between
market participants at the measurement date; and establishes a three level hierarchy for fair value measurements based upon the
transparency of inputs to the valuation of an asset or liability as of the measurement date. Inputs refers broadly to the assumptions
that market participants would use in pricing the asset or liability, including assumptions about risk. To increase consistency
and comparability in fair value measurements and related disclosures, the fair value hierarchy prioritizes the inputs to valuation
techniques used to measure fair value into three broad levels. The three levels of the hierarchy are defined as follows:
Level 1 inputs are quoted prices (unadjusted)
in active markets for identical assets or liabilities.
Level 2 inputs are inputs other than quoted
prices included within Level 1 that are observable for the asset or liability, either directly or indirectly for substantially
the full term of the financial instrument.
Level 3 inputs are unobservable inputs
for asset or liabilities.
The categorization within the valuation
hierarchy is based upon the lowest level of input that is significant to the fair value measurement.
|
(i)
|
The Company calculates expected volatility based on historical volatility of the Company’s peer group that is publicly
traded for options.
|
An increase/decrease in the volatility
would have resulted in an increase/decrease in the fair value of the options.
The carrying values of cash, trade and
other receivable, accounts payable and accrued liabilities and shareholder loans payable approximates their fair values because
of the short-term nature of these instruments.
Zomedica Pharmaceuticals Corp.
Notes to the consolidated financial statements
For the years ended December 31, 2017 and 2016
(Stated in United States dollars)
|
|
13.
|
Financial instruments (continued)
|
|
(b)
|
Interest rate and credit risk
|
Interest rate risk is the risk that the
value of a financial instrument might be adversely affected by a change in interest rates. The Company does not believe that the
results of operations or cash flows would be affected to any significant degree by a sudden change in market interest rates, relative
to interest rates on cash and cash equivalents, due to related parties due to the short-term nature of these balances.
The Company is also exposed to credit risk
at period end from the carrying value of its cash. The Company manages this risk by maintaining bank accounts with a Canadian Chartered
Bank. The Company’s cash is not subject to any external restrictions.
|
(c)
|
Foreign exchange risk
|
The Company has balances in Canadian dollars
that give rise to exposure to foreign exchange (“FX”) risk relating to the impact of translating certain non-U.S. dollar
balance sheet accounts as these statements are presented in U.S. dollars. A strengthening U.S. dollar will lead to a FX loss while
a weakening U.S. dollar will lead to a FX gain. For each Canadian dollar balance of $1.0 million, a +/- 10% movement in the
Canadian currency held by the Company versus the U.S. dollar would affect the Company’s loss and other comprehensive
loss by $0.1 million.
Liquidity risk is the risk that the Company
will encounter difficulty raising liquid funds to meet commitments as they fall due. In meeting its liquidity requirements, the
Company closely monitors its forecasted cash requirements with expected cash drawdown.
The following are the contractual maturities
of the undiscounted cash flows of financial liabilities as at December 31, 2017 and 2016:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
December 31, 2017
|
|
|
|
Less than
3 months
|
|
|
3 to 6
months
|
|
|
6 to 9
months
|
|
|
9 months
1 year
|
|
|
Greater than
1 year
|
|
|
Total
|
|
|
|
|
$
|
|
|
|
$
|
|
|
|
$
|
|
|
|
$
|
|
|
|
$
|
|
|
|
$
|
|
Third parties
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Accounts payable and accrued liabilities
|
|
|
828,737
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
828,737
|
|
Related parties
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Shareholder's loan payable
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
|
828,737
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
828,737
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
December 31, 2016
|
|
|
|
Less than
3 months
|
|
|
3 to 6
months
|
|
|
6 to 9
months
|
|
|
9 months
1 year
|
|
|
Greater than
1 year
|
|
|
Total
|
|
|
|
$
|
|
|
$
|
|
|
$
|
|
|
$
|
|
|
$
|
|
|
$
|
|
Third parties
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Accounts payable and accrued liabilities
|
|
|
734,431
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
734,431
|
|
Related parties
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Shareholder's loan payable
|
|
|
6,726
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
6,726
|
|
|
|
|
741,157
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
741,157
|
|
Zomedica Pharmaceuticals Corp.
Notes to the consolidated financial statements
For the years ended December 31, 2017 and 2016
(Stated in United States dollars)
|
14.
|
Segmented information
|
The Company's operations comprise a single
reportable segment engaged in the research, development targeting health and wellness solutions for the companion pet. As the operations
comprise a single reportable segment, amounts disclosed in the financial statements for loss for the period, depreciation and total
assets also represent segmented amounts. In addition, all of the Company's long-lived assets are in the United States of America
(“US”).
|
|
December 31,
2017
|
|
|
December 31,
2016
|
|
|
|
$
|
|
|
$
|
|
Total assets
|
|
|
|
|
|
|
|
|
Canada
|
|
|
3,519,918
|
|
|
|
114,912
|
|
US
|
|
|
1,695,904
|
|
|
|
4,460,646
|
|
|
|
|
|
|
|
|
|
|
Total property and equipment
|
|
|
|
|
|
|
|
|
US
|
|
|
371,157
|
|
|
|
289,034
|
|
|
|
For the year ended December 31,
2017
|
|
|
|
Research and
Development
|
|
|
Professional
Fees
|
|
|
General and
Administrative
|
|
|
|
|
|
|
|
|
|
|
|
Salaries, bonus and benefits
|
|
$
|
620,694
|
|
|
$
|
-
|
|
|
$
|
2,703,865
|
|
Contracted expenditures
|
|
|
821,927
|
|
|
|
-
|
|
|
|
5,610
|
|
Marketing and investor relations
|
|
|
-
|
|
|
|
-
|
|
|
|
168,623
|
|
Travel and accommodation
|
|
|
11,815
|
|
|
|
-
|
|
|
|
338,738
|
|
Insurance
|
|
|
76,628
|
|
|
|
-
|
|
|
|
182,753
|
|
License fees
|
|
|
480,131
|
|
|
|
-
|
|
|
|
-
|
|
Office
|
|
|
33,222
|
|
|
|
-
|
|
|
|
199,844
|
|
Consultants
|
|
|
325,388
|
|
|
|
1,294,044
|
|
|
|
-
|
|
Regulatory
|
|
|
103,100
|
|
|
|
-
|
|
|
|
138,289
|
|
Rent
|
|
|
39,129
|
|
|
|
-
|
|
|
|
164,250
|
|
Supplies
|
|
|
239,292
|
|
|
|
-
|
|
|
|
44,298
|
|
Total
|
|
$
|
2,751,326
|
|
|
$
|
1,294,044
|
|
|
$
|
3,946,270
|
|
|
|
For the year ended December 31,
2016
|
|
|
|
Research and
Development
|
|
|
Professional
Fees
|
|
|
General and
Administrative
|
|
|
|
|
|
|
|
|
|
|
|
Salaries, bonus and benefits
|
|
$
|
549,556
|
|
|
$
|
-
|
|
|
$
|
2,298,476
|
|
Contracted expenditures
|
|
|
322,165
|
|
|
|
-
|
|
|
|
-
|
|
Marketing and investor relations
|
|
|
-
|
|
|
|
-
|
|
|
|
194,187
|
|
Travel and accommodation
|
|
|
-
|
|
|
|
-
|
|
|
|
87,265
|
|
Insurance
|
|
|
47,207
|
|
|
|
-
|
|
|
|
133,827
|
|
Office
|
|
|
12,455
|
|
|
|
-
|
|
|
|
124,693
|
|
Consultants
|
|
|
308,582
|
|
|
|
1,245,182
|
|
|
|
23,904
|
|
Regulatory
|
|
|
101,100
|
|
|
|
-
|
|
|
|
-
|
|
Transfer agent and filing fees
|
|
|
-
|
|
|
|
-
|
|
|
|
25,357
|
|
Rent
|
|
|
19,264
|
|
|
|
-
|
|
|
|
28,895
|
|
Supplies
|
|
|
158,260
|
|
|
|
-
|
|
|
|
-
|
|
Total
|
|
$
|
1,518,589
|
|
|
$
|
1,245,182
|
|
|
$
|
2,916,604
|
|
Zomedica Pharmaceuticals Corp.
Notes to the consolidated financial statements
For the years ended December 31, 2017 and 2016
(Stated in United States dollars)
|
|
16.
|
Capital risk management
|
The capital of the Company includes equity,
which is comprised of issued common capital stock, additional paid-in capital, and accumulated deficit. The Company's objective
when managing its capital is to safeguard the ability to continue as a going concern in order to provide returns for its shareholders,
and other stakeholders and to maintain a strong capital base to support the Company's core activities.
|
|
For the year ended
December 31, 2017
|
|
|
For the year ended
December 31, 2016
|
|
|
|
|
|
|
|
|
Numerator
|
|
|
|
|
|
|
|
|
Net loss for the year
|
|
$
|
8,065,072
|
|
|
$
|
5,740,492
|
|
Denominator
|
|
|
|
|
|
|
|
|
Weighted average shares - basic
|
|
|
87,400,255
|
|
|
|
80,158,312
|
|
Stock options
|
|
|
-
|
|
|
|
-
|
|
Denominator for diluted loss per share
|
|
|
87,400,255
|
|
|
|
80,158,312
|
|
|
|
|
|
|
|
|
|
|
Loss per share - basic and diluted
|
|
$
|
(0.09
|
)
|
|
$
|
(0.07
|
)
|
For the above-mentioned periods, the Company had securities outstanding which
could potentially dilute basic earnings per share in the future, but were excluded from the computation of diluted loss per share
in the periods presented, as their effect would have been anti-dilutive.
|
18.
|
Related party transactions and key management compensation
|
During the years ended December 31, 2017
and 2016, the Company incurred the following related party transactions:
|
·
|
As at December 31, 2016, the Company owed
$6,726 to a director and executive officer, which is recorded as shareholder loans payable. The loan is unsecured and has no specific
repayment terms. As at December 31, 2017, this loan has been repaid.
|
Key management personnel are comprised
of the Company’s directors and executive officers. In addition to their salaries, key management personnel also receive share-based
compensation. Key management personnel compensation is as follows:
|
|
For the year ended
December 31, 2017
|
|
|
For the year ended
December 31, 2016
|
|
Salaries and benefits, including bonuses
|
|
$
|
1,357,264
|
|
|
$
|
912,640
|
|
Stock-based compensation
|
|
|
749,615
|
|
|
|
964,506
|
|
Total
|
|
$
|
2,106,879
|
|
|
$
|
1,877,146
|
|
Zomedica Pharmaceuticals Corp.
Notes to the consolidated financial statements
For the years ended December 31, 2017 and 2016
(Stated in United States dollars)
|
19.
|
Recapitalization involving a public shell
|
On April 21, 2016, Wise Oakwood Ventures
Inc. (“WOW”), a corporation existing under the laws of the Province of Alberta, closed its qualifying transaction with
ZoMedica Pharmaceuticals Inc. The transaction proceeded by way of a three-cornered amalgamation, pursuant to which Zomedica Pharmaceuticals
Inc. amalgamated with 9674128 Canada Inc., a wholly-owned subsidiary of WOW formed solely for the purposes of facilitating the
transaction. The amalgamated company changed its name to Zomedica Pharmaceuticals Ltd. The transaction constituted WOW’s
qualifying transaction under TSX Venture Exchange Policy 2.4 – Capital Pool Companies.
In accordance with the approvals of the
Company’s shareholders at its annual and special meeting on April 21, 2016, WOW changed its name to Zomedica Pharmaceuticals
Corp. and completed the consolidation of its outstanding common shares on a two and one-half (2½) pre-consolidated share
for each one (1) post-consolidated share basis. As a result of the transaction, Zomedica Pharmaceuticals Ltd. became a wholly-owned
subsidiary of Zomedica Pharmaceuticals Corp. The shares of Zomedica Pharmaceuticals Corp. began trading under the new symbol “ZOM”
on Monday May 2, 2016 on the TSX Venture Exchange.
WOW's share capital of CDN $309,589, contributed surplus of
CDN $32,467 and deficit of CDN $232,984 were all eliminated. The Company has accounted for the transaction as a recapitalization
involving a nonoperating public shell with ZoMedica Pharmaceuticals Inc. being the accounting acquirer and WOW being the accounting
acquiree. The transaction was not considered a business combination because the accounting acquiree, WOW did not meet the definition
of a business under ASC standards. Under U.S GAAP, any excess of the fair value of the shares issued by the private entity over
the value of the non-monetary assets of the public shell corporation is recognized as a reduction in equity.
As part of the transaction, WOW’s previously issued 200,000
stock options were converted to 80,000 post consolidation options. These options were exercised immediately after the close of
the qualifying transaction as disclosed in Note 10.
|
|
CDN
|
|
|
USD
|
|
Issuance of 1,900,000 Zomedica Pharmaceuticals Corp. shares
|
|
$
|
475,000
|
|
|
$
|
373,207
|
|
Issuance of 80,000 options
|
|
|
2,737
|
|
|
|
2,058
|
|
Total issuance
|
|
$
|
477,737
|
|
|
$
|
375,265
|
|
|
|
|
|
|
|
|
|
|
Cash
|
|
$
|
138,687
|
|
|
$
|
108,966
|
|
Prepaid fees
|
|
|
94,778
|
|
|
|
74,467
|
|
Accounts payable and accrued liabilities
|
|
|
(102,485
|
)
|
|
|
(80,522
|
)
|
Excess of purchase price over net asset value
|
|
|
346,757
|
|
|
|
272,354
|
|
|
|
$
|
477,737
|
|
|
$
|
375,265
|
|
Subsequent to December 31, 2017,
224,000 stock options were exercised for proceeds of $45,289.
F-
25
77,255,205 Common Shares
Zomedica Pharmaceuticals Corp.
PROSPECTUS
March 30, 2018
Zomedica (AMEX:ZOM)
Historical Stock Chart
From Mar 2024 to Apr 2024
Zomedica (AMEX:ZOM)
Historical Stock Chart
From Apr 2023 to Apr 2024